WO2003027090A2 - Bicyclic heterocycles as rxr ligands - Google Patents

Bicyclic heterocycles as rxr ligands Download PDF

Info

Publication number
WO2003027090A2
WO2003027090A2 PCT/US2002/029298 US0229298W WO03027090A2 WO 2003027090 A2 WO2003027090 A2 WO 2003027090A2 US 0229298 W US0229298 W US 0229298W WO 03027090 A2 WO03027090 A2 WO 03027090A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
tetrahydro
compound
mmol
tetramethyl
Prior art date
Application number
PCT/US2002/029298
Other languages
French (fr)
Other versions
WO2003027090A3 (en
Inventor
Curt Dale Haffner
Istvan Kaldor
Darryl Lynn Mcdougald
Aaron Bayne Miller
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to AU2002333655A priority Critical patent/AU2002333655A1/en
Priority to US10/490,805 priority patent/US7173134B2/en
Priority to JP2003530678A priority patent/JP2005511516A/en
Priority to EP02799584A priority patent/EP1430042A2/en
Publication of WO2003027090A2 publication Critical patent/WO2003027090A2/en
Publication of WO2003027090A3 publication Critical patent/WO2003027090A3/en
Priority to US11/614,091 priority patent/US20070099991A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Definitions

  • the present invention generally relates to compounds interacting with retinoid binding proteins, and more particularly to compounds that interact selectively with retinoid X receptors ("RXRs”) as well as methods for their production and therapeutic use.
  • RXRs retinoid X receptors
  • RARs and RXRs have distinct differences in their tissue distribution.
  • RARs are expressed at high levels in visceral tissues, whereas RXR ⁇ is most abundant in the liver, kidney, lung, muscle, and intestine.
  • RXR ⁇ is most abundant in the liver, kidney, lung, muscle, and intestine.
  • X is CR 1 or N, where R 1 is halogen, H, or CH 3 ; Z is O, S, or NH; M is N, C, or CR 2 , when M is N, the A ring is non-aromatic, when M is C, the A ring is aromatic, when M is CR 2 , then R 2 is H or - Y(CH 2 ) n R 6 , and the A ring is non-aromatic; Y is O or CH 2 ; when n is 0 to 6, R 6 is H, alkyl, or CF 3 , but when n is 2 to 5, R 6 is H, alkyl, CF 3 , SO 2 NHR 23 , NHSO 2 R 23 , or NR 23 R 24 , where R 23 is alkyl, aryl optionally substituted, heteroaryl optionally substituted or combined with R 24 to form a ring of 3 -7
  • J is CHO, CO 2 R 7 , SQR 7 , PO3R 7 , CONHOH, or J forms a thiazolidinedione ring with R 8 ;
  • R 7 is H or alkyl;
  • R 8 and R 9 are independently H, halogen, alkyl, or CF 3 ;
  • y and z are each 0, 1 , or 2;
  • Q is CR 4 , CR 4 R 5 , O, NR 10 , or S, where R 4 and R 5 are independently H or alkyl, provided that when Q is CR 4 , the A ring is aromatic;
  • R 10 is alkyl, COR 11 , CONHR 11 , CO 2 R 11 , CONR 11 R 12 , SO 2 R 11 , aryl, or cycloalkyl;
  • R 1 and R 12 are independently alkyl or cycloalkyl;
  • R 3 is
  • each R 19 is, independently, H or alkyl; y and z are as defined above; or R 3 is
  • each R 18 is, independently, as defined above; and M3 is C-(R 16 ) 3 or N-(R 16 ) 2 , when M3 is N-(R 16 ) 2 , an R 16 may combine with an R 18 to form a 5- or 6-membered ring.
  • said alkyl is C 1-5 alkyl; when R 6 is alkyl, said alkyl is C 1-6 alkyl; when R 7 is alkyl, said alkyl is C 1-5 alkyl; when either R 8 or R 9 or both are alkyl, said alkyl is C 1-3 alkyl; when R 10 is alkyl, said alkyl is C 1-6 alkyl; when either R 11 or R 12 or both are alkyl, said alkyl is C 1-5 alkyl; when either R 13 or R 14 or both are alkyl, said alkyl is C 1-3 alkyl; when R 5 is alkyl, said alkyl is C M alkyl; when either R 16 or R 17 or both are alkyl, said alkyl is C 1-4 alkyl; when R 18 is alkenyl, said alkenyl is C 1- alkenyl; when R 18 is alkyl, said alkyl is C 1-4 alkyl; when R 18 is alkenyl, said alkenyl is C 1-
  • X is CH
  • Z is O
  • Q is CH 2
  • M is CH
  • G is
  • X is CR 1 or N, where R 1 is halogen, H, or CH 3 ;
  • Z is O, S, or NH;
  • G is CO 2 R 7 , SQR 7 , PO 3 R 7 , CONHOH, or
  • J is CHO, CO 2 R 7 , SQR 7 , PO 3 R 7 , CONHOH, or J forms a thiazolidinedione ring with R 8 ;
  • R 7 is H or C 1-5 alkyl;
  • R 8 and R 9 are independently H, halogen, C 1-3 alkyl, or CF 3 ;
  • y and z are each 0, 1 , or 2;
  • R 3 is
  • R is as defined above; or R is
  • R 18 is as defined above; and M3 is C-(R 16 ) 3 or N-(R 16 ) 2 , when M3 is N-(R 16 ) 2 , an R 16 may combine with an R 18 to form a 5- or 6-membered ring;
  • R 20 is H or C 1-4 alkyl;
  • R 21 is H, OR 6 , where R 6 is as defined for Formula I, or may combine with R 22 to form a carbonyl; and R 22 is H, or may combine with R 21 to form a carbonyl.
  • J is CO 2 H
  • R 8 and R 9 are each H
  • y and z are each 1
  • the double bond exists
  • the olefin geometry is trans.
  • R 3 is where D is CR 13 R 14 ; R 13 , R 4 , R 16 , and R 17 are each methyl; and R 18 is H.
  • Particularly preferred compounds of formula II include:
  • Another aspect of the present invention includes methods for treating, including treatment and prophylaxis, a disorder in a mammal, wherein the disorder is characterized by the need for retinoid therapym through the administration to the mammal an effective amount of a compound of formula I or II.
  • disorders characterized by the need for retinoid therapy and therefore included herein, but without exclusion include metabolic conditions and disorders, dermatological conditions, cancerous and pre-cancerous conditions, hyperthyroidism, dyslipidemia, and hypertension.
  • the disorder is diabetes or obesity.
  • Another aspect of the present invention includes compounds of formulas I or II for use as an active therapeutic substance. Preferably such use is for retinoid therapy.
  • Another aspect of the present invention includes the use of a compound of formulas I or II in the manufacture of a medicament for use in retinoid therapy, preferably for use in the treatment or prophylaxis of diabetes or obesity.
  • Another aspect of the present invention includes compounds of formulas I or
  • Another aspect of the present invention includes a method for manufacturing a retinoid comprising: a) reacting a compound of Formula III, Formula IV, a combination of Formulas
  • cycloalkyl represents a saturated carbon chain forming a ring and includes, but should not be limited to cyclopropyl, cyclobutyl, cyclopentyl, and the like.
  • carbonyl refers to the group -C(O)-.
  • R 21 and R 22 combine to form a carbonyl the following example compounds are referred to:
  • the present invention includes salts, solvates, and physiologically functional derivatives of the compounds of the present invention.
  • Salts include addition salts, metal salts, or optionally alkylated ammonium salts, such as hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, trifluoroacetic, trichloroacetic, oxalic, maleic, pyruvic, malonic, succinic, citric, mandelic, benzoic, cinnamic, methane sulphonic, ethane sulphonic, picric and the like. Salts also include acids related to the salts listed within Journal of Pharmaceutical Science 1997, 66, 2 , incorporated herein by reference as relevant to salts. Further acceptable salts include lithium, sodium, potassium, magnesium, and the like.
  • solvate refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of formula I or II, or a salt or physiologically functional derivative thereof) and a solvent.
  • solvents for the purpose of the invention, should not interfere with the biological activity of the solute.
  • suitable solvents include, but are not limited to water, methanol, ethanol, and acetic acid.
  • the solvent used is a pharmaceutically acceptable solvent.
  • suitable pharmaceutically acceptable solvents include water, ethanol, and acetic acid. Most preferably the solvent used is water.
  • the term "effective amount” means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal, or human that is being sought, for instance, by a researcher or clinician.
  • therapeutically effective amount means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder.
  • the term also includes within its scope amounts effective to enhance normal physiological function.
  • a therapeutically effective amount of a compound of the present invention will depend upon a number of factors including, for example, the age and weight of the animal, the precise condition requiring treatment and its severity, the nature of the formulation, and the route of administration. Therapeutic effectiveness ultimately will be at the discretion of the attendant physician or veterinarian. Generally, however, an effective amount of a compound of formula (I) or (II) for RXR mediated diseases and conditions should be in the range of about 0.1 to about 100 mg/kg body weight of recipient (mammal, preferably human) per day. Preferably the effective amount will be in the range of 0.5 to 10 mg/kg body weight per day. More preferably in the range of about 1 to 5 mg/kg body weight per day. An effective amount of a salt or solvate, or physiologically functional derivative thereof, may be determined as a proportion of the effective amount of the compound of formula (I) or (II) per se.
  • compositions of the present invention include those especially formulated for oral, buccal, parental, transdermal, inhalation, intranasal, transmucosal, implant, or rectal administration. Among the variety of administrations, oral administration typically is preferred. For buccal administration, the formulation may take the form of tablets or lozenges formulated in conventional manner.
  • formulations of the present invention may be formulated for parenteral administration by injection or continuous infusion.
  • Formulations for injection may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, for example, sterile, pyrogen-free water, before use.
  • E represents either bromine, preferably, or iodine and, as is relevant throughout this description, wherein D, M3, R 16 , R 17 , and R 18 are defined as above for formula I.
  • Compounds of formula II can be prepared by reacting a compound of Formula XVII, wherein X, Z, and R 20 are defined as before, with compounds of Formula V, VI or VII, shown above, where E is as hereinabove defined.
  • a toluene solution (10 mL) was mixed with 4-(5,5,8,8-tetramethyl-5,6,7,8- tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1-benzofuran]-2-carboxaldehyde (100 mg, 0.30 mmol), 2,5-thiazolidinedione (62 mg, 0.53 mmol), morpholine (200 mg, 2.3 mmol), molecular sieves and 10 mL of anhydrous toluene.
  • the reaction mixture was stirred at reflux for 4.0 hours at which time it was cooled to 0-5 °C.
  • the resulting yellow solid was filtered in vacuo and washed with 10 mL of cold toluene.
  • the resulting solid was dried in vacuo for 17 hours to afford 34 mg of pure solid.
  • the reaction was allowed to warm to RT where it stirred for 4.0 hours followed by quenching via the addition of 1.0 N HCI (20 mL).
  • the reaction mixture was extracted using ether.
  • the organics were separated and dried over MgSO 4 followed by concentrating to dryness.
  • the resulting oil was chromatographed on silica gel (90%hexanes/10% ethyl acetate) to afford 487 mg of pure oil.
  • the resulting mixture was made acidic using 3.0 N HCI.
  • the reaction mixture was then extracted into ether and dried over MgSO 4 .
  • the mixture was concentrated to dryness and chromatographed on silica gel (80%hexanes/ 20%EtOAc) yielding 45 mg of pure acid.
  • the reaction was allowed to warm to RT where it stirred for 7 hours.
  • the reaction was quenched by the addition of 1.0 N HCI (100 mL).
  • the reaction mixture was extracted using ether.
  • the organics were separated and dried over MgSO 4 followed by concentrating to dryness.
  • the resulting oil was dried under high vacuum to give a total of 8.2 g (100%) of crude oil.
  • the product was used without further purification.
  • the magnesium turnings were agitated until the Grignard salt began to form.
  • the formation was allowed to proceed for a period of 1.0 hour.
  • the reaction mixture was mixed with a THF solution (25 mL) of compound B (3.5 g, 0.0129 moles).
  • the reaction was allowed to warm to RT over a period of 1.0 hour and was then cooled to 0-5 °C.
  • the reaction was slowly quenched with water.
  • the aqueous mixture was neutralized (pH 7.0) with dilute HCI and extracted with ether.
  • the organics were dried over MgSO and concentrated to afford a crude oil.
  • the oil was purified using silica gel chromatography (90%hexanes/10% EtOAc) to yield a total of 2.6 g of pure oil (53%).
  • Binding Assay The compounds were tested for their ability to bind to hRXR ⁇ using a
  • SPA Scintillation Proximity Assay
  • the RXR ⁇ ligand binding domain (LBD) was expressed in E. coli as an amino-terminal polyhistidine tagged fusion protein. The LBD was then labeled with biotin and immobilized on streptavidin-modified scintillation proximity beads. 9-cis[3H]-Retinoic acid (9-cis) was the radioligand used for the assay. To each well to be assayed was added the desired concentration of the previously prepared solution of 9-cis previously incubated with receptor-coated SPA bead slurry.
  • the plates were incubated for at least 1 hour at room temperature and bound radioactivity for each well was determined in a Wallac 1450 Microbeta counter.
  • Transfection mixes contained 4 ng of receptor expression vector, 8 ng of reporter plasmid, 25 ng of ⁇ -galactosidase expression vector (used as an internal control), and 43 ng of carrier plasmid. Transfections were performed with Lipofectamine according to the manufacturer's instructions. Drug dilutions were prepared in phenol red-free DMEM/F-12 with 15 mM HEPES supplemented with 10% charcoal-stripped, delipidated calf serum. Cells were incubated for 24 h in the presence of drugs, after which the medium was sampled and assayed for SPAP activity.
  • B-galactosidase which measures transfection efficiency activity, was determined by using 3.6 mM o-nitrophenyl-D-galactopyranoside in 0.1 M sodium phosphate pH 7.2 buffer containing 0.13% Triton X-100 as substrate. These plates were read on a Molecular Devices Vmax spectrophotometer, at a 405nm endpoint reading. Data were reduced using RoboFit.
  • pEC 50 values were > 6.0 for all examples with the exception of Examples 13, 18, and 19, which each had pEC 50 ⁇ 6.0.

Abstract

The present invention includes novel retinoid compounds that have selectivity as RXR agonists on one or more isoforms of RXR, currently, RXRα RXRβ, or RXRϜ. The present compounds, an d ph armaceutical compositions incorporating these compounds, therefore, are effective in treating conditions mediated by RXRs. Among other physiological responses, the compounds of the present invention reduce blood glucose and maintain body weight, and, thus, are useful for the treatment of diabetes (NIDDIM) and obesity

Description

Selective RXR Ligands
Field of the Invention The present invention generally relates to compounds interacting with retinoid binding proteins, and more particularly to compounds that interact selectively with retinoid X receptors ("RXRs") as well as methods for their production and therapeutic use.
Background of the Invention Retinoids, both natural and synthetic, are derivatives of vitamin A. Retinoids have been recognized to induce a broad spectrum of biological effects. Thus, retinoid therapy ranges from therapeutic treatments for dermatological conditions, such as acne and psoriasis, to the treatment of metabolic disorders. In addition, RXR selective compounds are believed to be useful for the treatment and prevention of skin diseases, actinic keratoses, arsenic keratoses, inflammatory and noninflammatory acne, psoriasis, ichthyoses, keratinization and hyperproliferative skin disorders, eczema, atopic dermatitis, Darrier's disease, lichen planus, steroid atrophy, topical microbial infections, skin photodamage, type II diabetes, eye disease, retinal detachment, dry eye, comeopathies, cardiovascular disease, dyslipidemias, post-angioplasty restenosis, HPV infections, genital warts, inflammatory disease, ileitis, colitis, Crohn's disease, neurodegeneration, Alzheimer's disease, Parkinson's disease, stroke, pituitary dysfunction, growth hormone deficiency, hair loss, organ rejection, immune disorders, wounds, as well as a variety of cancerous and pre-cancerous conditions, such as acute promyleocytic leukemia, cutaneous T-cell lymphoma, epithelial cancers, squamous cell carcinoma, and breast cancer, as well as in the treatment of hyperthyroidism, dyslipidemia, and hypertension. See, e.g, WO 9712853, WO 0026173, WO 9321146, WO 9504036, WO 0020397, WO 0020370, WO 9845242, EP 0790228, EP 0933350, WO 9908992, WO 9420093, WO 9417796, WO 9639374, EP 0933350, WO 9710819, WO 9963980, WO 9958487, WO 995848, WO 0001679 and Vuligonda et al., Bioorg. Med. Chem. Lett., 9:589-594 (1999).
Retinoids regulate the activity of two distinct nuclear receptor families, the retinoic acid receptors ("RAR") and the retinoid X receptors ("RXR"). As with the RAR subfamily (currently including α, β, and γ isoforms), the RXR subfamily (currently including α, β, and γ isoforms) are recognized as ligand-induced transcription factors. Nevertheless, RARs and RXRs diverge in their primary structure and have only a 27% homology in the ligand binding domains. Thus, these structural differences provide for relative degrees of responsiveness among different retinoids. For example, certain retinoids have been identified that show selective binding to RXRs, but only a weak affinity for RARs. See, e.g., Lala et al., Nature, 83, 450-453 (1996). Furthermore, RARs and RXRs have distinct differences in their tissue distribution. RARs are expressed at high levels in visceral tissues, whereas RXRα is most abundant in the liver, kidney, lung, muscle, and intestine. Thus, while the subfamilies are related, each elicits distinct physiological responses apart from the other. Therefore, retinoids that are selective for either RARs or RXRs would provide for the independent control of the physiological responses mediated by the particular receptors. In addition, RXR dimerizes with many nuclear receptors (e.g., RAR, LXR, VDR, FXR, PPAR, and TR), as well as with itself to form a homodimer. Thus, retinoids that preferentially affect the RXR receptor, may additionally exhibit selectivity for specific heterodimer pairs as well.
Summary of the Invention The present invention includes novel retinoid compounds that have selectivity as RXR agonists on one or more isoforms of RXR, namely, RXRα, RXRβ, or RXRγ. The present compounds, and pharmaceutical compositions incorporating these compounds, therefore, are effective in treating conditions mediated by RXRs. Among other physiological responses, the compounds of the present invention reduce blood glucose and maintain body weight, and, thus, are useful for the treatment of diabetes (particularly type II diabetes, or NIDDIM) and obesity. The present invention also includes methods of producing the compounds and methods for the therapeutic use of these novel retinoids and their pharmaceutical compositions.
The present invention includes compounds of Formula I:
Figure imgf000003_0001
including salts, solvates, and physiologically functional derivatives thereof, wherein the broken lines represent optional double bonds; X is CR1 or N, where R1 is halogen, H, or CH3; Z is O, S, or NH; M is N, C, or CR2, when M is N, the A ring is non-aromatic, when M is C, the A ring is aromatic, when M is CR2, then R2 is H or - Y(CH2)nR6, and the A ring is non-aromatic; Y is O or CH2; when n is 0 to 6, R6 is H, alkyl, or CF3, but when n is 2 to 5, R6 is H, alkyl, CF3, SO2NHR23, NHSO2R23, or NR23R24, where R23 is alkyl, aryl optionally substituted, heteroaryl optionally substituted or combined with R24 to form a ring of 3 -7 atoms; and R24 is H, alkyl, cycloalkyl or combined with R23 to form a ring of 3 to 7 atoms; G is CO2R7, SQR7, PO3R7, CONHOH, or
Figure imgf000004_0001
where the broken line represents an optional double bond; J is CHO, CO2R7, SQR7, PO3R7, CONHOH, or J forms a thiazolidinedione ring with R8; R7 is H or alkyl; R8 and R9 are independently H, halogen, alkyl, or CF3; y and z are each 0, 1 , or 2; Q is CR4, CR4R5, O, NR10, or S, where R4 and R5 are independently H or alkyl, provided that when Q is CR4, the A ring is aromatic; R10 is alkyl, COR11, CONHR11, CO2R11, CONR11R12, SO2R11, aryl, or cycloalkyl; R 1 and R12 are independently alkyl or cycloalkyl; R3 is
Figure imgf000004_0002
wherein D is CR13R14, O, S, NR15, CHOH, CO, SO, SO2, where R13 and R14 are independently H, alkyl, or cycloalkyl; and where R15 is H, alkyl, or cycloalkyl; R16 and R17 independently are H, C1-4 alkyl, cycloalkyl, or together form a carbocyclic ring having from 3 to 7 atoms; R18 is H, OR6, halogen, CF3, alkenyl, SR16, C alkyl, CO2R16, COR11, or NR16R17, where R16 and R17 are as above defined; m is 0 or 1 ; or R3 is
Figure imgf000004_0003
where R18 is as defined above; or R3 is
Figure imgf000005_0001
where M2 is C or N, provided however that the optional double bond represented by the broken line is optionally present only when M2 is C; each R19 is, independently, H or alkyl; y and z are as defined above; or R3 is
Figure imgf000005_0002
where each R18 is, independently, as defined above; and M3 is C-(R16)3 or N-(R16)2, when M3 is N-(R16)2, an R16 may combine with an R18 to form a 5- or 6-membered ring.
Preferably when either R4 or R5or both are alkyl, said alkyl is C1-5 alkyl; when R6 is alkyl, said alkyl is C1-6 alkyl; when R7 is alkyl, said alkyl is C1-5 alkyl; when either R8 or R9 or both are alkyl, said alkyl is C1-3 alkyl; when R10 is alkyl, said alkyl is C1-6 alkyl; when either R11 or R12or both are alkyl, said alkyl is C1-5 alkyl; when either R13 or R14or both are alkyl, said alkyl is C1-3 alkyl; when R 5 is alkyl, said alkyl is CM alkyl; when either R16 or R17or both are alkyl, said alkyl is C1-4 alkyl; when R18 is alkenyl, said alkenyl is C1- alkenyl; when R18 is alkyl, said alkyl is C1-4 alkyl; when R 9 is alkyl, said alkyl is C1-4 alkyl; when R23 is alkyl, said alkyl is C1-6 alkyl; and when R24 is alkyl, said alkyl is C1-7 alkyl.
Preferably, X is CH, Z is O, Q is CH2, M is CH, G is
Figure imgf000005_0003
J is CO2H, y and z are each 1 , R8 and R9 are H; the double bond exists, and the olefin geometry is trans. In one embodiment preferably R is
Figure imgf000006_0001
) where D is CR13R14; R13, R14, R16, and R17 are each methyl; and R18 is H. Particularly preferred compounds of formula (I) include: (2E)-3[4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)tetrahydro-1- benzofuran-2-yl]-2-propenoic acid;
(2E)-3-[4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7- tetrahydro-1 -benzofuran-2-yl]-2-propenoic acid;
(2E)-3-[4-(3-methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7- tetrahydro-1-benzofuran-2-yl]-2-propenoic acid;
(2E)-3-[4-(5,5,8,8-tetramethyl-3-propoxy-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7- tetrahydro-1 -benzofuran-2-yl]-2-propenoic acid;
(2E)-3-[6-methyl-4-(5,5,8,8,-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7- tetrahydro[2,3-c]pyridin-2-yl]-2-propenoic acid; (2E)-3-[4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-1-benzofuran-2-yl]-
2-propenoic acid;
(2E)-3-[4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-
1 -benzothien-2-yl]-2-propenoic acid;
(2E)-3-[4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro- 1 ,3-benzoxazol-2-yl]-2-propenoic acid;
(2E)-3-(4-{[(2,6,6-trimethylcyclohexen-1-yl)methyl]amino}benzofuran-2-yl)-2- propenoic acid;
(2E)-3[4-(4-lsopropoxy-1-naphthalenyl)tetrahydro-1-benzofuran-2-yl]-2-propenoic acid; (2E)-3-{4-[4-Dimethylamino)-3-ethylphenyl]-4,5,6,7-tetrahydro-1-benzofuran-2-yl}-2- propenoic acid;
(2E)-3-{4-[(E)-2-(2,6,6-Trimethyl-1 -cyclohexen-1 -yl)ethenyl]-1 -benzofuran-2-yl}-2- propenoic acid;
4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1- benzofuran-2-carboxylic acid;
[4-(5,5,8,8,-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1- benzofuran]-2-(2,4-thiazolidinedione); [4-(5,5,8,8,-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1- benzothiaphene]-2-propionic acid;
4-(5,5,8,8,-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1- benzofuran]-2-(2,3(cis)propenoic acid; (2E)-3-{4-[7-Dimethylamino)-1 -methyl-2,3-dihydro-1 H-indol-5-yl]-4,5,6,7-tetrahydro-1 - benzofuran-2-yl}prop-2-enoic acid;
(2E)-3-[4-butyl-4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-4,5,6,7- tetrahydro-1-benzofuran-2-yl]prop-2-enoic acid; and salts, solvates, or pharmaceutically functional derivatives thereof. The present invention also includes compounds of formula II:
Formula
Figure imgf000007_0001
including salts, solvates, and pharmaceutically functional derivatives thereof, wherein X is CR1 or N, where R1 is halogen, H, or CH3; Z is O, S, or NH; G is CO2R7, SQR7, PO3R7, CONHOH, or
Figure imgf000007_0002
where the broken line represents an optional double bond; J is CHO, CO2R7, SQR7, PO3R7, CONHOH, or J forms a thiazolidinedione ring with R8; R7 is H or C1-5 alkyl; R8 and R9 are independently H, halogen, C1-3 alkyl, or CF3; y and z are each 0, 1 , or 2; R3 is
Figure imgf000007_0003
wherein D is CR13R14, O, S, NR15, CHOH, CO, SO, SO2, where R13 and R14 are independently H, C1-3 alkyl, or cycloalkyl; and where R15 is H, C1-4 alkyl, or cycloalkyl; R16 and R17 independently are H, CM alkyl, cycloalkyl, or together form a carbocyclic ring having from 3 to 7 atoms; R18 is H, OR6, halogen, CF3, alkenyl, SR16, Q^ alkyl, CO2R16, COR11, or NR16R17, where R16 and R17 are as above defined; m is 0 or 1 ; R11 is C1-5 alkyl, or cycloalkyl; or R3 is
Figure imgf000008_0001
where R is as defined above; or R is
Figure imgf000008_0002
where M2 is C or N, provided however that the optional double bond represented by the broken line is optionally present only when M2 is C; R19 is H or C1-4 alkyl; or R3 is
Figure imgf000008_0003
where R18 is as defined above; and M3 is C-(R16)3 or N-(R16)2, when M3 is N-(R16)2, an R16 may combine with an R18 to form a 5- or 6-membered ring; R20 is H or C1-4 alkyl; R21 is H, OR6, where R6 is as defined for Formula I, or may combine with R22 to form a carbonyl; and R22 is H, or may combine with R21 to form a carbonyl.
Preferably, X is C, R1 is H, Z is O, R20 is -CH3, R21 and R22 are each H, G is
Figure imgf000008_0004
J is CO2H, R8 and R9 are each H, y and z are each 1 , the double bond exists, and the olefin geometry is trans.
In one embodiment preferably R3 is
Figure imgf000009_0001
where D is CR13R14; R13, R 4, R16, and R17 are each methyl; and R18 is H. Particularly preferred compounds of formula II include:
(2E)-3-{4-[(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-2-furyl}-2- propenoic acid;
(2E)-3-{4-[(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-2-thienyl}-
2-propenoic acid;
(2E)-3-{4-[(3-Methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-
2-furyl}-2-propenoic acid; (2E)-3-{5-Methyl-4-[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-2- furyl}-2-propenoic acid; and salts, solvates, or pharmaceutically functional derivatives thereof.
Another aspect of the present invention includes pharmaceutical compositions that include compounds of formula I or II along with one or more of a pharmaceutically acceptable carrier.
Another aspect of the present invention includes methods for treating, including treatment and prophylaxis, a disorder in a mammal, wherein the disorder is characterized by the need for retinoid therapym through the administration to the mammal an effective amount of a compound of formula I or II. Particular disorders characterized by the need for retinoid therapy and therefore included herein, but without exclusion, include metabolic conditions and disorders, dermatological conditions, cancerous and pre-cancerous conditions, hyperthyroidism, dyslipidemia, and hypertension. Preferably the disorder is diabetes or obesity.
Another aspect of the present invention includes compounds of formulas I or II for use as an active therapeutic substance. Preferably such use is for retinoid therapy.
Another aspect of the present invention includes compounds of formula I or II for use in the treatment or prophylaxis of diabetes or obesity.
Another aspect of the present invention includes the use of a compound of formulas I or II in the manufacture of a medicament for use in retinoid therapy, preferably for use in the treatment or prophylaxis of diabetes or obesity. Another aspect of the present invention includes compounds of formulas I or
II substantially as herein described with reference to any of the Examples.
Another aspect of the present invention includes a method for manufacturing a retinoid comprising: a) reacting a compound of Formula III, Formula IV, a combination of Formulas
III and IV, or Formula XVII, with one of a compound of Formulas V, VI, or VII:
Figure imgf000010_0001
Formula
Figure imgf000010_0002
Figure imgf000010_0003
Formula XVII
Figure imgf000010_0004
Figure imgf000010_0005
Formula VI Formula VII wherein, X is CR1 or N, where R1 is halogen, H, or CH3; Z is O, S, or NH; Q is CR4, CR4R5, O, NR10, or S, where R4 and R5 are independently H or C1-5 alkyl, provided that when Q is CR4, the A ring is aromatic; R 0 is C1-6 alkyl, COR11, CONHR11, CO2R11, CONR11R12, SO2R11, aryl, or cycloalkyl; R11 and R12 are independently C1-5 alkyl or cycloalkyl; E is Br or I; D is CR13R14, O, S, NR15, CHOH, CO, SO, SO2, where R13 and R14 are independently H, C -3 alkyl, or cycloalkyl; and where R15 is H, C1- alkyl, or cycloalkyl; R16 and R17 independently are H, C1-4 alkyl, cycloalkyl, or together form a carbocyclic ring having from 3 to 7 atoms; R18 is H, OR6, halogen, CF3, alkenyl, SR16, C1-4 alkyl, CO2R16, COR11, or NR16R17, where R16 and R17 are as above defined; R 9 is H or alkyl; m is 0 or 1 ; and M3 is C-(R16)3 or N-(R16)2, when M3 is N- (R16)2, an R16 may combine with an R18 to form a 5- or 6-membered ring; b) generating an organometallic species from the product of step (a) via Grignard or metal halogen exchange reaction; c) condensing the organometallic species produced in step (b); d) reducing or oxidizing the condensed product produced in step (c); e) deprotonating the product of step (d) via organolithiums; f) formylating the deprotonated product produced in step (e); and g) treating the formylated product with a stabilized Wittig reagent and subsequent aqueous basic hydrolysis, to form a compound having activity for a retinoid receptor.
Brief Description of the Preferred Embodiment The term "alkyl" represents a straight or branched alkyl group, preferably having the specified number of carbon atoms. Typical alkyl groups include, but are not limited to methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, and the like.
The term "alkenyl" represents an olefinically unsaturated branched or straight group having the specified number of carbon atoms and at least one double bond. Examples of such groups include, but are not limited to vinyl, 1 -propenyl, allyl, 1- butenyl, hexenyl, and the like.
The term "cycloalkyl" represents a saturated carbon chain forming a ring and includes, but should not be limited to cyclopropyl, cyclobutyl, cyclopentyl, and the like.
The term "carbocyclic" represents a homocyclic carbon ring system, for example, a benzene ring or naphthalene ring.
The term "aryl" represents cyclic aromatic groups that may include one or more heteroatoms, such as, without limitation, phenyl, pyridyl, furanyl, and the like. The term "halogen" includes fluorine, chlorine, bromine, or iodine.
The term "carbonyl" refers to the group -C(O)-. In the case of the present invention where R21 and R22 combine to form a carbonyl the following example compounds are referred to:
Figure imgf000011_0001
The term "thiazolidinedione," with reference to when J combines with R8 refers to the following:
Figure imgf000012_0001
Some of the compounds of the present invention may contain one or more chiral centers and therefore may exist in enantiomeric and diastereomeric forms. Although particularly preferred compounds of the present invention include a defined stereochemistry, the scope of the present invention is intended to cover all isomers per se, as well as mixtures of cis and trans isomers, mixtures of diastereomers, and racemic mixtures of enantiomers as well.
When referred to herein, compounds of the present invention include compounds within the scope of both formula (I) and formula (II) as defined above unless specifically limited by the definition of each formula or specifically limited otherwise. The preferred embodiments of the present invention described herein, including uses and compositions, when applicable, apply to both formula (I) and formula (II).
As noted above, the present invention includes salts, solvates, and physiologically functional derivatives of the compounds of the present invention.
Salts include addition salts, metal salts, or optionally alkylated ammonium salts, such as hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, trifluoroacetic, trichloroacetic, oxalic, maleic, pyruvic, malonic, succinic, citric, mandelic, benzoic, cinnamic, methane sulphonic, ethane sulphonic, picric and the like. Salts also include acids related to the salts listed within Journal of Pharmaceutical Science 1997, 66, 2 , incorporated herein by reference as relevant to salts. Further acceptable salts include lithium, sodium, potassium, magnesium, and the like.
As used herein, the term "solvate" refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of formula I or II, or a salt or physiologically functional derivative thereof) and a solvent. Such solvents, for the purpose of the invention, should not interfere with the biological activity of the solute. Non-limiting examples of suitable solvents include, but are not limited to water, methanol, ethanol, and acetic acid. Preferably the solvent used is a pharmaceutically acceptable solvent. Non-limiting examples of suitable pharmaceutically acceptable solvents include water, ethanol, and acetic acid. Most preferably the solvent used is water. As used herein, the term "physiologically functional derivative" refers to any pharmaceutically acceptable derivative of a compound of the present invention; for example, an ester or an amide, which upon administration to a mammal is capable of providing (directly or indirectly) a compound of the present invention or an active metabolite thereof. Such derivatives will be clear to those skilled in the art, without undue experimentation, and with reference to the teaching of Burger's Medicinal Chemistry And Drug Discovery, 5th Edition, Vol 1 : Principles and Practice, which is incorporated herein by reference to the extent that it teaches physiologically functional derivatives. As used herein, the term "effective amount" means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal, or human that is being sought, for instance, by a researcher or clinician. Furthermore, the term "therapeutically effective amount" means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder. The term also includes within its scope amounts effective to enhance normal physiological function. A therapeutically effective amount of a compound of the present invention will depend upon a number of factors including, for example, the age and weight of the animal, the precise condition requiring treatment and its severity, the nature of the formulation, and the route of administration. Therapeutic effectiveness ultimately will be at the discretion of the attendant physician or veterinarian. Generally, however, an effective amount of a compound of formula (I) or (II) for RXR mediated diseases and conditions should be in the range of about 0.1 to about 100 mg/kg body weight of recipient (mammal, preferably human) per day. Preferably the effective amount will be in the range of 0.5 to 10 mg/kg body weight per day. More preferably in the range of about 1 to 5 mg/kg body weight per day. An effective amount of a salt or solvate, or physiologically functional derivative thereof, may be determined as a proportion of the effective amount of the compound of formula (I) or (II) per se.
As noted earlier, RXR selective ligands are believed useful for a variety of diseases and conditions, including but not limited to treatments for metabolic conditions and disorders, dermatological conditions such as acne and psoriasis, the treatment and prevention of a variety of cancerous and pre-cancerous conditions such as acute promyleocytic leukemia, cutaneous T-cell lymphoma, epithelial cancers, squamous cell carcinoma, and breast cancer, as well as in the treatment of hyperthyroidism, dyslipidemia, and hypertension.
While it is possible that compounds of the present invention may be therapeutically administered as the raw chemical, it is preferable to present the active ingredient as a pharmaceutical formulation. Accordingly, the scope of the present invention further includes pharmaceutical formulations including compounds of Formula I or Formula II, or pharmaceutically acceptable salts or solvates thereof, with one or more pharmaceutically acceptable carrier. Optionally, other therapeutic and/or prophylactic ingredients may be included in any pharmaceutical formulation. Formulations of the present invention include those especially formulated for oral, buccal, parental, transdermal, inhalation, intranasal, transmucosal, implant, or rectal administration. Among the variety of administrations, oral administration typically is preferred. For buccal administration, the formulation may take the form of tablets or lozenges formulated in conventional manner. For oral administration tablets, capsules, and caplets may contain conventional excipients such as binding agents, fillers, lubricants, disintegrants, and/or wetting agents. Non-limiting examples of binding agents include syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of starch, or polyvinylpyrrolidone. Non-limiting examples of fillers include, for example, lactose, sugar, microcrystalline cellulose, maize-starch, calcium phosphate or sorbitol. Non-limiting examples of lubricants include, for example, magnesium sterate, stearic acid, talc, polyethylene glycol or silica. Non-limiting examples of disintegrants include, for example, potato starch or sodium starch glycollate. A non- limiting example of a wetting agent includes sodium lauryl sulfate. The tablets additionally may be coated according to methods known in the art. Alternatively, the compounds of the present invention may be incorporated into oral liquid preparations such as aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs. Moreover, formulations containing these compounds may be presented as a dry product for constitution with water or other suitable vehicle before use. Liquid preparations may contain conventional additives. Non- limiting examples of such additives include suspending agents such as sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminum sterate gel or hydrogenated edible fats. Additionally, emulsifying agents such as lecithin, sorbitan mono-oleate or acacia; non-aqueous vehicles (which may include edible oils) such as almond oil, fractionated coconut oil, oily esters, propylene glycol or ethyl alcohol my be included. Further, preservatives such as methyl or propyl p-hydroxybenzoates or sorbic acid, may be incorporated into the preparation. Such preparations may also be formulated as suppositories, for example, containing conventional suppository bases such as cocoa butter or other glycerides.
Additionally, formulations of the present invention may be formulated for parenteral administration by injection or continuous infusion. Formulations for injection may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, for example, sterile, pyrogen-free water, before use.
The formulations according to the invention may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation, for example, subcutaneously or intramuscularly, or by intramuscular injection. Accordingly, the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials, such as an emulsion in an acceptable oil, ion exchange resins, or as sparingly soluble derivatives, such as a sparingly soluble salt.
The formulations according to the invention may contain between about 0.1- about 99% of the active ingredient. Pharmaceutical formulations may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose. Such a unit may contain certain amounts of a compound of formula (I) depending on the condition being treated, the route of administration and the age, weight and condition of the patient. Preferred unit dosage formulations are those containing a daily dose, or an appropriate fraction thereof, of an active ingredient. Such pharmaceutical formulations may be prepared by any of the methods well known in the pharmacy art.
General Synthetic Scheme In accordance with the present invention, compounds of Formula I can be prepared by reacting a compound of Formula III and/or Formula IV, with compounds of Formulas V, VI or VII, depending upon the desired value for R3, as is shown below:
Figure imgf000015_0001
wherein, as is relevant throughout this description, X, Z, and Q have the meanings as defined above for formula I;
Figure imgf000016_0001
Formula V Formula VI
wherein E represents either bromine, preferably, or iodine and, as is relevant throughout this description, wherein D, M3, R16, R17, and R18 are defined as above for formula I.
Condensation of the organometallic species, generated via Grignard or metal halogen exchange reaction, with formula III or formula IV produces the hydroxy compounds of formula VIII, XI or X, below:
Figure imgf000016_0002
Formula VIII Formula XI Formula X wherein K is H or CH3. Reducing conditions (preferably NaBH , BF3Εt2O or Et3SiH, TFA) generates the reduced compounds of formula XI, XII or XIII, shown below:
Figure imgf000016_0003
Formula XI Formula XI I Formula XI 11
Or alternatively, oxidizing conditions (preferably DDQ, dioxane, 100 °C) produces the compounds of Formula XI, XII and XIII whereby the A ring, as is defined in formula I, becomes aromatic. Deprotonation via organolithiums, (preferably with n-butyl lithium) followed by formylation, preferably with N,N- dimethylformamide, generates compounds of formula XIV, XV or XVI illustrated below:
Figure imgf000017_0001
Formula XIV Formula XV Formula XVI
Treatment of these compounds with a stabilized Wittig reagent, preferably triethylphosphonoacetate, followed by aqueous basic hydrolysis affords compounds of formula I.
Alternatively, when K is methyl, treatment of the compound of formula XI under brominating conditions (preferably NBS, AIBN, CCI4) followed by SN2 displacement, preferably with potassium acetate, generates the acetoxy compound. Basic hydrolysis (preferably K2CO3, H2O, MeOH) and oxidation (preferably TPAP, NMO, CH3CN) generates compounds of formula XIV that can then be converted to compounds of formula I as outlined above.
Compounds of formula II can be prepared by reacting a compound of Formula XVII, wherein X, Z, and R20 are defined as before, with compounds of Formula V, VI or VII, shown above, where E is as hereinabove defined.
Formula XVII
Figure imgf000017_0002
where L is CHO; CONMeOMe. Condensation of the appropriate organometallic species, generated via the Grignard or metal halogen exchange reaction, with formula XVII produces the hydroxy compound of formula XVIII or the ketone of formula XIX, each of which is shown below, where R3 is as defined above and is determined through respective choice of Formulas V, VI, and VII: Formula XVIII Formula XIX
Figure imgf000018_0001
Figure imgf000018_0002
Subsequent reduction (preferably NaBH4, BF3Εt2O or Et3SiH, TFA) followed by deprotonation via organometallics, preferably n-butyl lithium, and formylation, preferably N,N-dimethylformamide, generates compounds of formula XX.
Formula XX
Figure imgf000018_0003
Treatment of these compounds with a stabilized Wittig reagent (preferably triethylphosphonoacetate) followed by basic aqueous hydrolysis affords compounds of formula II.
Regarding compounds where R3 is
Figure imgf000018_0004
Examples 9 and 12, below, particularly demonstrate their manufacture. For example, Example 9:
Figure imgf000019_0001
1)ϋBH4, THF 1)BOC20,THF 2)Na0H(aq), heat' 2) Dess-Martin oxidation
Figure imgf000019_0003
Figure imgf000019_0002
2 7) LiO7H, THF), MeOH,
Figure imgf000019_0004
or Example 12:
1)DIBAL, CH2CI2
Figure imgf000019_0005
Figure imgf000019_0006
2) Mn02, CHCI3
Figure imgf000019_0007
2) t-BuLi, DMF, -78 °C
Figure imgf000019_0008
The following examples more particularly demonstrate the method of the present invention.
Examples The following examples illustrate this invention, but should not be construed as limitations. The abbreviations, symbols, and conventions used in these examples are consistent with those used in the contemporary chemical literature, for example, the Journal of the American Chemical Society, such as: THF: tetrahydrofuran CDCI3: deuterated chloroform Rt: room temperature Min: minutes
Hr: hours DME: dimethoxyethane
DMF: N,N-dimethylformamide EtOAc: ethyl acetate
TPAP: tetrapropylammonium peruthenate NaOH: sodium hydroxide
Et2O: diethyl ether MgSO4: magnesium sulfate DDQ: dichlorodicyanohydroquinone CH2CI2: dichloromethane
MeOH: methanol CH3CN: acetonitrile
CCI4: carbon tetrachloride NBS: N-bromosuccinimide
AIBN: azobisisobutyronitrile HCI: hydrochloric acid
NMO: N-methylmorpholine N-oxide K2CO3: potassium carbonate n-BuLi: n-butyl lithium EtOAc: ethyl acetate
Example 1
(2E)-3[4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)tetrahydro-1- benzofuran-2-yl]-2-propenoic acid A. 4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1 - benzofuran-4-ol
To a THF solution (200 mL) containing 6-bromo-1 ,1 ,4,4-tetramethyl- 1 ,2,3,4- tetrahydronaphthalene (43.2 g, 161.8 mmol) cooled to -78 °C was added 68.0 mL of a 2.5 M hexanes solution of n-BuLi (170.0 mmol). The resulting reddish-orange solution stirred for 30 min when 6,7-dihydro-4(5H)-benzofuranone (20.0 g, 147.0 mmol) in 100 mL of THF was added. After stirring for 45 min the reaction was quenched with H2O. Upon warming the solution was poured into additional H2O and the organics were extracted with Et2O. After drying over MgSO4 the solvent was removed in vacuo and the residual oil purified via column chromatography (hexanes/EtOAc (7:1 )) yielding 40.9 g (126.2 mmol, 86% yield) of compound A as white solid m.p. 55-57 °C. 1H NMR (CDCI3) 400 MHz δ 7.29 (d, 1 H, J = 2.0 Hz), 7.25 (d, 1 H, J = 1.6 Hz), 7.19 (d, 1 H, J = 8.2 Hz), 7.07 (dd, 1 H, J = 8.3 & 2.1 Hz), 6.15 (d, 1 H, J = 1.8 Hz), 2.71-2.62 (m, 2H), 2.05-2.00 (m, 3H), 1.92-1.78 (m, 2H), 1.63 (s, 4H), 1.26 (s, 6H), 1.23 (s, 3H), 1.20 (s, 3H) ppm.
B. 4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1- benzofuran
To a THF solution (100 mL) containing sodium borohydride (12.2 g, 324 mmol) cooled to 0 °C was added BF3Εt2O (69.0 g, 486 mmol). The resulting white slurry stirred for 10 min when compound A (described above) (10.5 g, 32.4 mmol) in 200 mL of THF was added. After 0 min the reaction mixture was very carefully poured into sat. NaHCO3. The solution was then poured into additional sat. NaHCO3 and the organics were extracted with Et2O. After drying over MgSO the solvent was removed in vacuo and the residual oil was purified via column chromatography (hexanes/EtOAc (19:1)) yielding 8.18 g (26.6 mmol, 82% yield) of compound B. 1H NMR (CDCI3) 400 MHz δ 7.26 (s, 1 H), 7.19 (d, 1H, J = 8.3 Hz), 7.07 (d, 1 H, J = 1.9 Hz), 6.89 (dd, 1 H, J = 8.1 & 1.8 Hz), 6.06 (d, 1 H, J = 1.6 Hz), 3.81 (m, 1 H), 2.69 - 2.66 (m, 2H), 2.08 (m, 1 H), 1.96-1.91 (m, 1 H), 1.80-1.76 (m, 1 H), 1.69- 1.64 (m, 5H), 1.30 (s, 6H), 1.27 (s, 3H), 1.23 (s, 3H) ppm.
C. [4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1- benzofuran]-2-carboxaldehyde.
To a THF solution (380 mL) containing compound B (30.4 g, 98.7 mmol) cooled to 0 °C was added 41.4 mL of a 2.5 M hexanes solution of n-BuLi (103.6 mmol). The yellow-orange solution stirred for 15 min at which time DMF (10.8 g, 148.0 mmol) was added at which point the solution turned nearly colorless. After 10 min the reaction was quenched with sat. NaHSO4, poured into additional sat. NaHSO4 and the organics extracted with Et2O. After drying over MgSO4the solvent was removed in vacuo and the residual yellow oil purified via column chromatography (hexanes/EtOAc (9:1)) affording 29.3 g (87.2 mmol, 88% yield) of compound C as a white solid m.p. 91-94 °C. H NMR (CDCI3) 400 MHz δ 9.45 (s, 1 H), 7.22 (d, 1 H, J = 8.1 Hz), 7.05 (d, 1 H, J = 1.8 Hz), 6.91 (s, 1 H), 6.85 (dd, 1 H, J = 8.2 & 2.0 Hz), 3.84 (m, 1 H), 2.80-2.78 (m, 2H), 2.17-2.11 (m, 1 H), 2.10-2.01 (m, 1 H), 1.88-1.82 (m, 1 H), 1.75-1.66 (m, 5H), 1.31 (s, 6H), 1.26 (s, 3H), 1.23 (s, 3H) ppm. D. Ethyl (2E)-3-[4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7- tetrahydro-1-benzofuran-2-yl]-2-propenoate.
To a DME solution (300 mL) containing sodium hydride (5.23 g, 130.8 mmol, 60% dispersion in mineral oil) was added tiethylphosphonoacetate (29.3 g, 130.8 mmol) at room temperature. To the resulting solution was added compound C (29.3 g, 87.2 mmol) in 100 mL of DME. The reaction stirred for 20 min at which time it was quenched with H2O. The solution was diluted with Et2O and the organic layer separated. The aqueous layer was extracted with Et2O and then the combined organic layers were dried over MgSO4. Removal of the solvent in vacuo and purification via column chromatography (hexanes/EtOAc (9:1)) yielded 32.3 g (80.7 mmol, 92% yield) of compound D as a light yellow foam m.p. 47-49 °C.
1H NMR (CDCIs) 400 MHz δ 7.32 (d, 1 H, J = 15.6 Hz), 7.20 (d, 1 H, J = 8.3 Hz), 7.05 (d, 1 H, J = 1.7 Hz), 6.86 (dd, 1 H, J = 8.0 & 1.9 Hz), 6.28 (s, 1H), 6.22 (d, 1H, J = 15.6 Hz), 4.22 (q, 2H, J = 7.2 Hz), 3.81-3.78 (m, 1 H), 2.73-2.71 (m, 2H), 2.11-2.00 (m, 1 H), 1.99-1.95 (m, 1 H), 1.83-1.79 (m, 1 H), 1.70-1.64 (m, 5H), 1.30 (t, 3H, J = 7.1 Hz), 1.26 (s, 6H), 1.22 (s, 3H), 1.19 (s, 3H) ppm.
The enantiomers were separated utilizing supercritical fluid chromatography with a chiralpak-AS column eluting with CO2/10%MeOH (containing 0.2% isopropylamine). The separated antipodes were taken directly into the ester hydrolysis step outlined below.
E. (2E)-3[4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl) tetrahydro-1 - benzofuran-2-yl]-2-propenoic acid.
To a dioxane solution (200 mL) containing compound D (30.5 g, 75.0 mmol) was added lithium hydroxide hydrate (31.5 g, 750 mmol) followed by 60 mL of H2O. After stirring overnight TLC showed some starting material left so the solution was heated at 60 °C for 3 hr. The solution was acidified with sat. NaHSO4, extracted with EtOAc and dried (MgSO4). The organics were then heated with Darco and the solution filtered through a bed of celite with the celite being rinsed thoroughly with EtOAc. The solvent was removed in vacuo and the residual light yellow solid triturated with hexanes and collected via vacuum filtration yielding 24.5 g (64.8 mmol, 86% yield) of compound E as a light yellow solid m.p. 210-213 °C decomp. 1H NMR (CDCI3) 400 MHz δ 7.39 (d, 1 H, J = 15.4 Hz), 7.21 (d, 1 H, J = 8.0 Hz), 7.05 (d, 1 H, J = 1.6 Hz), 6.86 (dd, 1 H, J = 8.2 & 1.8 Hz), 6.35 (s, 1 H), 6.21 (d, 1 H, J = 15.4 Hz), 3.82-3.79 (m, 1 H), 2.74-2.72 (m, 2H), 2.12-2.07 (m, 1 H, 2.00-1.98 (m, 1H), 1.81-1.70 (m, 1H), 1.67 (s(br), 5H), 1.26 (s, 6H), 1.22 (s, 3H), 1.19 (s, 3H) ppm.
The separated ethyl ester enantiomers (see above) were hydrolyzed using the aforementioned conditions yielding both the (+) and (-) enantiomers identical in all respects to racemic material, (+)-(2E)-3[4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro- 2-naphthalenyl)tetrahydro-1-benzofuran-2-yl]-2-propenoic acid and (-)-(2E)-3[4-
(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)tetrahydro-1-benzofuran-2-yl]- 2-propenoic acid.
Example 2 (2E)-3-[4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthaienyl)-4,5,6,7- tetrahydro-1-benzofuran-2-yl]-2-propenoic acid.
A. 4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1- benzofuran-4-ol.
To a THF solution (15 mL) containing 6-bromo-1 ,1 ,4,4,7-pentamethyl-1 ,2,3,4- tetrahydronaphthalene (2.48 g, 8.82 mmol) cooled to -78 °C was added 3.88 mL of a 2.5 M hexanes solution of n-Buϋ (9.70 mmol). After 10 min 6,7 -dihydro-4(5H)- benzofuranone (1.0 g, 7.35 mmol) in 5 mL THF was added dropwise. The resulting amber solution stirred for 30 min at which time it was quenched with H2O. Upon warming the solution was poured into H2O and the organics were extracted with Et2O. After drying over MgSO4 the solvent was removed in vacuo and the residual oil purified via column chromatography (hexanes/EtOAc (9:1 )) affording 1.32 g (3.91 mmol, 53%) yield) of compound A as a white solid m.p. 122-124 °C.
1H NMR (CDCIs) 400 MHz δ 7.42 (s, 1 H), 7.27 (d, 1 H, J = 1.7 Hz), 7.00 (s, 1 H), 6.15 (d, 1 H, J = 1.9 Hz), 2.73 (m, 1 H), 2.63 (m, 1 H), 2.11-1.96 (m, 4H), 1.85 (m, 1 H), 1.66 (s, 4H), 1.25 (s, 6H), 1.22 (s, 6H) ppm.
B. 4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1- benzofuran.
To a THF solution (10 mL) containing sodium borohydride (749 mg, 19.8 mmol) cooled to 0 °C was added BF3Εt2O (4.22 g, 29.7 mmol). The resulting white slurry stirred for 30 min at 0 °C when compound A (668 mg, 1.98 mmol) in 10 mL of
THF was added. After 10 min the reaction mixture was carefully pored into sat.
NaHCO3. The 2-phase solution was then poured into additional sat. NaHCO3 and the organics were extracted with Et2O. After drying over MgSO4 the solvent was removed in vacuo and the residual oil purified via column chromatography (hexanes/EtOAc
(19:1 )) yielding 383 mg (1.19 mmol, 60% yield) of compound B as a white solid m.p.
68-71 °C.
1H NMR (CDCI3) 400 MHz δ 7.26 (d, 1 H, J = 1.5 Hz), 7.06 (s, 1 H), 6.85 (s,
1 H), 6.03 (d, 1 H, J = 1.9 Hz), 4.02 (m, 1 H), 2.33 (s, 3H), 2.71-2.66 (m, 2H), 1.92 (m, 1 H), 1.79 (m, 1 H), 1.66-1.54 (m, 6H), 1.27 (s, 6H), 1.15 (s, 3H), 1.12 (s, 3H) ppm.
C. 4-(3, 5,5,8, 8-pentamethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4, 5,6, 7-tetrahydro-1 - benzofuran-2-carbaldehyde.
To a Et2O solution (10 mL) containing compound B (813 mg, 2.32 mmol) cooled to -40 °C was added 2.46 mL of a 1.7 M pentane solution of t-BuLi (4.18 mmol). The resulting solution stirred for 10 min at which time DMF (340 mg, 4.65 mmol) was added. Upon warming to -20 °C (~ 10 min) the reaction was quenched with H2O. The solution was poured into additional H2O and the organics were extracted with Et2O. After drying (MgSO4) the solvent was removed in vacuo and the residual semi-solid purified via column chromatography (hexanes/EtOAc (9:1 )) yielding 508 mg (1.45 mmol) of compound C as a white solid, m.p. 126-128 °C plus 209 mg (0.65 mmol) of unreacted B (87% yield based on unreacted starting material).
1H NMR (CDCI3) 400 MHz δ 9.46 (s, 1 H), 7.08 (s, 1 H), 6.89 (s, 1 H), 6.78 (s, 1 H), 4.06 (m, 1 H), 2.83-2.79 (m, 2H), 2.33 (s, 3H), 2.12 (m, 1 H), 2.06 (m, 1 H), 1.86 (m, 1 H), 1 .67-1.61 (m, 5H), 1.28 (s(br), 6H), 1 .15 (s, 3H), 1 .11 (s, 3H) ppm.
D. Ethyl (2E)-3-[4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7- tetrahydro-1 -benzofuran-2-yl]2-propenoate. To a DME solution (5 mL) containing sodium hydride (86 mg, 2.16 mmol, 60% dispersion in mineral oil) was added triethylphosphonoacetate (484 mg, 2.16 mmol). After 10 min compound C ( 504 mg, 1.44 mmol) in 5 mL DME was added. The reaction stirred for 10 min at which time it was quenched with H2O. The solution was then poured into additional H2O and the organics were extracted with Et2O. After drying over MgSO the solvent was removed in vacuo and the residual oil purified via column chromatography (hexanes/EtOAc (19:1 )) yielding 541 mg (1.29 mmol, 89% yield) of compound D as a clear oil which solidified on standing m.p. 59-61 °C.
1H NMR (CDCI3) 400 MHz δ 7.32 (d, 1 H, J = 15.6 Hz), 7.06 (s, 1 H), 7.00 (s, 1H), 6.82 (s, 1 H), 6.24 (d, 1 H, J = 15.6 Hz), 4.22 (q, 2H, J = 7.2 Hz), 4.02 (m, 1 H), 2.77-2.71 (m, 2H), 2.32 (s, 3H), 2.08 (m, 1 H), 1.98 (m, 1 H), 1.81 (m, 1 H), 1.66-1.55 (m, 5H), 1.31 (t, 3H, J = 7.1 Hz), 1.27 (s, 6H), 1.15 (s, 3H), 1.11 (s, 3H) ppm.
E. (2E)-3-[4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7- tetrahydro-1-benzofuran-2-yl]-2-propenoic acid. To a dioxane solution (9 mL) containing compound D ( 527 mg, 1.26 mmol) was added lithium hydroxide hydrate ( 264 mg, 6.28 mmol) followed by 3 mL of H2O.
The reaction stirred overnight and was them acidified with sat. NaHSO4. The organics were extracted with EtOAc (2X), dried (MgSO4) and the solvent removed in vacuo. The residual oil was purified via column chromatography (CH2CI2/MeOH (15:1)) yielding 477 mg of a yellow foam which was triturated with hexanes and then collected via vacuum filtration affording 398 mg (1.02 mmol, 80% yield) of compound
E as light yellow solid m.p. 220-225 °C decomp.
1H NMR (CDCI3) 400 MHz δ 7.40 (d, 1 H, J = 15.5 Hz), 7.07 (s, 1 H), 6.82 (s,
1 H), 6.31 (s, 1 H), 6.23 (d, 1 H, J = 15.6 Hz), 4.00 (m, 1 H), 2.77-2.74 (m, 2H), 2.32 (s, 3H), 2.08 (m, 1 H), 1.98 (m, 1 H), 1.81 (m, 1 H), 1.66-1.56 (m, 5H), 1.27 (s, 6H), 1.15
(s, 3H), 1.11 (s, 3H) ppm.
Example 3 <
(2E)-3-[4-(3-methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7- tetrahydro-1 -benzofuran-2-yl]-2-propenoic acid.
A. 4-(3-methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7- tetrahydro-1 -benzofuran-4-ol.
To a THF solution (80 mL) containing 6-bromo-7-methoxy-1 , 1 ,4,4- tetramethyl-1 ,2,3,4-tetrahydronaphthalene (10.0 g, 33.7 mmol) cooled to -78 °C was added 15.4 mL of a 2.4 M hexanes solution of n-BuLi (37.0 mmol). The resulting solution stirred for 30 min at which time 6,7-dihydro-4(5H)-benzofuranone (4.35 g, 32.0 mmol) in 20 mL of THF was added. After 30 min the reaction was quenched with H2O. Upon warming the solution was poured into additional H2O and the organics were extracted with Et2O. After drying over MgSO4 the solvent was removed in vacuo and the residual yellow oil was purified via column chromatography (hexanes/EtOAc (9:1 )) yielding 5.41 g (15.3 mmol, 48% yield) of compound A as a white solid m.p. 124-127 °C.
1H NMR (CDCIs) 400 MHz δ 7.31 (d, 1 H, J = 1.8 Hz), 6.79 (s, 1 H), 6.77 (s, 1H), 6.32 (d, 1 H, J = 1.9 Hz), 4.74 (s, 1H), 3.89 (s, 3H), 2.68-2.56 (m, 2H), 2.14-2.11 (m, 2H), 1.96 (m, 1 H), 1.64-1.56 (m, 5H), 1.27 (s, 3H), 1.24 (s, 3H), 1.09 (s, 3H), 1.05 (s, 3H) ppm.
B. 4-(3-methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7- tetrahydro-1-benzofuran.
To a THF solution containing sodium borohydride (3.55 g, 93.8 mmol) cooled to 0 °C was added BF3Εt2O (20.0 g, 140.7 mmol). The resulting white slurry stirred for 5 min when compound A (3.32 g, 9.38 mmol) in 60 mL of THF was added. The reaction stirred for 10 min at 0 °C when it was carefully poured into sat. NaHCO3. This solution was then pored into Et2O and the organic layer separated. After drying over MgSO4 the solvent was removed in vacuo and the residual oil purified via column chromatography (hexanes/EtOAc (19:1)) yielding 2.65 g (7.84 mmol, 84% yield) of compound B as a white solid m.p. 94-96 °C.
1H NMR (CDCI3) 400 MHz δ 7.24 (d, 1 H, J = 1.5 Hz), 6.81 (s, 1 H), 6.73 (s, 1H), 6.04 (d, 1H, J = 1.5 Hz), 4.21 (m, 1H), 3.82 (s, 3H), 2.66-2.61 (m, 2H), 2.05 (m, 1 H), 1.84-1.73 (m, 2H), 1.66-1.56 (m, 5H), 1.27 (s, 3H), 1.26 (s, 3H), 1.11 (s, 3H), 1.10 (s, 3H) ppm.
C. 4-(3-methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7- tetrahydro-1 -benzofuran-2-carbaldehyde.
To a Et2O solution (20 mL) containing compound B (2.77g, 8.19 mmol) cooled to -40 °C was added 12.0 mL of a 1.7 M pentane solution of t-BuLi (20.5 mmol). The resulting yellow solution stirred for 30 min when DMF (1.50 g, 20.5 mmol) was added. The reaction slowly warmed to -20 °C over 20 min and was quenched with H2O. The solution was poured into additional H2O and the organics extracted with Et2O. After drying over MgSO4 the solvent was removed in vacuo and the residual oil purified via column chromatography (hexanes/EtOAc (4:1)) yielding 1.64 g (4.48 mmol, 55% yield of compound C as a viscous oil which solidified on standing m.p. 58-60 °C. 1H NMR (CDCI3) 400 MHz δ 9.45 (s, 1 H), 6.92 (s, 1 H), 6.78 (s, 2H), 4.27 (m, 1 H), 3.83 (s, 3H), 2.80-2.76 (m, 2H), 2.08 (m, 1 H), 1.96 (m, 1 H), 1.85 (m, 1 H), 1.74- 1.61 (m, 5H), 1.26 (s, 6H), 1.14 (s, 3H), 1.12 (s, 3H) ppm.
D. Ethyl (2E)-3-[4-(3-methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)- 4,5,6,7-tetrahydro-1-benzofuran-2-yl]-2-propenoate.
To a DME solution (10 mL) containing sodium hydride (269 mg, 6.72 mmol, 60% dispersion in mineral oil) was added triethylphosphonoacetate (1.51 g, 6.72 mmol). After 5 min compound C (1.64 g, 4.48 mmol) in 10 mL DME was added. After 15 min the reaction was quenched with H2O and the organics were extracted with Et2O. Upon drying over MgSO4 the solvent was removed in vacuo and the residual oil purified via column chromatography (3% EtOAc/hexanes) affording 1.40 g (3.20 mmol, 71 % yield) of compound D as an oil which solidified on standing m.p. 67-69 °C. 1H NMR (CDCI3) 400 MHz δ 7.32 (d, 1 H, J = 15.5 Hz), 6.78 (s, 1 H), 6.74 (s,
1H), 6.27 (s, 1 H), 6.21 (d, 1 H, J = 15.6 Hz), 4.23-4.18 (m, 3H), 3.81 (s, 3H), 2.71- 2.66 (m, 2H), 2.05 (m, 1 H), 1.86 (m, 1 H), 1.79-1.58 (m, 6H), 1.31-1.27 (m, 9H), 1.11 (s, 3H), 1.10 (s, 3H) ppm.
E. (2E)-3-[4-(3-methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-
4,5,6,7-tetrahydro-1 -benzofuran-2-yl]-2-propenoic acid.
To a dioxane solution (10 mL) containing compound D (1.32 g, 3.04 mmol), was added 3 mL H2O and lithium hydroxide hydrate (1.28 g, 30.4 mmol) at room temperature. After 2 days the reaction was acidified with sat. NaHSO4 and the organics extracted with EtOAc. After drying over MgSO4 the solvent was removed in vacuo and the residual yellow oil was purified via column chromatography
(CH2CI2/MeOH (15:1 )) yielding 922 mg (2.26 mmol, 74% yield, recrystallized from hexanes) of compound E as a white solid m.p. 231-233 °C.
1H NMR (CDCI3) 400 MHz δ 7.42 (d, 1 H, J = 15.3 Hz), 6.80 (s, 1 H), 6 76 (s, 1 H), 6.36 (s, 1 H), 6.23 (d, 1 H, J = 15.6 Hz), 4.22 (m, 1 H), 3.38 (s, 3H), 2.74-2.70 (m,
2H), 2.08 (m, 1 H), 1.19 (m, 1 H), 1.81 (m, 1 H), 1.68-1.61 (m, 6H), 1.29 (s, 6H), 1.14
(s, 3H), 1.12 (s, 3H) ppm.
Example 4 (2E)-3-r4-(5,5,8,8-tetramethyl-3-propoxy-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7- tetrahydro-1-benzofuran-2-yl]-2-propenoic acid.
A. 4-(5,5,8,8-tetramethyl-3-propoxy-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7- tetrahydro-1-benzofuran-4-ol. To a THF solution (50 mL) containing 6-bromo-1 ,1 ,4,4-tetramethyl-7-propoxy-
1 ,2,3,4-tetrahydronaphthalene (4.29 g, 13.2 mmol) cooled to -78 °C was added 5.3 mL of a 2.6 M heptane solution of n-BuLi (13.9 mmol). After 30 min 6,7-dihydro- 4(5H)-benzofuranone (1.62 g, 11.9 mmol) in 12 mL of THF was added. The resulting solution stirred for 1h and was then quenched with H2O, poured into additional H2O and the organics extracted with Et2O. After drying over MgSO the solvent was removed in vacuo and the residual oil purified via column chromatography (hexanes/EtOAc (6:1 )) yielding 2.1 g (5.50 mmol, 46% yield) of compound A as a white solid m.p. 139-142 °C.
1H NMR (CDCI3) δ 7.30 (d, 1 H, J = 1.7 Hz), 6.79 (s, 1 H), 6.77 (s, 1 H), 6.31 (d, 1 H, J = 1 .9 Hz), 4.81 (s, 1 H), 4.06-3.95 (m, 2H), 2.70-2.54 (m, 2H), 2.21-2.09 (m, 2H), 1.98 (m, 1 H), 1.88-1.80 (m, 2H), 1.65-1.58 (m, 5H), 1.26 (s, 3H), 1.23 (s, 3H), 1.09 (s, 3H), 1.07-1.04 (m, 6H) ppm.
B. 4-(5,5,8,8-tetramethyl-3-propoxy-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7- tetrahydro-1-benzofuran.
To a THF solution (20 mL) containing sodium borohydride (1.76 g, 46.7 mmol), cooled to 0 °C was added BF3-Et2O (9.94 g, 70.0 mmol). To the resulting white slurry was added compound A (1.78 g, 4.67 mmol) in 25 mL THF. After 10 min the solution was carefully poured into sat. NaHCO3. The two-phase solution was poured into additional sat. NaHCO3 and the organics were extracted with Et2O. After drying over MgSO4 the solvent was removed in vacuo and the residual oil purified via column chromatography (5% EtOAc/hexanes) affording 1.56 g (4.26 mmol, 91% yield) of compound B as a clear oil.
1H NMR (CDCI3) 400 MHz δ 7.23 (d, 1 H, J = 1.5 Hz), 6.81 (s, 1 H), 6.71 (s, 1H), 6.05 (d, 1 H, J = 1.7 Hz), 4.23 (m, 1 H), 3.93-3.88 (m, 2H), 2.66-2.60 (m, 2H), 2.05 (m, 1 H), 1.84-1.73 (m, 4H), 1.66-1.57 (m, 5H), 1.26 (s, 3H), 1.25 (s, 3H), 1.11 (s, 3H), 1.10 (s, 3H), 1.02 (t, 3H, J = 7.4 Hz) ppm.
C. 4-(5,5,8,8-tetramethyl-3-propoxy-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7- tetrahydro-1 -benzofuran-2-carbaldehyde. To a Et2O solution (10 mL) containing compound B (1.41 g, 3.86 mmol) cooled to -30 °C was added 3.4 mL of a 1.7 M pentane solution of t-BuLi (5.79 mmol). After 30 min DMF (423 mg, 5.79 mmol) was added. The reaction slowly warmed and after an additional 30 min it was quenched with H2O. The solution was then poured into additional H2O and the organics extracted with Et2O. After drying over MgSO the solvent was removed in vacuo and the residual oil purified via column chromatography (hexanes/EtOAc (9:1)) yielding 1.13 g (2.86 mmol, 74% yield) of compound C as a clear oil.
1H NMR (CDCI3) 400 MHz δ 9.43 (s, 1 H), 6.90 (s, 1 H), 6.76 (s, 1 H), 6.72 (s, 1 H), 4.23 (m, 1 H), 3.95-3.84 (m, 2H), 2.77-2.73 (m, 2H), 2.06 (m, 1 H), 1.94 (m, 1 H), 1.84-1.71 (m, 4H), 1.65-1.58 (m, 4H), 1.26 (s, 3H), 1.25 (s, 3H), 1.12 (s, 3H), 1.10 (s, 3H), 0.99 (t, 3H, J = 7.4 Hz) ppm.
D. Ethyl (2E)-3-[4-(5,5,8,8-tetramethyl-3-propoxy-5,6,7,8-tetrahydro-2-naphthalenyl)- 4,5,6,7-tetrahydro-1 -benzofuran-2-yl]-2-propenoate.
To a DME solution (10 mL) containing sodium hydride (156 mg, 3.89 mmol, 60% dispersion in mineral oil) was added triethylphophonoacetate (872 mg, 3.89 mmol), followed by compound C (1.02 g, 2.59 mmol) in 10 mL DME. After 15 min the reaction was quenched with H2O and the organics extracted with Et2O. After drying over MgSO the solvent was removed in vacuo and the residual oil purified via column chromatography (hexanes/EtOAc (19:1)) yielding 748 mg (1.61 mmol, 62% yield) of compound D as an oil which solidified on standing m.p. 52-54 °C.
1H NMR (CDCI3) 400 MHz δ 7.31 (d, 1 H, J = 15.7 Hz), 6.78 (s, 1 H), 6.71 (s, 1 H), 6.28 (s, 1 H), 6.20 (d, 1 H, J = 15.7 Hz), 4.23-4.17 (m, 3H), 3.93-3.85 (m, 2H), 2.70-2.66 (m, 2H), 2.03 (m, 1 H), 1.88 (m, 1 H), 1.79-1.69 (m, 2H), 1.68-1.57 (m, 6H), 1.28 (t, 3H, J = 7.2Hz), 1.26 (s, 3H), 1.25 (s, 3H), 1.11 (s, 3H), 1.10 (s, 3H), 1.01 (t, 3H, J = 7.4 Hz) ppm.
E. (2E)-3-[4-(5,5,8,8-tetramethyl-3-propoxy-5,6,7,8-tetrahydro-2-naphthalenyl)- 4,5,6,7-tetrahydro-1-benzofuran-2-yl]-2-propenoic acid.
To a dioxane solution (15 mL) containing compound D (1.02 g, 2.20 mmol) was added lithium hydroxide hydrate (924 mg, 22.0 mmol) followed by 5 mL of H2O. The reaction stirred for 2 days at which time it was acidified with sat. NaHSO4. The organics were extracted with EtOAc, dried (MgSO4) and the solvent removed in vacuo. The residual material was purified via column chromatography (CH2CI2/MeOH (15:1)) yielding 921 mg (2.11 mmol, 96% yield, recrystallized from hexanes) of compound E as a white solid, m.p. 195-196 °C.
1H NMR (CDCI3) 400 MHz δ 7.42 (d, 1 H, J = 15.5 Hz), 6.81 (s, 1 H), 6.74 (s, 1 H), 6.37 (s, 1 H), 6.22 (d, 1 H, J = 15.5 Hz), 4.23 (m, 1 H), 3.95-3.89 (m, 2H), 2.74- 2.70 (m, 2H), 2.08 (m, 1 H), 1.92 (m, 1 H), 1.83-1.69 (m, 2H), 1.67-1.60 (m, 6H), 1.28 (s, 3H), 1 .14 (s, 3H), 1.12 (s, 3H), 1.03 (t, 3H, J = 7.3 Hz) ppm.
Example 5 (2E)-3-[6-methyl-4-(5,5,8,8,-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7- tetrahydro[2,3-c]pyridin-2-yl]-2-propenoic acid.
A. Ethyl 4-hydroxy-4-(5, 5,8, 8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,7- dihydrofuro[2,3-c]pyridine-6(5H)-carboxylate.
To a THF solution (40 mL) containing 6-bromo-1 ,1 ,4,4-tetramethyl- 1 ,2,3,4- tetrahydronaphthalene (3.82 g, 14.3 mmol) cooled to -78 °C was added 6.0 mL of a 2.5 M hexanes solution of n-BuLi (15.0 mmol). After 30 min at -78 °C ethyl 4-oxo-4,7- dihydrofuro[2,3-c]pyridine-6(5H)-carboxylate (2.71 g, 13.0 mmol) in 40 mL of THF was added. The dark orange solution stirred for 1 h and was then quenched with H2O. The solution was then poured into additional H2O and the organics extracted with EtOAc. After drying over MgSO4the solvent was removed in vacuo and the residual oil purified via column chromatography (hexanes/EtOAc (7:3)) yielding 2.56 g (6.45 mmol, 50% yield) of compound A as a waxy solid m.p. 56-57 °C.
1H NMR signals were very broad due to rotomers however GC-MS showed 1 peak.
B. Ethyl 4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,7- dihydrofuro[2,3-c]pyridine-6(5H)-carboxylate.
To a THF solution (3 mL) containing sodium borohydride (297 mg, 7.86 mmol) was added BF3-Et2O (1.67 g, 11.8 mmol) at room temperature. The resulting white slurry stirred for 5 min when compound A (323 mg, 0.79 mmol) in 4 mL THF was added. After stirring for 1 h at room temperature, the solution was poured into sat. NaHCO3. The organics were extracted with Et2O, dried (MgSO4) and the solvent removed in vacuo. The residual foam was purified via column chromatography (hexanes/EtOAc (4:1 )) yielding 149 mg (0.38 mmol, 48% yield) of compound B as a white solid, m.p. 92-94 °C. 1H NMR signals were very broad due to rotomers, however GC-MS showed a single peak EI+ m/z 382. C. 6-Methyl-4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)- 4,5,6,7tetrahydrofuro[2,3-c]pyridine.
To a THF solution (10 mL) containing compound B (528 mg, 1.39 mmol) was added 3.5 mL of a 1.0M Et2O solution of LiAIH4 (3.5 mmol) at room temperature. The resulting solution was then heated to reflux for 30 min. Upon cooling to room temperature, the reaction was carefully quenched with 1 mL of 2.0 M NaOH. The heterogeneous solution then had MgSO4 added to it and was diluted with Et2O. The slurry was filtered through a bed of celite and rinsed thoroughly with Et2O. The filtrate was washed with 2.0 M NaOH, dried (MgSO4) and the solvent removed in vacuo. The residual oil was purified via column chromatography (hexanes/EtOAc (1 :1)) yielding 353 mg (1.10 mmol, 79% yield) of compound C as a clear oil.
1H NMR (CDCI3) 400 MHz δ 7.25 (d, 1 H, J = 1.4 Hz), 7.18 (d, 1 H, J = 8.1 Hz), 7.09 (d, 1 H, J = 1.9 Hz), 6.90 (dd, 1 H, J = 8.1 & 1.9 Hz), 6.10 (d, 1 H, J = 1.8 Hz), 3.97 (m, 1 H), 3.69 (d, 1 H, J= 14.4 Hz), 3.38 (dd, 1 H, J = 14.3 & 2.4 Hz), 2.99 (dd, 1 H, J = 11.6 & 5.1 Hz), 2.45 (2, 3H), 2.34 (dd, 1 H, J = 11.6 & 9.2 Hz), 1.65 (s, 4H), 1.24- 1.22 (m, 12H) ppm.
D. 6-Methyl-4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)'- 4,5,6,7tetrahydrofuro[2,3-c]pyridin-2-carbaldehyde.
To a Et2O solution (8 mL) containing compound C (350 mg, 1 .08 mmol) cooled to -40 °C was added 1.9 mL of a 1.7 M pentane solution of t-BuLi (3.25 mmol). The yellow solution was allowed to warm to -30 °C where it was held, and after 30 min DMF (237 mg, 3.24 mmol) was added. The reaction slowly warmed and was quenched with H2O after 15 min. The orange solution was poured into additional H2O and the organics were extracted with Et2O. After drying over MgSO4 the solvent was removed in vacuo and the residual oil purified via column chromatography (EtOAc/hexanes (3:2)) yielding 194 mg (0.55 mmol, 51 % yield) of compound D as an oil. 1H NMR (CDCI3) 400 MHz δ 9.47 (s, 1 H), 7.20 (d, 1 H, J = 8.1 Hz), 7.07 (d,
1 H, J = 1.9 Hz), 6.94 (s, 1 H), 6.86 (dd, 1 H, J = 8.0 & 1.9 Hz), 4.0 (m, 1 H), 3.78 (d, 1 H, J = 16.1 Hz), 3.45 (dd, 1 H, J = 16.0 & 2.1 Hz), 3.03 (dd, 1 H, J = 12.0 & 5.3 Hz), 2.48 (s, 3H), 2.41 (dd, 1 H, J = 12.0 & 9.1 Hz), 1.67 (s, 3H), 1.26-1.18 (m, 12H) ppm. E. Ethyl (2E)-3-[6-methyl-4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthaienyl)- 4,5,6,7-tetrahydrofuro[2,3-c]pyridin-2-yl]-2-propenoate.
To a DME solution (2 mL) containing sodium hydride (33 mg, 0.83 mmol, 60% dispersion in mineral oil) was added triethylphosphonoacetate (186 mg, 0.83 mmol) at room temperature. After 5 min compound D (194 mg, 0.55 mmol) in 2 mL DME was added. The reaction stirred for 20 min at which time it was quenched with H2O. The solution was poured into additional H2O and the organics extracted with Et2O. After drying over MgSO the solvent was removed in vacuo and the residual oil purified via column chromatography (hexanes/EtOAc (3:2)) yielding 169 mg (0.30 mmol, 71 % yield) of compound E as an oil.
1H NMR (CDCI3) 400 MHz δ 7.31 (d, 1 H, J = 15.5 Hz), 7.19 (d, 1 H, J = 8.1 Hz), 7.06 (d, 1 H, J = 1.7 Hz), 6.88 (dd, 1 H, J = 8.2 & 1.7 Hz), 6.32 (s, 1 H), 6.20 (d, 1 H, J = 15.7 Hz), 4.19 (q, 2H, J = 7.1 Hz), 3.95 (m, 1 H), 3.72 (d, 1 H, J = 15.6 Hz), 3.42 (dd, 1 H, J = 15.4 & 2.2 Hz), 2.99 (dd, 1 H, J = 11.8 & 5.3 Hz), 2.46 (s, 3H), 2.36 (dd, 1 H, J = 11.8 & 9.4 Hz), 1.64 (s, 4H), 1.28 (t, 3H, J = 7.1 Hz), 1.24-1.21 (m, 12H) ppm.
F. (2E)-3-[6-methyl-4-(5,5,8,8,-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7- tetrahydro[2,3-c]pyridin-2-yl]-2-propenoic acid. To a dioxane solution (2 mL) containing compound E (169 mg, 0.39 mmol) was added lithium hydroxide hydrate (164 mg, 3.92 mmol) followed by 0.7 mL of H2O. The reaction went for 24 h at room temperature, at which time 702 mg of NaHSO4 was added along with H2O and EtOAc. After stirring for 10 min the solution was poured into additional H2O and the organics extracted with EtOAc. After drying over MgSO4 the solvent was removed in vacuo and the residual material purified via column chromatography (CH2CI2/MeOH (9:1)) affording 101 mg (0.26 mmol, 66% yield) of compound F as an off-white solid, m.p. 128-130 °C decomp.
1H NMR (CDCI3) 400 MHz δ 7.32 (d, 1H, J = 15.7 Hz), 7.28 (d, 1H, J = 8.1 Hz), 7.23 (d, 1 H, J = 1.5 Hz), 6.96 (dd, 1 H, J = 8.2 & 1.6 Hz), 6.22 (d, 1 H, J = 15.7 Hz), 4.46 (d, 1 H, J = 15.6 Hz), 4.36 (m, 1 H), 4.30 (d, 1 H, J = 15.6 Hz), 3.63 (dd, 1 H, J = 12.2 & 5.4 Hz), 3.13 (t, 1 H, J = 11.7 Hz), 2.98 (s, 3H), 1 .68 (s, 4H), 1.26-1.22 (m, 12H) ppm. Example 6
(2E)-3-[4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-1-benzofuran-2-yQ- 2-propenoic acid.
A. 4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-1-benzofuran. To a dioxane solution (25 mL) containing 4-(5,5,8,8-Tetramethyl-5,6,7,8- tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1 -benzofuran-4-ol (synthesized in example 1 part A) (985 mg, 3.04 mmol) was added DDQ (1.73 g, 7.60 mmol). The solution was then heated to 100 °C for 4 h at which time the dark solution was filtered through a bed of celite. The celite was rinsed thoroughly with Et2O followed by washing the filtrate with H2O (2X) and then drying over MgSO . The solvent was then removed in vacuo and the residual dark oil was purified via column chromatography (hexanes/2% EtOAc) yielding 430 mg (1.42 mmol, 47% yield) of compound A as a white solid after trituration with hot MeOH and filtration, m.p. 153-154 °C.
1H NMR (CDCI3) 400 MHz δ 7.69 (d, 1 H, J = 2.2 Hz), 7.61 (d, 1 H, J = 1.1 Hz), 7.52-7.35 (m, 5H), 6.99 (d, 1 H, J = 2.1 Hz), 1.78 (s, 4H), 1.39 (s, 6H), 1.38 (s, 6H) ppm.
B. 4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-1-benzofuran-2- carbaldehyde. A Et2O solution (20 mL) containing compound A (2.43 g, 7.99 mmol) cooled to
-40 °C had 7.0 mL of a 1.7 M pentane solution of t-BuLi (11.9 mmol) added to it. The orange solution stirred for 30 min at which time DMF (876 mg, 12.0 mmol) was added. The reaction slowly warmed to 0 °C over 1 h and was then quenched with H2O. The solution was poured into H2O and the organics extracted with Et2O. After drying over MgSO4 the solvent was removed in vacuo and the residual yellow solid was purified via column chromatography (3% hexanes/EtOAc) yielding 1.98 g (5.97 mmol, 75% yield) of compound B as a white solid m.p. 122-124 °C.
1H NMR (CDCI3) 400 MHz δ 9.84 (s, 1 H), 7.70 (s, 1 H), 7.56-7.34 (m, 6H), 1.73 (s, 4H), 1.34 (s, 6H), 1.33 (s, 6H) ppm.
C. Ethyl (2E)-3-[4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-1- benzofuran-2-yl]-2-propenoate.
To a DME solution (10 mL) containing sodium hydride (358 mg, 8.96 mmol, 60% dispersion in mineral oil) was added triethylphosphonoacetate (2.01 g, 8.96 mmol) at room temperature. After 5 min compound B (1.98 g, 5.97 mmol) in 20 mL of DME was added. The resulting orange solution stirred for 30 min at which time it was quenched with H2O. The solution was poured into additional H2O and the organics were extracted with Et O. After drying over MgSO4 the solvent was removed in vacuo and the residual oil purified via column chromatography (hexanes/EtOAc 3%) yielding 2.12 g (5.28 mmol, 88% yield) of compound C as a white solid m.p. 119-121 °C.
1H NMR (CDCI3) 400 MHz δ 7.54-7.51 (m, 2H), 7.41-7.33 (m, 4H), 7.29 (dd, 1 H, J = 6.6 & 1.8 Hz), 7.08 (s, 1 H), 6.56 (d, 1 H, J = 15.7 Hz), 4.25 (q, 2H, J = 7.1 Hz), 1.72 (s, 4H), 1.34-1.30 (m, 15H) ppm.
D. (2E)-3-[4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-1-benzofuran-2- yl]-2-propenoic acid.
To a dioxane solution (2 mL) containing compound C (88 mg, 0.22 mmol) was added lithium hydroxide hydrate (46 mg, 1.09 mmol) and 0.5 mL of H2O at room temperature. After 2 days the solution was acidified with sat. NaHSO4 and the organics were extracted with EtOAc. After drying over MgSO4 the solvent was removed in vacuo and the residual liquid was purified via column chromatography
(CH2CI2/MeOH (15:1)) yielding 63 mg (0.17 mmol, 76% yield) of compound D as a white solid, m.p. 216-219 °C decomp. 1H NMR (CDCI3) 400 MHz δ 7.63 (d, 1 H, J = 15.5 Hz), 7.53 (d, 1 H, J = 1.5
Hz), 7.44-7.32 (m, 5H), 7.16 (s, 1 H), 6.60 (d, 1 H, J = 15.6 Hz), 1.75 (s, 4H), 1.36 (s,
6H), 1.35 (s, 6H) ppm.
Example 7 (2E)-3-[4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro- 1 -benzothien-2-yl]-2-propenoic acid.
A. 4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1- benzothiophen-4-ol.
To a THF solution (10 mL) containing 6-bromo-1 ,1 ,4,4-tetramethyl- 1 ,2,3,4- tetrahydronaphthalene (1.04 g, 3.90 mmol) cooled to -78 °C was added 1.7 mL of a 2.4 M hexanes solution of n-BuLi (4.09 mmol). The solution stirred for 45 min when 6,7-dihydro-1-benzothiophen-4(5H)-one (563 mg, 3.70 mmol) in 10 mL of THF was added. After 45 min at -78 °C the reaction was quenched with H2O and the organics extracted with Et2O. After drying over MgSO4 the solvent was removed in vacuo and the residual oil purified via column chromatography (hexanes/EtOAc (9:1 )) yielding 564 mg (1.66 mmol, 45% yield) of compound A as an oil which solidified on standing m.p. 42-44 °C.
1H NMR (CDCI3) 400 MHz δ 7.27 (d, 1 H, J = 1.9 Hz), 7.18 (d, 1 H, J = 8.2 Hz), 7.02 (d, 1 H, J = 5.2 Hz), 6.97 (dd, 1 H, J = 8.2 & 2.0 Hz), 6.67 (d, 1 H, J = 5.2 Hz), 2.89-2.83 (m, 2H), 2.11-1.99 (m, 4H), 1.81 (m, 1 H), 1.64 (s, 4H), 1.29-1.19 M, 9H), 0.86 (s, 3H) ppm.
B. 4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1- benzothiophene. To a CH2CI2 solution (10 mL) containing compound A (654 mg, 1.92 mmol) and triethylsilane (671 mg, 5.77 mmol) was added TFA (680 mg, 5.96 mmol) at -40 °C. After 30 min the reaction was quenched with dilute NaHCO3. The two phase solution was poured into additional sat. NaHCO3 and the organics extracted with CH2CI2. After drying over MgSO4 the solvent was removed in vacuo and the residual oil was purified via column chromatography (hexanes/EtOAc (19:1 )) yielding 557 mg (1.72 mmol, 90% yield) of compound B as a white solid m.p. 79-81 °C.
1H NMR (CDCI3) 400 MHz δ 7.17 (d, 1 H, J = 8.0 Hz), 7.03 (d, 1 H, J = 1.8 Hz), 6.98 (d, 1 H, J = 5.2 Hz), 6.81 (dd, 1 H, J = 8.0 & 1.8 Hz), 6.53 (d, 1 H, J = 5.3 Hz), 3.93 (m, 1 H), 2.88-2.84 (m, 2H), 2.12 (m, 1 H), 1.96 (m, 1 H), 1.82-1.76 (m, 2H), 1.66 (s, 4H), 1.26-1.25 (m, 9H), 1.21 (s, 3H) ppm.
C. 4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1- benzothiophene-2-carbaldehyde.
To a Et2O solution (50 mL) containing compound B (6.40 g, 19.8 mmol) cooled to -20 °C was added 34.9 mL of a 1.7 M pentane solution of t-BuLi (59.4 mmol). The resulting yellow solution stirred at -20 °C for 30 min at which time DMF (2.17 g, 29.7 mmol) was added. After 30 min the reaction had warmed to -10 °C at which time it was quenched with H2O. The solution was then poured into sat. NaHSO4 and the organics extracted with Et2O. After drying over MgSO4 the solvent was removed in vacuo. The residual yellow solid was dissolved in MeOH and a small amount of Et2O added. After storing in the freezer overnight the precipitated solid was collected via vacuum filtration yielding 6.73 g (19.1 mmol, 96% yield) of compound C as a light orange solid m.p. 142-145 °C.
1H NMR (CDCI3) 400 MHz δ 9.71 (s, 1 H), 7.23 (s, 1 H), 7.21 (d, 1 H, J = 8.0 Hz), 7.04 (d, 1 H, J = 1.9 Hz), 6.81 (dd, 1 H, J = 8.0 & 2.0 Hz), 3.93 (m, 1 H), 2.95-2.92 (m, 2H), 2.15 (m, 1H), 2.01 (m, 1H), 1.86-1.77 (m, 2H), 1.68 (s, 4H), 1.27 (s, 6H), 1.26 (s, 3H), 1.22 (s, 3H) ppm.
D. Ethyl (2E)-3-[4-(5,5,8,8-tetramethyI-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7- tetrahydro-1-benzothien-2-yl]-2-propenoate. To a DME solution (20 mL) containing sodium hydride (523 mg, 13.1 mmol,
60%) dispersion in mineral oil) was added triethylphosphonoacetate (2.94 g, 13.1 mmol). To this solution was added compound C (3.07 g, 8.72 mmol) in 20 mL of DME. The reaction went for 30 min and was then quenched with H2O. The solution was poured into additional H2O and the organics extracted with Et2O. After drying over MgSO4 the solvent was removed in vacuo and the residual oil purified via column chromatography (hexanes/EtOAc (19:1 )) yielding 3.51 g (8.32 mmol, 95% yield) of compound D as an oil which solidified on standing m.p. 52-55 °C.
1H NMR (CDCI3) 400 MHz δ 7.59 (d, 1 H, J = 15.6 Hz), 7.17 (d, 1 H, J = 8.1 Hz), 7.01 (s(br), 1 H), 6.79 (d, 1 H, J = 8.0 Hz), 6.67 (s, 1 H), 6.04 (d, 1 H, J = 15.6 Hz), 4.18 (q, 2H, J = 7.1 Hz), 3.86 (m, 1 H), 2.84-2.82 (m, 2H), 2.11 (m, 1 H), 1.94 (m, 1 H), 1.79-1.73 (m, 2H), 1.65 (s, 4H), 1.29-1.25 (m, 12H), 1.20 (s, 3H) ppm.
E. (2E)-3-[4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7- tetrahydro-1-benzothien-2-yl]-2-propenoic acid. To a dioxane solution (4 mL) containing compound D (286 mg, 0.68 mmol) was added lithium hydroxide hydrate (142 mg, 3.39 mmol) and 1 mL of H2O. After 30 h the heterogeneous solution was diluted with EtOAc and acidified with sat. NaHSO4.
The organic layer was separated, dried (MgSO4) and the solvent removed in vacuo.
The residual oil was purified via column chromatography (CH2CI2/MeOH (15:1 )) yielding a foam that was triturated with Et2O/hexanes. The resulting precipitate was collected via vacuum filtration yielding 202 mg (0.51 mmol, 75% yield) of compound
E as a white solid, m.p. 225-229 °C decomp.
1H NMR (CDCI3) 400 MHz δ 7.68 (d, 1H, J = 15.6 Hz), 7.19 (d, 1H, J = 8.0
Hz), 7.03 (d, 1 H, J = 1.6 Hz), 6.80 (dd, 1 H, J = 8.0 & 1.7 Hz), 6.73 (s, 1 H), 6.04 (d, 1 H, J = 15.5 Hz), 3.88 (m, 1 H), 2.87-2.85 (m, 2H), 2.12 (m, 1 H), 1.97 (m, 1H), 1.81-
1.76 (m, 2H), 1.67 (s, 4H), 1.27 (s, 6H), 1.22 (s, 3H), 1.19 (s, 3H) ppm. Example 8
(2E)-3-[4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro- 1 ,3-benzoxazol-2-yl]-2-propenoic acid. A. 2-Methyl-4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7- tetrahydro-1 ,3-benzoxazol-4-ol.
To a THF solution (50 mL) containing 6-bromo-1 ,1 ,4,4-tetramethyl- 1 ,2,3,4- tetrahydronaphthalene (5.21 g, 19.5 mmol) cooled to -78 °C was added 8.5 mL of a 2.4 M hexanes solution of n-BuLi (20.5 mmol). The resulting orange solution stirred for 30 min when 2-methyl-6,7-dihydro-1 ,3-benzoxazol-4(5H)-one (2.68 g, 17.7 mmol) in 50 mL of THF was added. The dark solution went for 45 min at -78 °C and was then quenched with H2O. Upon warming the solution was poured into additional H2O and the organics extracted with Et2O (2X). After drying (MgSO4) the solvent was removed in vacuo and the residual yellow oil purified via column chromatography (hexanes/EtOAc (3:2)) yielding 4.0 g (11.8 mmol, 67% yield) of compound A as an oil.
1H NMR (CDCIg) 400 MHz δ 7.37 (d, 1 H, J = 2.0 Hz), 7.17 (d, 1 H, J = 8.3 Hz), 6.91 (dd, 1 H, J = 8.2 & 2.0 Hz), 2.68-2.64 (m, 2H), 2.53 (s, 1 H, -OH), 2.40 (s, 3H), 2.11-1.95 (m, 3H), 1.78 (m, 1 H), 1.63 (s, 4H), 1.25-1.21 (m, 12H) ppm.
B. 2-Methyl-4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7- tetrahydro-1 ,3-benzoxazole.
To a THF solution (40 mL) containing sodium borohydride (4.46 g, 118.0 mmol) cooled to 0 °C was added BF3Εt2O (25.1 g, 178 mmol). The resulting white slurry then had compound A (4.0 g, 11.8 mmol) in 75 mL of THF added to it. After 15 min the reaction was quenched by carefully pouring it into sat. NaHCO3. After the foaming had subsided the organics were extracted with Et2O (2X). After drying over MgSO the solvent was removed in vacuo and the residual oil purified via column chromatography (hexanes/EtOAc (9:1 )) yielding 1.44 g (4.47 mmol, 38% yield) of compound B.
1H NMR (CDCI3) 400 MHz δ 7.13 (d, 1 H, J = 8.0 Hz), 7.03 (d, 1 H, J = 2.0 Hz), 6.77 (dd, 1 H, J = 8.1 & 2.0 Hz), 3.83 (m, 1 H), 2.65-2.60 (m, 2H), 2.36 (s, 3H), 2.07 (m, 1 H), 1.91 (m, 1 H), 1.77-1.68 (m, 2H), 1.61 (s, 4H), 1.20 (s, 9H), 1.19 (s, 3H) ppm. C. 2-(Bromomethyl)-4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)- 4,5,6,7-tetrahydro-1 ,3-benzoxazoIe.
To a CCI4 solution (60 mL) containing compound B (4.79 g, 14.8 mmol) was added AIBN (24 mg, 0.15 mmol, 1 mol%) and NBS (3.16 g, 17.8 mmol). The solution was then immersed in an oil bath which had been preheated to 90 °C. After 30 min the solution was allowed to cool to room temperature and the precipitated succinimide was removed via filtration. Removal of the solvent in vacuo and purification via column chromatography (hexanes/EtOAc (15:1)) yielded 2.23 g (5.55 mmol, 37% yield) of compound C as a white foam. 1H NMR (CDCI3) 400 MHz δ 7.16 (d, 1 H, J = 8.1 Hz), 7.02 (d, 1 H, J = 1.9 Hz),
6.78 (dd, 1 H, J = 8.1 & 1.9 Hz), 4.41 (s, 2H), 2.73-2.67 (m, 2H), 2.12 (m, 1H), 1.94 (m, 1 H), 1.82-1.69 (m, 2H), 1.62 (s, 4H), 1.21 (s, 12H) ppm.
D. [4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro- 1 ,3benzoxazol-2-yl]methyl acetate.
To an CH3CN solution (50 mL) containing compound C (2.0 g, 4.98 mmol) was added potassium acetate (978 mg, 9.96 mmol) at room temperature. The resulting slurry stirred for 24 h at which time it was diluted with H2O and the organics were extracted with EtOAc (2X). After drying over MgSO4 the solvent was removed in vacuo and the residual oil purified via column chromatography (hexanes/EtOAc (4:1)) yielding 1.54 g (4.04 mmol, 81 % yield) of compound D.
1H NMR (CDCI3) 400 MHz δ 7.15 (d, 1 H, J = 8.1 Hz), 7.03 (d, 1 H, J = 1.9 Hz), 6.78 (dd, 1 H, J = 8.1 & 1.9 Hz), 5.08 (s, 2H), 3.90 (m, 1 H), 2.72-2.66 (m, 2H), 2.13- 2.08 (m, 4H), 1.94 (m, 1H), 1.79-1.73 (m, 2H), 1.62 (s, 4H), 1.21 (s, 6H0, 1.20 (s, 6H) ppm.
E. [4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphtalenyl)-4,5,6,7-tetrahydro-1 ,3- benzoxazol-2-yl]methanol.
To a MeOH solution (50 mL) containing compound D (1.62 g, 4.24 mmol) was added 75 DL of H2O and potassium carbonate (1.17 g, 8.48 mmol) at room temperature. After 15 min the solution was diluted with H2O and the organics extracted with EtOAc. After drying over MgSO4 the solvent was removed in vacuo yielding 1.33 g (3.92 mmol, 92% yield) of compound E as a white solid which was pure enough to take on. 1H NMR (CDCI3) 400 MHz δ 7.15 (d, 1H, J = 8.1 Hz), 7.04 (d, 1H, J = 1.4 Hz), 6.77 (dd, 1 H, J = 8.1 & 1.6 Hz), 4.62-4.51 (m, 2H), 3.89 (m, 1 H), 2.69-2.64 (m, 2H), 2.48 (t, 1 H, J = 6.4 Hz), 2.10 (m, 1 H), 1.92 (m, 1 H), 1.78-1.72 (m, 2H0, 1.62 (s, 4H), 1.22 (s, 6H), 1.21 (s, 3H), 1.20 (s, 3H) ppm.
F. 4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1 ,3- benzoxazole-2-carbaldehyde.
To a CH2CI2 solution (30 mL) containing compound E (1.43 g, 4.23 mmol), NMO (743 mg, 6.34 mmol) and 2.1 g of 4A powdered molecular sieves was added TPAP (74 mg, 0.21 mmol, 5 mol%). After stirring for 30 min at room temperature the dark slurry was filtered through a bed of celite. The celite was rinsed thoroughly with CH2CI2 and then the solvent was removed in vacuo. The residual dark oil was purified via column chromatography (hexanes/EtOAc (4:1)) yielding 671 mg (1.99 mmol, 47% yield) of compound F. 1H NMR (CDCI3) 400 MHz δ 9.62 (s, 1 H), 7.19 (d, 1 H, J = 8.1 Hz), 7.04 (d,
1H, J = 1.8 Hz), 6.77 (dd, 1 H, J = 8.1 & 1.9 Hz), 4.00 (m, 1 H), 2.84-2.79 (m, 2H), 2.18 (m, 1H), 1.86-1.80 (m, 2H), 1.63 (s, 4H), 1.23 (s, 6H), 1.22 (s, 3H), 1.21 (s, 3H) ppm.
G. Ethyl (2E)-3-[4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7- tetrahydro-1 ,3-benzoxazol-2-yl]-2-propenoate.
To a DME solution (10 mL) containing sodium hydride (121 mg, 3.03 mmol, 60% dispersion in mineral oil) was added triethylphosphonoacetate (679 mg, 3.03 mmol) at room temperature. To this solution was added compound F (682 mg, 2.02 mmol) in 10 mL of DME. After 15 min the reaction was quenched with H2O and the organics were extracted with Et2O. Upon drying over MgSO4 the solvent was removed in vacuo and the residual oil was purified via column chromatography (hexanes/EtOAc (9:1)) yielding 648 mg (1.59 mmol, 79% yield) of compound G. 1H NMR (CDCI3) 400 MHz δ 7.36 (d, 1 H, J = 16.0 Hz), 7.15 (d, 1 H, J = 8.1 Hz), 7.04 (d, 1 H, J = 1.9 Hz), 6.77 (dd, 1 H, J = 8.1 & 1.9 Hz), 6.61 (d, 1H, J = 16.1 Hz), 4.21 (q, 2H, J = 7.2 Hz), 3.93 (m, 1 H), 2.75-2.69 (m, 2H), 2.12 (m, 1 H), 1.95 (m, 1 H), 1.82-1.75 (m, 2H), 1.61 (s, 4H), 1.27 (t, 3H, J = 7.1 Hz), 1.21 (s, 6H), 1.20 (s, 6H) ppm. H. (2E)-3-[4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7- tetrahydro-1 ,3-benzoxazol-2-yl]-2-propenoic acid.
To a dioxane solution (12 mL) containing compound G (645 mg, 1.58 mmol) was added 3 mL of H2O followed by lithium hydroxide hydrate (664 mg, 15.8 mmol). After stirring overnight at room temperature the reaction was acidified with sat.
NaHSO4 and the organics were extracted with EtOAc. Upon drying over MgSO4 and removal of the solvent in vacuo the residual material was purified via column chromatography (CH2CI2/MeOH (9:1 )) affording 599 mg (1.58 mmol, 100% yield) of compound H as an off-white solid, m.p. 176-178 °C. 1H NMR (CDCI3) 400 MHz δ 7.44 (d, 1 H, J = 15.9 Hz), 7.16 (d, 1 H, J = 8.1
Hz), 7.05 (d, 1 H, J = 1.9 Hz), 6.78 (dd, 1 H, J = 8.1 & 1.9 Hz), 6.62 (d, 1 H, J = 16.1
Hz), 3.95 (m, 1 H), 2.78-2.72 (m, 2H), 2.15 (m, 1 H), 1.96 (m, 1 H), 1.82-1.77 (m, 2H),
1.62 (s, 4H), 1.22 (s, 6H), 1.21 (s, 6H) ppm.
Example 9
(2E)-3-(4-{[(2,6,6-trimethylcyclohexen-1-yl)methyl]amino}benzofuran-2-yl)-2- propenoic acid.
A. N-[2-Formyl-3-(methoxymethoxy)phenyl]-2,2-dimethylpropanamide
1-(Trimethylacetamido)-3-(methoxymethoxy)benzene (17.314 g, 73.0 mmol) was dissolved in THF (200 mL) and the solution was cooled to 0°C under nitrogen. BuLi (2.5 M solution in hexanes, 58.5 mL, 146 mmol) was added and the mixture was allowed to stir at 0°C for 2 hours at which time DMF (6.20 mL, 80.4 mmol) was added. The resulting mixture was warmed to room temperature and stirred for 3 hours. Saturated aqueous KH2PO4 (100 mL) and water (100 mL) were added. The two layers were separated and the aqueous layer was extracted with Et2O (2 x 50 mL). The combined organics were dried (MgSO4) and concentrated. The residue was purified by silica gel chromatography (4:1 hexane:EtOAc) yielding 15.0 g of compound A (56.5 mmol, 77% yield) as a pale yellow solid.
1H NMR (CDCI3) 400 MHz δ 11.79 (br s, 1 H), 10.48 (s, 1 H), 8.33 (d, 1 H, J = 8.4 Hz), 7.40 (t, 1 H, J = 8Hz), 6.76 (d, 1 H, J = 8.4 Hz), 5.21 (s, 2H), 3.43 (s, 3H), 1.26 (s, 9H) ppm.
B. N-(2-Formyl-3-hydroxyphenyl)-2,2-dimethylpropanamide.
Compound A (15.0 g, 56.5 mmol) was dissolved in methanol (120 mL). 4- Toluenesulfonic acid monohydrate (12.956 g, 68.0 mmol) was added and the solution was stirred at room temperature for 18 hours, then was concentrated. The residue was dissolved in Et2O/CH2CI2 (125 mL, 4:1 ) and was washed with saturated aqueous NaHCO3 (3 x 50 mL). The organics were dried (Na2SO4) and concentrated to provide 12.2 g (55.3 mmol, 98% yield) of compound B as a yellow solid that was used without further purification.
1H NMR (CDCI3) 400 MHz δ 10.26 (s, 1 H), 9.18 (br s, 1 H), 7.64 (d, 1 H, J = 8.4 Hz), 7.37 (t, 1 H, J = 8.4 Hz), 6.65 (d, 1 H, J = 8.4 Hz), 1.33 (s, 9H) ppm.
C. Methyl {3-[(2,2-dimethylpropanoyl)amino]-2-formylphenoxy}acetate Compound B (12.2 g, 55.3 mmol) was dissolved in DMF (100 mL). K2CO3
(7.664 g, 55.5 mmol) was added followed by methyl bromoacetate (5.25 mL, 55.5 mmol). The mixture was stirred at room temperature for 5 hours, then was filtered. 1.0 N aqueous HCI (100 mL) was added and the mixture was extracted with Et2O (4 x 25 mL). The combined organics were dried (Na2SO4) and concentrated and the crude residue was recrystallized from Et2O/hexane (9:1 ) to provide 9.44 g (32.2 mmol, 58% yield) of compound C as a tan solid.
1H NMR (CDCI3) 400 MHz δ 11.86 (s, 1 H), 10.58 (s, 1 H), 8.38 (d, 1 H, J = 8.6 Hz), 7.44 (t, 1 H, J = 8.6 Hz), 6.45 (d, 1 H, J = 8.6 Hz), 4.72 (s, 2H), 3.77 (s, 3H), 1.31 (s, 9H) ppm.
D. Methyl 4-[(2,2-dimethylpropanoyl)amino]benzofuran-2-carboxylate
Compound C (9.44 g, 32.2 mmol) was dissolved in DMF (100 mL). K2CO3 (17.793 g, 129 mmol) was added and the mixture was heated to 120 °C for 5 hours. The mixture was cooled to room temperature and filtered. To the filtrate was added 1.0 N HCI (200 mL) and the mixture was extracted with EtOAc (4 x 50 mL). The combined organics were dried (MgSO4) and concentrated. The crude residue was purified by silica gel chromatography (4:1 hexane:EtOAc) to provide 3.61 g (13.2 mmol, 41%) of compound D as a cottony white solid, along with the decarboxylated material (white solid, 1.21 g, 17%). 1H NMR (CDCI3) 400 MHz δ 7.71 (s, 1 H), 7.52 (d, 1 H, J = 6.7 Hz), 7.41 (s,
1H), 7.29 (m, 2H), 3.90 (s, 3H), 1.31 (s, 9H) ppm.
E. N-[2-(Hydroxymethyl)benzofuran-4-yl]-2,2-dimethylpropanamide.
LiBH4 (0.1095 g, 5.03 mmol) was suspended in THF (5 mL). A solution of compound D (0.996 g, 3.62 mmol) in THF (6 mL) was slowly added (gas evolution occurred) and the mixture was heated to reflux for 3 hours. The mixture was cooled to room temperature and treated with saturated aqueous ammonium chloride (20 mL). The mixture was extracted with Et2O (4 x 10 mL). The combined organics were dried (MgSO4) and concentrated. The crude residue was purified by silica gel chromatography (1 :1 hexanes: EtOAc) to provide 0.53 g (2.14 mmol, 59% yield) of compound E as a white solid.
1H NMR (CDCI3) 400 MHz δ 7.51 (s, 1 H), 7.50 (d, 1 H, J = 8.3 Hz), 7.20 (t, 1 H, J = 8.3 Hz), 7.17 (d, 1 H, J = 8.3 Hz), 6.52 (s, 1 H), 4.68 (s, 3H), 2.43 (br s, 1H), 1.33 (s, 9H) ppm.
F. (4-Aminobenzofuran-2-yl)methanol.
Compound E (2.29 g, 9.28 mmol) and 5.0 N NaOH (50 mL) were heated to 110 °C for 3 days. The mixture was cooled to room temperature and extracted with Et2O (4 x 25 mL). The organics were dried (Na2SO4) and concentrated. The crude residue was purified by silica gel chromatography (1 :1 hexanes:EtOAc) to provide 0.47 g (2.88 mmol, 31 % yield) of compound F as a yellow solid, along with recovered starting material (0.65 g).
1H NMR (CDCI3) 400 MHz δ 7.06 (t, 1 H, J = 8.1 Hz), 6.89 (d, 1 H, J = 8.1 Hz), 6.55 (s, 1 H), 6.47 (d, 1 H, J = 8.1 Hz), 4.71 (s, 2H) ppm.
G. Tert-butyl 2-(hydroxymethyl)benzofuran-4-ylcarbamate.
Compound F (0.47 g, 2.88 mmol) was dissolved in THF (5 mL). Di-tert-butyl dicarbonate (0.627 g, 2.87 mmol) was added and the solution was heated to reflux for 18 hours. The solution was cooled to room temperature and concentrated. The crude residue was purified by silica gel chromatography (1 :1 hexanes: EtOAc) to provide 0.65 g (2.49 mmol, 86% yield) of the compound G as a pale yellow solid.
1H NMR (CDCI3) 400 MHz δ 7.48 (d, 1 H, J = 8.1 Hz), 7.20 (t, 1 H, J = 8.1 Hz), 7.19 (d, 1 H, J = 8.1 Hz), 6.64 (s, 1 H), 6.56 (s, 1 H), 4.73 (s, 2H), 1.85 (br s, 1 H), 1.52 (s, 9H) ppm.
H. Tert-butyl-2-formylbenzofuran-4-ylcarbamate
Compound G (0.65 g, 2.49 mmol) was dissolved in CH2CI2 (24 mL). Dess- Martin periodinane (1.179 g, 2.78 mmol) was added and the mixture was stirred at room temperature for 2 hours. The mixture was concentrated and the crude residue was purified by silica gel chromatography (3:1 hexanes: EtOAc) to provide 0.53 g (2.02 mmol, 81 % yield) of compound H as a yellow solid.
1H NMR (CDCI3) 400 MHz δ 9.81 (s, 1 H), 7.67 (s, 1 H), 7.53 (d, 1 H, J = 8.2 Hz), 7.44 (t, 1 H, J = 8.2 Hz), 7.28 (d, 1 H, J = 8.2 Hz), 6.90 (br s, 1 H), 1.53 (s, 9H) ppm.
I. Methyl (2E)-3-{4-[(tert-butoxycarbonyl)amino]benzofuran-2-yl}-2-propenoate.
Compound H (0.53 g, 2.02 mmol) was dissolved in CH2CI2 (4 mL). Methyl
(triphenylphosphoranylidene)acetate (0.751 g, 2.25 mmol) was added and the solution was stirred at room temperature for 16 hours. The mixture was concentrated and the crude residue was purified by silica gel chromatography (3:1 hexanes: EtOAc) to provide 0.50 g (1.58 mmol, 78% yield) of compound I as a pale yellow solid.
1H NMR (CDCI3) 400 MHz δ 7.53 (d, 1 H, J = 8.0 Hz), 7.49 (d, 1 H, J = 15.7 Hz), 7.28 (t, 1 H, J = 8.0 Hz), 7.17 (d, 1 H, J = 8.0 Hz), 6.93 (s, 1 H), 6.66 (s, 1 H), 6.53
(d, 1 H, J = 15.7 Hz), 3.79 (s, 3H), 1.52 (s, 9H) ppm.
J. Methyl (2E)-3-(4-aminobenzofuran-2-yl)-2-propenoate
Compound I (0.50 g, 1.58 mmol) was dissolved in CH2CI2 (1.5 mL) and trifluoroacetic acid (1.5 mL). The solution was stirred at room temperature for 45 minutes. The solution was diluted with CH2CI2 (10 mL) and saturated aqueous sodium bicarbonate was added slowly until the solution reached pH 8. The two layers were separated and the aqueous layer was extracted with CH2CI2 (3 x 10 mL).
The organics were dried (Na2SO ) and concentrated to provide 0.24 g (1.11 mmol, 70% yield) of compound J as a yellow solid.
1H NMR (CDCI3) 400 MHz δ 7.49 (d, 1 H, J = 15.5 Hz), 7.13 (t, 1 H, J = 8.2 Hz),
6.88 (d, 1 H, J = 8.2 Hz), 6.84 (s, 1 H), 6.48 (d, 1 H, J = 15.5 Hz), 6.47 (d, 1 H, J = 8.2
Hz), 3.79 (s, 3H) ppm.
K. Methyl (2E)-3-(4-{[(2,6,6-trimethyl-1-cyclohexen-1-yl)methyl]amino}benzofuran-2- yl)-2-propenoate.
Compound J (0.048 g, 0.221 mmol) was dissolved in acetone (0.50 mL). K2CO3 (0.0374 g, 0.271 mmol) was added, followed by a solution of 2- (bromomethyl)-1 ,3,3-trimethyl-1-cyclohexene (0.049 g, 0.224 mmol) in acetone (0.50 mL). The mixture was stirred at room temperature for 2.5 days. Saturated aqueous KH2PO4 (15 mL) was added and the mixture was extracted with EtOAc (3 x 7 mL). The organics were dried (Na2SO4) and concentrated. The crude residue was purified by silica gel chromatography (3:1 hexanes: EtOAc) to provide 0.041 g (0.12 mmol , 52% yield) of compound K as a yellow oil. 1H NMR (CDCI3) 400 MHz δ 7.46 (d, 1 H, J = 15.5 Hz), 7.20 (t, 1 H, J = 8.1 Hz),
6.85 (s, 1 H), 6.81 (d, 1 H, J = 8.1 Hz), 6.46 (d, 1 H, J = 15.5 Hz), 6.35 (d, 1 H, J = 8.1 Hz), 3.78 (s, 3H), 3.70 (s, 2H), 1.99 (t, 1 H, J = 8.2 Hz), 1.66 (s, 3H), 1.64 (m, 2H), 1.48 (m, 2H), 1.02 (s, 6H) ppm.
L. (2E)-3-(4-{[(2,6,6-trimethylcyclohexen-1-yl)methyl]amino}benzofuran-2-yl) 2- propenoic acid.
Compound K (0.0409 g, 0.116 mmol) was dissolved in THF/MeOH/H2O
(4:1 :1 , 1.5 mL). Lithium hydroxide (0.0164 g, 0.391 mmol) was added and the solution was stirred at room temperature for 7 hours. Saturated aqueous KH2PO4 (15 mL) was added and the mixture was extracted with EtOAc (3 x 10 mL). The organics were dried (Na2SO ) and concentrated. The crude residue was purified by silica gel chromatography (1 :1 hexanes: EtOAc) to provide 0.0271 g (.080 mmol, 69% yield) of compound L as a yellow solid m.p. 202 °C (dec).
1H NMR (CD3OD) 400 MHz δ 7.47 (d, 1 H, J = 15.5 Hz), 7.30 (s, 1 H), 7.17 (t, 1 H, J = 8.1 Hz), 6.72 (d, 1 H, J = 8.1 Hz), 6.32 (d, 1 H, J = 15.5 Hz), 6.31 (d, 1 H, J =
8.1 Hz), 3.70 (s, 2H), 2.02 (app t, 1 H, J = 8.1 Hz), 1.68 (s, 3H), 1.65 (m, 2H), 1.50 (m,
2H), 1.04 (s, 6H) ppm.
Example 10 (2E)-3[4-(4-lsopropoxy-1-naphthalenyl)tetrahydro-1-benzofuran-2-yl]-2-propenoic acid. A. 4-Bromo-1-naphthol.
To an acetonitrile solution (275 mL) containing 1-naphthol (10 g, 69 mmol) at room temperature was added N-bromosuccinimide (1 eq, 12.35 g, 69 mmol) in portions over 10 minutes. The resulting mixture was stirred for 1 h at room temperature. The mixture was concentrated under reduced pressure and was then diluted with ether (100 mL). The mixture was poured into water (100 mL) and extracted with ether (2 x 100 mL). The combined organic layer was dried (MgSO4) and concentrated under reduced pressure to provide 15.0 g of a brown solid that was identified as 4-bromo-1-naphthol, m.p. 125-127°C. 1H NMR (CDCI3) 400 MHz δ 8.16 (d, 1 H, J = 8.5 Hz), 8.14 (d, 1 H, J = 8.4 Hz), 7.58 (ddd, 1 H, J = 1.6, 6.7, 8.2 Hz), 7.55 (d, 1 H, J = 8.0 Hz), 7.51 (ddd, 1 H, J = 1.3, 7.0, 8.3 Hz), 6.67 (d, 1 H, J = 8.0 Hz), 5.25 (s, 1 H) ppm.
B. 4-isopropoxy-1-bromonaphthalene.
The following is an adaptation of the method of Bringmann. A solution containing 4-bromo-1-naphthol (10.0 g, 0.045 mol), potassium carbonate (31 g, 0.224 mol), and 2-bromopropane (27.6 g, 0.224 mol) in DMF was heated at reflux for 1 h under a nitrogen atmosphere. The mixture was cooled to room temperature and the solvent was removed under reduced pressure. The resultant residue was subjected to silica gel chromatography using a 50% ethyl acetate-hexane mixture as the eluent to provide 4-isopropoxy-1-bromonaphthalene.
1H NMR (CDCI3) 400 MHz δ 8.26 (d,1 H, J = 7.9 Hz), 8.11 (d, 1 H, J = 8.4 Hz),
7.60 (d, 1 H, J = 8.3 Hz), 7.55 (ddd, 1 H, J = 1.5, 6.8, 8.3 Hz), 7.46 (ddd, 1 H, J = 1.1 , 6.8, 8.3 Hz), 6.67 (d, 1H, J = 8.2 Hz), 4.68 (sept, 1 H, J = 5.8 Hz), 1.41 (d, 6H, J = 6.1
Hz) ppm.
C. 4-(4-lsopropoxy-1-naphthalenyl)-4,5,6,7-tetrahydro-1-benzofuran-4-ol.
To a THF solution (30 mL) containing 4-isopropoxy-1-bromonaphthalene (4.0 g, 15.1 mmol) cooled to -78 °C was added 9.3 mL of a 1.54 M hexanes solution of n- BuLi (14.3 mmol). The resulting solution was stirred for 10 min and then 6,7-dihydro- 4(5H)-benzofuranone (1.87 g, 13.7 mmol) in 10 mL of THF was added. After stirring for 30 min the reaction was quenched with H2O. Upon warming the solution was poured into additional H2O and the organics were extracted with Et2O. After drying over MgSO the solvent was removed in vacuo and the residual oil purified via column chromatography (hexanes/EtOAc (5:1)) yielding 3.6 g (11.2 mmol, 78% yield) of compound C.
1H NMR (acetone-d6) 400 MHz δ 8.23-8.35 (m, 2H), 7.51 (d, 1 H, J= 7.8 Hz), 7.35 (ddd, 1 H, J = 1.5, 6.8, 8.3 Hz), 7.28-7.33 (m, 2H), 6.83 (d, 1H, J = 8.2 Hz), 6.08 (d, 1 H, J = 2.1 Hz), 4.79 (sept, 1 H, J = 6.1 Hz), 4.42 (s, 1 H), 2.81 (bs, 1 H), 2.68 (t, 2H, J = 6.2 Hz), 2.00-2.51 (m, 3H), 1.41 (d, 3H, J = 2.8 Hz), 1.39 (d, 3H, J = 2.7 Hz) ppm.
D. 4-(4-lsopropoxy-1-naphthalenyl)-4,5,6,7-tetrahydro-1-benzofuran. To a THF solution (100 mL) containing sodium borohydride (3.75 g, 99 mmol) cooled to 0 °C was added BF3Εt2O (69.0 g, 486 mmol). The resulting white slurry stirred for 15 min when compound C (described above) (3.20 g, 9.9 mmol) in 65 mL of THF was added. After 15 min the reaction mixture was very carefully poured into sat. NaHCO3. The solution was then poured into water and the mix was extracted with ether. The combined organic layer was dried (MgSO4) and concentrated in vacuo and the residual yellow oil was purified via flash chromatography (hexanes/EtOAc (49:1) yielding 2.33 g (7.6 mmol, 77% yield) of compound D as a colorless glass. 1H NMR (CDCI3) 400MHz δ 8.34 (d, 1 H, J = 5.2 Hz), 8.08 (d, 1 H, J = 8.3 Hz),
7.40-7.60 (m, 2H), 7.29 (dd, 1 H, J = 0.8, 1.9 Hz), 6.99 (d, 1 H, J = 8.1 Hz), 6.70 (d, 1H, J = 8.1 Hz), 6.05 (d, 1 H, J = 1.8 Hz), 4.67 (sept, 1H, J = 6.1 Hz), 4.60-4.65 (m, 1 H), 2.60-2.78 (m, 2H), 2.11-2.24 (m, 1 H), 1.72-1.92 (m, 3H), 1.42 (d, 6H, J = 6.1 Hz) ppm.
E. [4-(4-lsopropoxy-1 -naphthalenyl)-4,5,6,7-tetrahydro-1 -benzofuran]-2- carboxaldehyde.
To a THF solution (6 mL) containing compound D (0.500 g, 1.63 mmol) cooled to 0 °C was added 1.06 mL of a 1.54 M hexanes solution of n-BuLi (1.63 mmol). The blue solution stirred for 15 min at which time DMF (0.2 mL) was added and the solution turned yellow. After 15 min the reaction was quenched with sat. NaHSO4, poured into water, and the organics extracted with Et2O. The combined organic layer was dried (MgSO4)and the solvent was removed in vacuo and the residual amber gum purified via flash chromatography (hexanes/EtOAc (85/15)) affording 0.444 g (1.33 mmol, 81% yield) of compound E as a yellow foam.
1H NMR (CDCI3) 400 MHz δ 9.44 (s, 1 H), 8.35 (dd, 1 H, J = 1.1 , 8.2 Hz), 8.01 (d, 1 H, J = 7.9 Hz), 7.43-7.58 (m, 2H), 6.91 (d, 1 H, J = 8.1 Hz), 6.88 (s, 1 H), 6.69 (d, 1 H, J = 8.1 Hz), 4.69 (sept, 1 H, J = 6.0 Hz), 4.62-4.68 (bs, 1 H), 2.71-2.90 (m, 2H), 2.13-2.25 (m, 1H), 1.80-1.99 (m, 3H), 1.41 (d, 6H, J = 6.1 Hz) ppm.
F. Ethyl (2E)-3-[4-(4-lsopropoxy-1 -naphthalenyl)-4,5,6,7-tetrahydro-1 -benzofuran-2- yl]-2-propenoate.
To a DME solution (5 mL) containing sodium hydride (0.080g, 1.99 mmol, 60%o dispersion in mineral oil) was added triethylphosphonoacetate (0.446 g, 1.99 mmol) at room temperature. To the resulting solution was added compound E (0.444 g, 1.33 mmol) in 5 mL of DME. The reaction stirred for 25 min at which time it was quenched with H2O. The solution was diluted with Et2O and the organic layer separated. The aqueous layer was extracted with Et2O and then the combined organic layers were dried over MgSO . Removal of the solvent in vacuo and purification via column chromatography (hexanes/EtOAc (9:1 )) yielded 0.475 g (1.17 mmol, 87% yield) of compound F as a light yellow foam.
1H NMR (CDCI3) 400 MHz δ 8.33 (dd, 1 H, J = 1.5, 8.2 Hz), 8.03 (d, 1 H, J = 8.0 Hz), 7.42-7.53 (m, 2H), 7.30 (d, 1 H, J = 15.6 Hz), 6.94 (1 H, J = 7.9 Hz), 6.68 (d, 1H, J = 8.1 Hz), 6.25 (s, 1H), 6.22 (d, 1 H, J = 15.6 Hz), 4.67 (sept, 1 H, J = 6.1 Hz), 4.59 (bs, 1 H), 4.19 (q, 2H, J = 7.2 Hz), 2.65-2.80 (m, 2H), 2.10-2.21 (m, 1 H), 1.77- 1.92 (m, 3H), 1.41 (d, 6H, J = 6.1 Hz), 1.26 (t, 3H, J = 7.2 Hz) ppm.
G. (2E)-3[4-(4-lsopropoxy-1-naphthalenyl)tetrahydro-1-benzofuran-2-yl]-2-propenoic acid. To a dioxane solution (200 mL) containing compound F (0.475 g, 1.17 mmol) was added lithium hydroxide hydrate (0.49 g, 11.7 mmol) followed by 1.5 mL of H2O.
After stirring 14 h TLC showed some starting material left so the solution was diluted with an additional 1 mL H2O and stirred an additional 22 h. The solution was acidified with sat. NaHSO4, extracted with EtOAc and dried (MgSO4). The crude acid was purified using a 2% methanol-dichloromethane mixture as the eluent to provide 0.374 g of product (0.99 mmol, 85% yield), m.p. 179-181 °C (d).
1H NMR (DMSO-d6) 400 MHz δ 11.90-12.50 (bs, 1 H), 8.17 (d, 1 H, J = 7.4
Hz), 8.07-8.12 (m, 1 H), 7.42-7.55 (m, 2H), 7.25 (d, 1 H, J = 15.7 Hz), 6.90 (d, 1 H, 7.9
Hz), 6.84 (d, 1 H, J = 7.8 Hz), 6.48 (s, 1 H), 6.02 (d, 1 H, J = 15.2 Hz), 4.70 (sept, 1 H, J = 6.1 Hz), 4.60 (bs, 1 H), 2.60-2.78 (m, 2H), 2.02-2.10 (m, 1 H), 1.64-1.80 (m, 3H),
1.32 (d, 6H, J = 6.1 Hz) ppm.
Example 11
(2E)-3-{4-[4-Dimethylamino)-3-ethylphenyl1-4,5,6,7-tetrahydro-1-benzofuran-2-yl}-2- propenoic acid.
A. 4-Bromo-2-ethyl-N,N-dimethylaniline.
To a 37% aqueous formaldehyde solution (158 mL) containing 126 mL of a
3.0 M sulfuric acid solution (378 mmol) was added at 0 °C a THF solution (800 mL) containing 4-bromo-2-ethyl aniline (10.0 g, 50 mmol) and sodium borohydride (47.4 g, 1.25 mol) portionwise. After complete addition the cold bath was removed and stirring continued for 2.5 hr. The reaction was quenched with H2O and MeOH and then the bulk of the THF removed in vacuo. The residual material was basified with 2.0 N NaOH and the organics were extracted with EtOAc (2X). After drying over MgSO the solvent was removed in vacuo and the residual oil purified via column chromatography (5% EtOAc/hexanes) yielding 5.46 g (23.9 mmol) of compound A plus unreacted starting material.
1H NMR (CDCI3) 400 MHz δ 7.31 (d, 1 H, J = 2.4 Hz), 7.23 (d, 1 H, J = 2.4 Hz), 6.92 (d, 1 H, J = 8.6 Hz), 2.68 (q, 2H, J = 7.6 Hz), 2.64 (s, 6H), 1.23 (t, 3H, J = 7.5 Hz) ppm.
B. N-[2-Ethyl-4-(4,5,6,7-tetrahydro-1-benzofuran-4-yl)phenyl]-N,N-dimethylamine.
To a THF solution (6 mL) containing compound A (648 mg, 2.84 mmol) cooled to -78 °C was added 1.2 mL of a 2.5 M hexanes solution of n-BuLi (2.98 mmol). After 30 min at -78 °C 6,7-dihydro-4(5H)-benzofuranone (367 mg, 2.70 mmol) in 5 mL THF was added. The reaction stirred for 3 hr at which time it was quenched with H2O and the organics were extracted with Et2O. After drying over MgSO the solvent was removed in vacuo. The residual oil was dissolved in 15 mL THF and then added dropwise to a THF solution (10 mL) containing sodium borohydride (1.02 g, 27.0 mmol) and BF3 Et2O (5.7 g, 40.5 mmol) at 0 °C. The reaction stirred for 10 min and was then carefully quenched with sat. NaHCO3. The two phase solution was then poured into 2.0 N NaOH and the organics were extracted with Et2O. Upon drying over MgSO the solvent was removed in vacuo and the residual oil purified via column chromatography (hexanes/EtOAc (15:1 )) yielding 456 mg (1.70 mmol, 63% for the 2 steps) of compound B. 1H NMR (CDCI3) 400 MHz δ 7.23 (d, 1 H, J = 1 .8 Hz), 6.99-6.97 (m, 2H), 6.89
(dd, 1 H, J = 8.1 & 2.2 Hz), 6.02 (d, 1 H, J = 1.7 Hz), 3.79 (m, 1 H), 2.70-2.62 (m, 10H), 2.05 (m, 1 H), 1 .91 (m, 1 H), 1.75 (m, 1 H), 1.64 (m, 1 H), 1.20 (t, 3H, J = 7.6 Hz) ppm.
C. 4-[4-Dimethylamino)-3-ethylphenyl]-4,5,6,7-tetrahydro-1-benzofuran-2- carbaldehyde.
To a Et2O solution (20 mL) containing compound B (1.73 g, 6.44 mmol) cooled to -40 °C was added 6.8 mL of a 1.7 M pentane solution of t-BuLi (11.6 mmol). The resulting orange solution stirred for 30 min when DMF (848 mg, 11.6 mmol) was added. The reaction went an additional 20 min and was then quenched with H2O. The two phase solution was poured into additional H2O and the organics were extracted with Et2O (2X). After drying over MgSO4 the solvent was removed in vacuo and the residual yellow oil was purified via column chromatography (hexanes/EtOAc (4:1)) yielding 1.32 g (4.45 mmol, 69% yield) of compound C.
1H NMR (CDCI3) 400 MHz δ 9.42 (s, 1 H), 7.00-6.95 (m, 2H), 6.86-6.85 (m, 1 H), 3.81 (m, 1 H), 2.78-2.62 (m, 10H), 2.09 (m, 1 H), 2.01 (m, 1 H), 1.80 (m, 1 H), 1.68 (m, 1 H), 1.19 (t, 3H, J = 7.6 Hz) ppm.
D. Ethyl (2E)-3-{4-[4-(dimethyIamino)-3-ethylphenyl]-4,5,6,7-tetrahydro-1 -benzofuran- 2-yl}-2-propenoate. To a DME solution (14 mL) containing sodium hydride (284 mg, 7.10 mmol,
60% dispersion in mineral oil) was added tiethylphosphonoacetate (1.59 g, 7.10 mmol). After 5 min compound C (1.41 g, 4.73 mmol) in 20 mL DME was added. Upon stirring an additional 20 min the reaction was quenched with H2O and the organics extracted with Et2O. After drying over MgSO4 and removal of the solvent in vacuo the residual oil was purified via column chromatography (hexanes/EtOAc (9:1 )) yielding 1.34 g, (3.65 mmol, 77% yield) of compound D.
1H NMR (CDCI3) 400 MHz δ 7.29 (d, 1 H, J = 15.5 Hz), 6.98-6.96 (m, 2H), 6.87 (d(br), 1 H, J = 8.1 Hz), 6.25 (s, 1 H), 6.20 (d, 1 H, J = 15.7 Hz), 4.19 (q, 2H, J = 7.1 Hz), 3.77 (m, 1 H), 2.70-2.64 (m, 10H), 2.05 (m, 1 H), 1.95 (m, 1 H), 1.78 (m, 1 H), 1.65 (m, 1 H), 1.28 (t, 3H, J = 7.1 Hz), 1.19 (t, 3H, J = 7.6 Hz) ppm.
E. (2E)-3-{4-[4-Dimethylamino)-3-ethylphenyl]-4,5,6,7-tetrahydro-1-benzofuran-2-yl}- 2-propenoic acid.
To a dioxane (15 mL)/H2O (4 mL) solution containing compound D (1.49 g, 4.05 mmol) was added lithium hydroxide hydrate (1.70 g, 40.5 mmol) at room temperature. The reaction stirred overnight and was then acidified with sat. NaHSO4 and the organics were extracted with EtOAc (2X). After drying over MgSO the solvent was removed in vacuo and the residual yellow oil was purified via column chromatography (CH2CI2/MeOH (15:1)) yielding 708 mg (2.09 mmol, 52% yield) of compound E as a yellow solid, m.p. 75-78 °C.
1H NMR (CDCI3) 400 MHz δ 7.32 (d, 1 H, J = 15.5 Hz), 6.99-6.96 (m, 2H), 6.87 (dd, 1 H, J = 8.2 & 2.2 Hz), 6.30 (s, 1 H), 6.19 (d, 1 H, J = 15.6 Hz), 3.77 (m, 1 H), 2.72- 2.64 (m, 10H), 2.07 (m, 1 H), 1.96 (m, 1 H), 1.78 (m, 1 H), 1.65 (m, 1 H), 1.19 (t, 3H, J = 7.5 Hz) ppm. Example 12
(2E)-3-{4-[(E)-2-(2,6,6-Trimethyl-1 -cyclohexen-1 -yl)ethenyl]-1 -benzofuran-2-yl}-2- propenoic acid.
A. 1-Benzofuran-4-ylmethanol.
To a CH2CI2 solution (15 mL) containing the methyl 1-benzofuran-4- carboxylate (1 g, 5.68 mmol) cooled to -78 ° C was added diisobutylaluminium hydride dropwise. After stirring for 30 min the reaction was quenched with the slow addition of MeOH. Upon warming the white precipitate was filtered through a bed of celite and rinsed thoroughly with EtOAc. The EtOAc layer was washed with sat. NaHSO and H2O. After drying over MgSO , the solvent was removed in vacuo yielding 0.75 g (5.13 mmol, 94% yield) of compound A as a white solid.
1H NMR (CDCI3) 400 MHz δ 7.63 (s, 1 H),.7.45 (d, 1 H, J=8 Hz), 7.28-7.19 (m, 2H), 6.90 (s, 1 H), 4.92 (d, 2H, J=5.6 Hz), 1.66 (t, 1 H, J=6 Hz) ppm.
B. 1-Benzofuran-4-carboxaldehyde
To a CHCI3 solution (10 mL) containing compound A (.5 g, 3.42 mmol) at room temperature, was added manganese dioxide (5.95g, 68.4 mmol). The reaction stirred overnight after which the black slurry was filtered through a bed of celite and rinsed thoroughly with CHCI3. The solvent was removed in vacuo yielding 0.41 g (2.86 mmol, 83% yield) of compound B as a clear liquid.
1H NMR (CDCI3) 400 MHz δ10.17 (s, 1 H), 7.77 (s, 1 H), 7.69-7.69 (m, 2H), 7.49 (s, 1 H), 7.44 (t, 1 H, J= 8 Hz) ppm.
C. 4-[(E)-2-(2,6,6-Trimethyl-1 -cyclohexen-1 -yl)ethenyl]-1-benzofuran.
To a THF solution (15 mL) containing the dimethyl (2,6,6-trimethyl-1- cyclohexen-1-yl)methylphosphonate (2.18 g, 4.55 mmol) cooled to -78 °C, was added n-butyl lithium (1.9 mL, 4.77 mmol) dropwise. After stirring for 2 hr compound B (.44 g, 3.03 mmol) in a THF (5 mL) solution was added dropwise. After stirring for a further 3 hr at room temperature the solution was quenched with H2O and the organics extracted with Et2O. The Et2O layer was washed with H2O and dried over MgSO4. The solvent was removed in vacuo and the brown residual oil purified via column chromatography (hexanes/EtOAc (9:1 )) yielding 90 mg (0.34 mmol, 8% yield) of compound C as a clear oil. 1H NMR (CDCI3) 400 MHz δ 7.62 (s, 1 H), 7.36-7.26. (m, 2H), 7.24 (d, 1 H, J= 4.5 Hz), 6.94 (s, 1 H), 6.80 (d, 1 H, J= 16 Hz), 6.63 (d, 1 H, J= 8 Hz), 2.06 (t, 2H, J= 8 Hz), 1.79 (s, 3H), 1.67-1.61 (m, 2H), 1.51-1.48 (m, 2H), 1.08 (s, 6H) ppm.
D. 4-[(E)-2-(2,6,6-Trimethyl-1 -cyclohexen-1 -yl)ethenyl]-1-benzofuran-2-carbaldehyde. To a Et2O solution (1.5 mL) containing compound C (90 mg, .34 mmol) cooled to -40 °C was added t-butyl lithium (0.5 mL, 0.845 mmol) dropwise. After stirring for 30 min DMF (65 μL, 0.84 mmol) was added dropwise. After stirring for an additional 30 min the reaction was quenched with H2O. The organics were extracted with Et2O and washed with H2O. After drying over MgSO4 the solvent was removed in vacuo yielding 80 mg (0.27 mmol, 88% yield) of compound D as a yellow oil. H NMR (CDCI3) 400 MHz δ 9.85 (s, 1 H), 7.72 (s, 1 H), 7.48-7.40 (m, 3H), 6.87 (d, 1 H, J= 16 Hz), 6.65 (d, 1 H, J= 16 Hz), 2.07 (t, 2H, J= 8 Hz), 1.79 (s, 3H), 1.67-1.63 (m, 2H), 1.51-1.48 (m, 2H), 1.08 (s, 6H) ppm.
E. Ethyl (2E)-3-{4-[(E)-2-(2,6,6-trimethyl-1 -cyclohexen-1 -yl)ethenyl]-1 -benzofuran-2- yl}-2-propenoate.
To a DME solution (1 mL) containing NaH (16.3 mg, 0.41 mmol) and triethylphosphonoacetate (81 μL, 0.41 mmol) was added compound D in 1 mL of DME dropwise. After stirring for 3 hr the reaction was quenched with H2O and the organics extracted with Et2O. The Et2O layer was washed with H2O and dried over MgSO4. The solvent was removed in vacuo yielding 65 mg (0.18 mmol, 66% yield) of compound E as a yellow oil.
1H NMR (CDCI3) 400 MHz δ 7.55 (d, 1 H, J= 16 Hz), 7.3 (s, 3H), 7.08 (s, 1 H), 6.80 (d, 1 H, J= 16 Hz), 6.6-6.5 (dd, 2H, J= 16, 12 Hz), 4.27 (q, 2H, J= 8 Hz), 2.06 (t, 2H, J= 8 Hz), 1.78 (s, 3H), 1.65-1.61 (m, 2H), 1.50-1.47 (m, 2H), 1.33 (t, 3H, J= 8 Hz), 1.07 (s, 6H) ppm.
F. (2E)-3-{4-[(E)-2-(2,6,6-trimethyl-1 -cyclohexen-1 -yl)ethenyl]-1 -benzofuran-2-yl}-2- propenoic acid.
To a dioxane solution (1 mL) containing compound E (65 mg, 0.18 mmol) at room temperature was added lithium hydroxide monohydrate (74 mg, 1.78 mmol) followed by 150 μL of H2O. After stirring for 12 hr the reaction was diluted with H2O, acidified with sat. NaHSO4 and the organics extracted with EtOAc. After drying with MgSO4 the solvent was removed in vacuo and the residual yellow solid was purified via column chromatography (CH2CI2/MeOH (15:1) yielding .044 g (0.13 mmol, 73% yield) of compound F as a yellow solid.
1H NMR (CDCI3) 400 MHz δ 7.63 (d, 1H, J= 16 Hz), 7.32 (s, 3H), 7.14 (s, 1H), 6.81 (d, 1 H, J= 16 Hz), 6.60-6.53 (dd, 2H, J= 12, 12 Hz), 2.06 (t, 2H, J= 8 Hz), 1.78 (s, 3H), 1.65-1.61 (m, 2H), 1.51-1.48 (m, 2H), 1.074 (s, 6H) ppm.
Example 13
4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1- benzofuran-2-carboxylic acid.
A. 4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1- benzofuran-2-carboxylic acid.
A methanol solution (20 mL) was mixed with 4-(5,5,8,8-tetramethyl-5,6,7,8- tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1 -benzofuran]-2-carboxaldehyde (100 mg, 0.30 mmol, see example 1 part C for preparation), 5.0 N NaOH (10 mL) and
Ag2O (138 mg, 0.59 mmol. The resulting black heterogeneous reaction mixture was allowed to stir at room temperature for a period of 17 hours. The reaction mixture was diluted with water and washed with ethyl ether. The ether washes were discarded and the aqueous mixture was made acidic (pH 3.0) using concentrated HCI. The resulting mixture was extracted with ether and dried over MgSO4. The solvent was evaporated in vacuo to yield 73 mg of pure solid.
1H NMR (CDCI3) 400 MHz δ 7.20 (d, 1 H), 7.04 (s, 1 H), 7.00 (s, 1 H), 6.83 (d,
1 H), 3.8 (s, 1H), 2.80(t, 2H), 2.15 (m, 1 H), 2.05-1.98 (m, 1 H), 1.90-1.80 (m, 1 H),
1.78-1.70 (m, 5H), 1.38-1.20 (m, 12H) ppm.
Example 14
[4-(5,5,8,8,-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1- benzofuran]-2-(2,4-thiazolidinedione). A. [4-(5, 5,8,8, -Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-
1-benzofuran]-2-(2,4-thiazolidinedione).
A toluene solution (10 mL) was mixed with 4-(5,5,8,8-tetramethyl-5,6,7,8- tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1-benzofuran]-2-carboxaldehyde (100 mg, 0.30 mmol), 2,5-thiazolidinedione (62 mg, 0.53 mmol), morpholine (200 mg, 2.3 mmol), molecular sieves and 10 mL of anhydrous toluene. The reaction mixture was stirred at reflux for 4.0 hours at which time it was cooled to 0-5 °C. The resulting yellow solid was filtered in vacuo and washed with 10 mL of cold toluene. The resulting solid was dried in vacuo for 17 hours to afford 34 mg of pure solid.
1H NMR (CDCI3) 400 MHz δ 7.95 (s, 1 H), 7.50 (s, 1 H), 7.22 (d, 1 H), 7.02 (s, 1 H), 6.83 (d, 1 H), 6.50 (s, 1 H), 3.82 (t, 1 H), 2.81-2.77 (m, 2H), 2.18-1.99 (m, 2H), 1.90-1.80 (m, 1 H), 1.79-1.60 (m, 5H), 1.35-1.20 (m, 12H) ppm.
Example 15
[4-(5,5,8,8,-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1- benzothiaphene]-2-propionic acid.
A. [4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1- benzothiaphene]-2-propionic acid.
A solution was made containing EtOAc (20 mL), [4-(5,5,8,8-tetramethyl-
5,6,7, 8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1-benzothiaphene]-2-trans- propenoic acid (200 mg, 0.51 mmol) and Peariman's catalyst (50 mg). The reaction mixture was degassed in vacuo and stirred under a hydrogen atmosphere (1 atm) for a period of 2.0 hours. The reaction mixture was degassed and filtered over celite in vacuo. The resulting solution was concentrated to dryness in vacuo. The resulting oil was dissolved into Et2O and washed with saturated NaCl. The organics were dried (MgSO4) and concentrated to afford 176 mg of desired acid.
1H NMR (CDCI3) 400 MHz δ 7.20 (d, 1 H), 7.00 (s, 1 H), 6.80 (d, 1 H), 6.13 (s,
1 H), 3.82 (m, 1 H), 3.00 (t, 2H), 2.80 (m, 2H), 2.61 (t, 2H), 2.17-2.03 (m, 1 H), 1.97-
1.80 (m, 1 H), 1.78-1.62 (m, 6H), 1.30-1.17 (m, 12H) ppm.
Example 16
4-(5,5,8,8,-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1- benzofuran]-2-(2,3(cis)propenoic acid.
A. 4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1- benzofuran]-2-acetophenone. A flame dried round bottom flask was charged with 4-(5,5,8,8-tetramethyl-
5,6,7, 8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1-benzofuran]-2- carboxaldehyde (500 mg, 1.6 mmol) and anhydrous ether (25 mL). This solution was cooled to -70 °C while stirring under a nitrogen blanket. To this solution was added 2.5 M t-butyl lithium (1.0 mL, 2.4 mmol). The reaction mixture was allowed to stir for 30 minutes at which time it was quenched via the addition of N-methoxy-N- methylacetamide (330 mg, 3.2 mmol). The reaction was allowed to warm to RT where it stirred for 4.0 hours followed by quenching via the addition of 1.0 N HCI (20 mL). The reaction mixture was extracted using ether. The organics were separated and dried over MgSO4 followed by concentrating to dryness. The resulting oil was chromatographed on silica gel (90%hexanes/10% ethyl acetate) to afford 487 mg of pure oil.
1H NMR (CDCI3) 400 MHz δ 7.30 (d, 1 H), 7.24 (s, 1 H), 7.00 (dd, 1 H), 6.95 (s, 1 H), 3.80 (m, 2H), 2.87(m, 2H), 2.40 (s, 3H), 2.18-2.05 (m, 2H), 1.90-1.80 (m, 1 H), 1.79-1.60 (m, 5H), 1.30-1.20 (m, 12H) ppm.
B. 4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1- benzofuran]-2-(2,3(cis)propenoic acid.
To a THF solution (20 mL) containing sodium hydride (138 mg, 5.5 mmol, 95%>) was added triethylphosphonoacetate (245 mg, 2.1 mmol) at 0-5 °C. To this reaction mixture was added 4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2- naphthalenyl)-4,5,6,7-tetrahydro-1-benzofuran]-2-acetophenone (480 mg, 1.4 mmol) and the mixture was allowed to warm to RT. The reaction mixture was stirred at RT for 1.0 hour at which time it was quenched via the addition of water (30mL). The mixture was stirred at RT for 16 hours. The resulting mixture was made acidic using 3.0 N HCI. The reaction mixture was then extracted into ether and dried over MgSO4. The mixture was concentrated to dryness and chromatographed on silica gel (80%hexanes/ 20%EtOAc) yielding 45 mg of pure acid.
1H NMR (CDCI3) 400 MHz δ7.20 (d, 1 H), 7.07 (s, 1 H), 6.98 (s, 1 H), 6.89 (d, 1 H), 6.06 (s, 1 H), 3.82(m, 1 H), 2.65 (m, 2H), 2.20 (s, 3H), 2.16-2.06 (m, 1 H), 1.97- 1.90 (m, 1 H), 1.82-1.73 (m, 1 H), 1.71-1.62 (m, 5H), 1.30-1.20 (m, 12H) ppm.
Example 17 " (2E)-3-{4-[(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-2-furyl}-2- propenoic acid.
A. 2-(4-Bromo-2-furyl)-1 ,3-dioxolane.
A toluene solution (100 mL) containing, p-toluenesulphonic acid monohydrate
(100 mg, 0.52 mmol), 4-bromo-2-furaldehyde (5.0 g, 28.6 mmol) and ethylene glycol (1.7 g, 28.6 mmol) was heated at reflux for a period of 4.0 hours. The reaction flask was fitted with a Dean-Stark trap to collect the water. After 4.0 hours the reaction mixture was concentrated to dryness and partitioned between saturated NaHCO3and ethyl ether. The solvent was dried over MgSO and concentrated to dryness to yield a total 4.9 g (79% yield) of compound A.
1H NMR (CDCI3) 400 MHz δ 7.42 (s, 1 H ,.6.50 (s, 1 H), 5.91 (s, 1 H), 4.17-3.98 (m, 4H) ppm.
B. 5,5,8, 8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenecarbaldehyde. A flame dried round bottom flask was charged with 6-bromo-1 ,1 ,4,4-tetramethyl- 1 ,2,3,4-tetrahydronaphtalene(.10 g, 37 mmol) and anhydrous THF (100mL). This solution was cooled to -70 °C while stirring under a nitrogen blanket. To this solution was added 2.5 M n-butyl lithium (14.9 mL, 37 mmol). The reaction mixture was allowed to stir for 30 minutes at which time it was quenched via the addition of dimethylformamide (5.0 mL). The reaction was allowed to warm to RT where it stirred for 7 hours. The reaction was quenched by the addition of 1.0 N HCI (100 mL). The reaction mixture was extracted using ether. The organics were separated and dried over MgSO4 followed by concentrating to dryness. The resulting oil was dried under high vacuum to give a total of 8.2 g (100%) of crude oil. The product was used without further purification.
1H NMR (CDCI3) 400 MHz δ 9.95 (s, 1 H), 7.82 (s, 1 H), 7.61 (d, 1 H), 7.46 (d, 1 H), 1.74-1.67 (m, 4H), 1.41-1.20 (m, 12H) ppm.
C. [5-(1 ,3-Dioxolan-2-yl)-3-furyl](5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2- naphthalenyl)methanol.
A mixture of 2-(4-bromo-2-furyl)-1 ,3-dioxolane (2.4 g, 11 mmol) and anhydrous THF (30 mL) was added to a flame dried round bottom flask and cooled to -70 °C. To this mixture was added 2.5 M n-butyl lithium (4.9 mL, 12.3 mmol) and the mixture stirred at -70 °C for 1.0 hour. To this mixture was added 5,5,8,8-tetramethyl- 5,6,7,8-tetrahydro-2-naphthalenecarbaldehyde (2.4 g, 11 mmol) and the reaction was allowed to stir at 0 °C for 3.0 hours. The reaction mixture was mixed with 1.0 N HCI while at 0 °C and partitioned with ether. The ether was separated and dried with MgSO4. The solvent was evaporated in vacuo to give a crude oil that was chromatographed using silica gel (95% hexanes/5% EtOAc) to afford 1.1 g of compound C. 1H NMR (CDCI3) 400 MHz δ7.36-7.24 (m, 3H), 7.10 (d, 1 H), 6.41 (s, 1 H), 5.85 (s, 1 H), 5.30 (s, 1 H), 4.17-3.98 (m, 4H), 1.70 (s, 4H), 1.25 (s, 12H) ppm.
D. 2-{4-[(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-2-furyl}-1 ,3- dioxolane.
A flask was mixed with [5-(1 ,3-dioxolan-2-yl)-3-furyl](5,5,8,8-tetramethyl- 5,6,7,8-tetrahydro-2-naphthalenyl)methanol (1.1g, 3.1 mmol), phenylchlorothionoformate (586 mg, 3.4 mmol), dimethylaminopyridine (25 mg, 0.205 mmol) and anhydrous CH2CI2(25 mL). This solution was allowed to stir at RT for 1.0 hour and concentrated to dryness. This crude reaction mixture was dissolved in toluene (50 mL). This toluene solution was mixed with Bu3SnH (2.7g, 9.3 mmol) and AIBN (10 mg, 0.061 mmol). The solution stirred at reflux for a period of 4.0 hours and was concentrated to dryness. The resulting crude was partitioned between saturated NaHCO3 and CH2CI2. The organics were dried over MgSO4and concentrated to afford a crude oil. This oil was chromatographed on silica gel (95%hexanes/5%EtOAc) to afford 246 mg of compound D.
1H NMR (CDCI3) 400 MHz δ 7.22-7.16 (m, 3H), 6.93 (d, 1 H), 6.32 (s, 1 H), 5.84 (s, 1 H), 4.17-3.98 (m, 4H), 3.64 (s, 2H), 1.63 (s, 4H), 1.25 (s, 12H) ppm.
E. 4-[(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-2-furaldehyde. A round bottom flask was mixed with 2-{4-[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro- 2-naphthalenyl)methyl]-2-furyl}-1 ,3-dioxolane (246 mg, 0.72 mmol), 3.0 N HCI (10 mL) and THF (20 mL). The reaction mixture stirred for 16 hours at room temperature and was concentrated to one half volume. The resulting mixture was partitioned between saturated NaCl and ether. The ether layer was dried over MgSO and concentrated to dryness. The resulting oil showed an inseparable impurity by TLC and the product was used without further purification.
F. Ethyl (2E)-3-{4-[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-2- furyl}-2-propenoate.
A flame dried round bottom flask was charged with anhydrous THF (15 mL) and sodium hydride (3.4 mg, 1.4 mmol). The solution was cooled to 0-5 °C and mixed with triethylphosphonoacetate (314 mg, 1.4 mmol). The reaction was stirred for 30 minutes at 0-5 °C. To this mixture was added 4-[(5,5,8,8-tetramethyl-5,6,7,8- tetrahydro-2-naphthalenyl)methyl]-2-furaldehyde (222 mg, 0.71 mmol) and the reaction stirred at RT for 16 hours. The reaction was quenched with water and made acidic using 1.0 N HCI. The reaction mixture was partitioned between water and ethyl acetate and the organics were dried over MgSO4. The organics were concentrated and the resulting oil was chromatographed on silica gel
(95%hexanes/5%EtOAc). The resulting pure compound F (76 mg) was used without further purification.
1H NMR (CDCI3) 400 MHz δ7.37 (d, 1 H), 7.30-7.20 (m, 2H), 6.99-6.89 (m, 2H), 6.47 (s, 1 H), 6.23 (d, 1 H), 4.22 (q, 2H), 3.70 (s, 2H), 1.65 (s, 4H), 1.42 (s, 6H), 1.38-1.18 (m, 9H) ppm.
G. (2E)-3-{4-[(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-2-furyl}- 2-propenoic acid. A mixture containing ethyl (2E)-3-{4-[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2- naphthalenyl)methyl]-2-furyl}-2-propenoate (76 mg, 0.21 mmol), methanol (1.0mL), THF (2.0ml_) and 5.0 N NaOH (5.0mL) was allowed to stir at RT for a period of 16 hours. The reaction mixture was cooled to 0-5 °C and made acidic using concentrated HCI (pH 3.5). The mixture was extracted with EtOAc, dried over MgSO4, and concentrated to dryness to afford a crude solid. The resulting solid was chromatographed on silica gel (90%hexanes/10%EtOAc) to give 15 mg of compound G.
1H NMR (d6-acetone) 400 MHz.δ7.51 (s, 1 H), 7.38 (d, 1 H), 7.26-7.22 (m, 2H), 6.98 (dd, 1 H), 6.73 (s, 1H), 6.19 (d, 1H), 3.72 (s, 2H), 1.63 (s, 4H), 1.22 (m, 12H) ppm.
Example 18
(2E)-3-{4-[(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-2-thienyl}- 2-propenoic acid.
A. 2-(4-Bromo-2-thienyl)-1 ,3-dioxolane.
A toluene solution (75 mL) containing, p-toluenesulphonic acid monohydrate
(500 mg, 2.63 mmol), 4-bromo-2-thiophene carboxaldehyde (7.5 g, 40 mmol) and ethylene glycol (12.1g, 0.20 mol) was heated at reflux for a period of 4.0 hours. The reaction flask was fitted with a Dean-Stark trap to collect the water. After 4.0 hours the reaction mixture was concentrated to dryness and partitioned between saturated NaHCO3 and CH2CI2. The solvent was dried over MgSO4 and concentrated to dryness to yield a total 9.1g (98% yield) of compound A.
1H NMR (CDCI3) 400 MHz δ 7.21 (s, 1 H),7.03 (s, 1 H), 6.02 (s, 1 H), 4.16-4.00 (m, 4H) ppm.
B. [5-(1 ,3-Dioxolan-2-yl)-3-thienyl](5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2- naphtha!enyl)methanol.
2-(4-Bromo-2-thienyl)-1 ,3-dioxolane (8.9 g, 38 mmol) and anhydrous THF (100 mL) was added to a flame dried round bottom flask and cooled to -70 °C. To this mixture was added 2.5 M n-butyl lithium(16.8 mL, 45 mmol) and the mixture stirred at -70 °C for 1.0 hour. To this mixture was added 5,5,8,8-tetramethyl-5,6,7,8- tetrahydro-2-naphthalenecarbaldehyde (8.2 g, 38 mmol) and the reaction was allowed to stir at 0 °C for 16 hours. The reaction mixture was mixed with 6.0 N HCI (pH 7.0) while at 0 °C and partitioned with ether. The ether was separated and dried with MgSO4. The solvent was evaporated in vacuo to give a crude oil that was chromatographed using silica gel (90%hexanes/10%EtOAc) to afford 5.8 g compound B.
1H NMR (CDCI3) 400 MHz δ 7.37 (d, 1 H), 7.25 (d, 1 H), 7.18 (s, 1 H), 7.09 (s, 1H), 6.99 (s, 1 H), 6.02 (m, 2H), 4.17-3.99 (m, 4H), 1.68 (s,' 4H), 1.24 (s, 12H) ppm.
C. 2-{4-[(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyi]-2-thienyl}- 1 ,3-dioxolane.
A flask was mixed with [5-(1 ,3-dioxolan-2-yl)-3-thienyl](5,5,8,8-tetramethyl- 5,6,7,8-tetrahydro-2-naphthalenyl)methanol (4.0 g, 11 mmol), phenylchlorothionoformate (2.4 g, 17 mmol), dimethyaminopyridine (2.7 g, 22 mmol) and anhydrous CH2CI2 (40mL). This solution was allowed to stir at RT for 17 hours and concentrated to dryness. This crude mixture was partitioned between saturated NaHCO3 and ether. The organics were dried over MgSO4 and concentrated to dryness to afford 9.8 g of crude oil. The crude solid was dissolved in toluene (100 mL). This toluene solution was mixed with Bu3SnH (10 mL, 37.1 mmol) and AIBN (100 mg, 0.61 mmol). The solution stirred at 80 °C for a period of 5.0 hours and was cooled to RT. This solution was charged with 3% NH4OH and stirred at RT for 1.0 hour. The organics were separated, dried over MgSO4and concentrated to afford a crude oil. This oil was chromatographed on silica gel (95%hexanes/5%EtOAc) to afford 5.1g of compound C (the compound contained an inseparable impurity but was confirmed by LCMS).
D. 4-[(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-2- thiophenecarbaldehyde
A round bottom flask was mixed with 2-{4-[(5,5,8,8-tetramethyl-5,6,7,8- tetrahydro-2-naphthalenyl)methyl]-2-thienyl}-1 ,3-dioxolane (5.1 g, 14.3 mmol), 3.0 N HCI (50 mL), methanol (20 mL) and THF (30 mL). The reaction mixture stirred for 6 hours at room temperature and was concentrated to one half volume. The resulting mixture was partitioned between water and ether. The ether layer was dried over MgSO4 and concentrated to dryness. The resulting oil showed an inseparable impurity by TLC from the starting material. The product was used without further purification (2.7 g).
E. (2E)-3-{4-[(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-2- thienyl}-2-propenoic acid.
A flame dried round bottom flask was charged with anhydrous THF (25 mL) and sodium hydride (192 mg, 4.8 mmol). The solution was cooled to 0-5 °C and mixed with triethylphosphonoacetate (1.1 g, 4.8 mmol) and the reaction was stirred for 30 minutes at 0-5 °C. To this mixture was added 4-[(5, 5,8, 8-tetramethyl-5, 6,7,8- tetrahydro-2-naphthalenyl)methyl]-2-thiophenecarbaldehyde (500 mg, 1.6 mmol) and the reaction stirred at RT for 16 hours. The reaction was quenched with water at 0 °C and this mixture was mixed with 10 mL of 2.5 N NaOH and 3.0 mL of methanol. The reaction mixture was stirred at RT for an additional 2.0 hours and was made acidic using 1.0 N HCI. The mixture was extracted into ether and dried over MgSO . The organics were concentrated and the resulting oil was triturated with a mixture of ether/hexanes. The resulting solid was filtered and dried in vacuo to yield 281 mg of compound E. 1H NMR (CDCI3) 400 MHz δ 7.80 (d, 1 H), 7.22 (d, 1 H), 7.14 (m, 2H), 7.02 (s,
1 H), 6.94 (d, 1 H), 6.19 (d, 1 H), 3.86 (s, 2H), 1.65 (s, 4H), 1.27 (s, 12H) ppm.
Example 19
(2E)-3-{4-[(3-Methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyll- 2-furyl}-2-propenoic acid. A. 3-Furyl(3-methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2- naphthalenyl)methanol.
6-Bromo-7-methoxy-1 ,1 ,4,4-tetramethyl-1 ,2,3,4-tetrahydronaphthalene (5.0 g, 17 mmol) and anhydrous THF (100 mL) was added to a flame dried round bottom flask and cooled to -70 °C. To this mixture was added 2.7 M n-butyl lithium(6.9 mL, 18.5 mmol) and the mixture stirred at -70 °C for 1.0 hour. To this mixture was added 3-furaldehyde (1.61 g, 17 mmol) and the reaction was allowed to stir at 0 °C for 4.0 hours. The reaction mixture was mixed with 1.0 N HCI (pH 4.0) while at 0 °C and partitioned with ether. The ether was separated and dried with MgSO . The solvent was evaporated in vacuo to give a crude oil that was chromatographed using silica gel (90%hexanes/10%oEtOAc) to afford 3.4 g of compound A.
1H NMR (CDCI3) 400 MHz δ 7.57 (s, 1 H), 7.38 (s, 1 H), 7.22 (s, 1 H), 7.04 (s, 1 H), 6.38 (s, 1 H), 5.90 (d, 1 H), 4.23 (d, 1 H), 3.80 (s, 3H), 1.67-1.56 (m, 4H), 1.32- 1.18 (m, 12H) ppm.
B. 4-[Hydroxy(3-methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2- naphthalenyl)methyl]-2-furaldehyde.
A solution containing anhydrous ether (50 mL) and 3-furyl(3-methoxy-5,5,8,8- tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methanol (3.4 g, 10.8 mmol) was cooled to -70 °C while stirring under nitrogen. To this mixture was added 2.7 M t- butyllithium (12.0 mL, 32.4 mmol). The reaction mixture was allowed to stir at -40 °C for 30 minutes at which time it was charged with DMF (1.2 g, 16.2 mmol). The reaction was stirred at -20 °C to 0 °C over a period of 30 minutes and the reaction was quenched using 1.0 N HCI. The reaction was extracted with ether followed by drying with MgSO . The organics were concentrated in vacuo to afford a crude oil. The oil was chromatographed on silica gel (90%hexanes/10%EtOAc) to yield 2.9 g of compound B as an oil.
1H NMR (CDCI3) 400 MHz δ 9.83 (s, 1 H), 7.52 (s, 1 H), 7.30 (s, 1 H), 6.77 (s, 1 H), 6.51 (s, 1 H), 6.27 (d, 1 H), 4.25 (d, 1 H), 3.82 (s, 3H), 1.65 (s, 4H), 1.31-1.19 (m, 12H) ppm.
C. 4-[(3-Methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-2- furaldehyde. A solution containing 4-[hydroxy(3-methoxy-5,5,8,8-tetramethyl-5,6,7,8- tetrahydro-2-naphthalenyl)methyl]-2-furaldehyde (2.9 g, 8.5 mmol), triethylsilane (2.9 g, 25.4 mmol) and anhydrous methylene chloride (40 mL) was cooled to 0 °C. To this mixture was added trifluoroacetic acid (-1.0 mL, 8.5 mmol) and the reaction was allowed to stir at RT for 16 hours. The reaction was quenched with saturated
NaHCO3 and the organics were separated and dried over MgSO4. The resulting oil (2.5 g) was used without further purification.
1H NMR (CDCIs) 400 MHz δ 9.80 (s, 1 H), 7.50 (s, 1 H), 7.09 (s, 1 H), 6.77 (s, 1H), 6.41 (s, 1H), 4.07 (s, 2H), 3.79 (s, 3H), 1.67 (s, 4H), 1.27 (s, 6H), 1.21 (s, 6H) ppm.
D. (2E)-3-{4-[(3-Methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2- naphthalenyl)methyl]-2-furyl}-2-propenoic acid.
A flame dried round bottom flask was charged with anhydrous THF (25 mL) and sodium hydride (276 mg, 1 1.5 mmol). The solution was cooled to 0-5 °C and mixed with triethylphosphonoacetate (2.6 g, 11.5 mmol) and the reaction was stirred for 30 minutes at 0-5 °C. To this mixture was added 4-[(3-methoxy-5, 5,8,8- tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-2-furaldehyde (2.5 g, 7.65 mmol) and the reaction stirred at RT for 16 hours. The reaction was quenched with water at 0 °C and this mixture was mixed with 2.5 N NaOH and methanol. The reaction mixture was stirred at RT for an additional 2.0 hours and was made acidic using 1.0 N HCI. The mixture was extracted into ether and dried over MgSO4. The organics were concentrated and the resulting oil was chromatographed on silica gel (90%hexanes/10%) EtOAc). The resulting solid was filtered and dried in vacuo to yield 1.9 g of the ethyl ester as an oil and 238 mg of compound D.
1H NMR (CDCI3) 400 MHz δ 7.76 (d, 1 H), 7.39 (s, 1 H), 7.02 (s, 1 H), 6.73 (s, 1 H), 6.36 (s, 1 H), 6.27 (d, 1 H), 3.80 (s, 5H), 1.64 (s, 4H), 1.28-1.19 (d, 12H) ppm.
Example 20 (2E)-3-{5-Methyl-4-[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-2- furyl}-2-propenoic acid.
A. N-methoxy-N-2-dimethyl-3-furamide
A solution of CH2CI2 (200 mL) containing 2-methyl-3-furoic acid (20 g, 159 mmol), HOBt (23.5 g, 174 mmol), N-methyl-O-methoxyamine hydrochloride (17 g, 174 mmol) and EDC (30 g, 174 mmol) was mixed with triethylamine (17.6 g, 174 mmol) while maintaining a temperature less than 15 °C. The reaction stirred at RT for 17 hours and was then concentrated to dryness. The reaction crude was partitioned between CH2CI2 and saturated NaHCO3. The organics were then washed with 0.5 N HCI and saturated NaCl. The organics were dried over MgSO and concentrated to dryness. The resulting solid was used without further purification 1H NMR (CDCI3) 400 MHz δ 7.04 (s, 1 H), 6.68 (s, 1 H), 3.63 (s, 3H), 3.32 (s, 3H), 2.55 (s, 3H) ppm.
B. (2-Methyl-3-furyl)(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2- naphthalenyl)methanone.
A solution containing 6-bromo-1 ,1 ,4,4-tetramethyl-1 ,2,3,4- tetrahydronaphthalene (10.0 g, 37 mmol) and THF (100 mL) was cooled to -70 °C. The reaction was mixed with 2.7 M n-butyl lithium (15.2 mL, 41 mmol) and the reaction mixture was allowed to stir at -70 °C for a period of 30 minutes. This solution was mixed with N-methoxy-N-2-dimethyl-3-furamide (7.0 g, 41 mmol) and was slowly allowed to warm to RT over a period of 17 hours. The reaction mixture was quenched at 0 °C using 1.0 N HCI and then extracted with ether. The organics were washed with saturated NaCl, dried over MgSO4 and concentrated to give a crude product. The crude oil was chromatographed on silica gel (90%hexanes/10% EtOAc) to yield 8.1 g of compound B as an oil that was mostly pure by NMR.
1H NMR (CDCI3) 400 MHz δ 7.78 (s, 1 H), 7.58 (d, 1 H), 7.39 (d, 1 H), 7.22 (s, 1 H), 6.60 (s, 1 H), 2.57 (s, 3H), 1.65 (s, 4H), 1.32 (s, 12H) ppm.
C. (2-Methyl-3-furyl)(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methanol. A solution containing (2-methyl-3-furyl)(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro- 2-naphthalenyl)methanol (8.0 g, 27 mmol) and dry methanol (100 mL) was cooled to 0-5 °C using an ice bath. The reaction was mixed with NaBH4 (2.0 g, 54 mmol) and allowed to stir at RT for a period of 16 hours. The reaction mixture was slowly made acidic using concentrated HCI. The resulting reaction mixture was partitioned between ether and water. The organics were dried over MgSO4 and concentrated to dryness. The crude oil was chromatographed on silica gel (90%hexanes/10% EtOAc) to give 6.6 g of compound C as an oil. 1H NMR (CDCI3) 400 MHz δ 7.35 (s, 1 H), 7.27 (d, 1 H), 7.23 (s, 1 H), 7.11 (d, 1 H), 6.19 (s, 1 H), 5.71 (d, 1 H), 2.29 (s, 3H), 1.96 (d, 1 H), 1.63 (s, 4H), 1.23 (s, 12H) ppm.
D. 4-[Hydroxy(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-5- methyl-2-furaldehyde.
A solution containing anhydrous ether (70 mL) and (2-methyl-3-furyl)(5,5,8,8- tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methanol (6.6 g, 22 mmol) was cooled to -70 °C while stirring under nitrogen. To this mixture was added 2.7 M t- butyllithium (20 mL, 54 mmol). The reaction mixture was allowed to stir at -70 °C for 30 minutes at which time it was charged with DMF (2.4 g, 33 mmol). The reaction was stirred at 0 °C over a period of 1.0 hour and the reaction was quenched using 1.0 N HCI. The reaction was extracted with ether followed by drying with MgSO4. The organics were concentrated in vacuo to afford a crude oil. The oil was chromatographed on silica gel (90%hexanes/10%EtOAc) to yield 4.1 g of compound D as an oil.
1H NMR (CDCI3) 400 MHz δ 9.45 (s, 1 H), 7.32 (m, 2H), 7.15 (s, 1 H), 7.15 (d, 1 H), 5.74 (d, 1 H), 2.40 (s, 3H), 2.09 (d, 1 H), 1.68 (s, 4H), 1.27 (s, 12H) ppm.
E. 5-Methyl-4-[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-2- furaldehyde.
A solution containing 4-[hydroxy-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2- naphthalenyl)methyl]-5-methyl-2-furaldehyde (3.6 g, 11 mmol), triethylsilane (3.8 g, 33.1 mmol) and anhydrous methylene chloride (50 mL) was cooled to 0 °C. To this mixture was added trifluoroacetic acid (~1.3 g, 11.4 mmol) and the reaction was allowed to stir at RT for 16 hours. The reaction was quenched with saturated NaHCO3 and the organics were separated and dried over MgSO4. The resulting oil was used without further purification (the product appears to quickly decompose).
F. (2E)-3-{5-Methyl-4-[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]- 2-furyl}-2-propenoic acid.
A flame dried round bottom flask was charged with anhydrous THF (20 mL) and sodium hydride (772 mg, 32.2 mmol). The solution was cooled to 0-5 °C and mixed with triethylphosphonoacetate (794 mg, 35.2 mmol) and the reaction was stirred for 30 minutes at 0-5 °C. To this mixture was added 5-methyl-4-[(5,5,8,8- tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-2-furaldehyde (1.0 g, 32.2 mmol) and the reaction stirred at RT for 4 hours. The reaction was quenched with water at 0 °C while maintaining a temperature of less than 15 °C and this mixture was stirred at RT overnight. The reaction mixture was made acidic using concentrated HCI. The mixture was partitioned between ether and water and dried over MgSO4. The oily solid was triturated with hexanes and the resulting solid was filtered and dried in vacuo to yield 254 mg of compound E. 1H NMR (d6 -acetone) 400 MHz δ 7.32 (d, 1 H), 7.24-7.18 (m, 2H), 6.93 (d,
1 H), 6.63 (s, 1 H), 6.11 (d, 1 H), 3.65 (s, 2H), 2.36 (s, 3H), 1.63 (s, 4H), 1.22 (s, 12H) ppm.
Example 21 (2E)-3-{4-[7-Dimethylamino)-1 -methyl-2,3-dihydro-1 H-indol-5-yl]-4,5,6,7-tetrahydro-1 - benzofuran-2-yl}prop-2-enoic acid.
A. 5-Bromoindol-7-amine.
An EtOH solution (300 mL) containing 5-bromo-7-nitroindoline (5.44 g, 22.4 mmol) and tin(ll)chloride dihydrate (25.2 g, 11 1.9 mmol) was immersed in an oil bath which had been preheated to 70 °C. The resulting orange solution which turned black within 15 min stirred for 22 hr. It was then diluted with sat. NaHCO3 and H2O. The organics were extracted with EtOAc (3X), dried (MgSO ) and the solvent removed in vacuo. The residual dark solid was purified via column chromatography (CH2CI2/MeOH (19:1 )) yielding 3.99 g (18.7 mmol, 84% yield) of compound A. 1H NMR (CDCI3) 400 MHz δ 6.76 (s, 1 H), 6.61 (d, 1 H, J = 1.3 Hz), 3.54 (t, 2H,
J = 8.6 Hz), 3.52 (s(br), 3H), 3.01 (t, 2H, J = 8.5 Hz) ppm.
B. 5-Bromo-N,N 1-trimethylindolin-7-amine.
To a 37% aqeous formaldehyde solution (26.2 mL) containing 21.0 mL of a 3.0 M aqueous H2SO4 solution (63 mmol) cooled to 0 °C was added, via pipet, a THF solution (90 mL) containing compound A (1.18 g, 5.54 mmol) and sodium borohydride (8.81 g, 236 mmol) portionwise (caution: rapid gas evolution). Upon complete addition the reaction stirred at RT for 1 hr. The reaction was quenched with MeOH and H2O. The resulting solution was basified with 2.0 M NaOH and the organics extracted with EtOAc. After drying over MgSO the solvent was removed in vacuo and the residual dark oil purified via column chromatography (hexanes/EtOAc (9:1)) yielding 850 mg (3.33 mmol, 60% yield) of compound B as a clear liquid.
1H NMR (CDCI3) 400 MHz δ 6.86 (s, 1 H), 6.81 (s, 1 H), 3.27 (t, 2H, J = 8.7 Hz), 2.88 (t, 2H, J = 8.7 Hz), 2.82 (s, 3H), 2.61 (s, 6H) ppm.
C. N,N 1-Trimethyl-5-(4,5,6,7-tetrahydro-1-benzofuran-4-yl)indolin-7-amine.
To a THF solution (20 mL) containing compound B (1.96 g, 7.70 mmol) cooled to -78 °C was added 3.3 mL of a 2.5 M hexanes solution of n-BuLi (8.31 mmol). The resulting solution stirred for 20 min at which time 6,7-dihydro-4(5H)- benzofuranone (1.42 g, 10.5 mmol) in 10 mL THF was added. The reaction stirred an additional 45 min and was then quenched with H2O. Upon warming the solution was poured into additional H2O and the organics extracted with Et2O. After drying over MgSO the solvent' was removed in vacuo and the residual yellow oil was dissolved in THF (5 mL). This solution was then added to a THF solution (40 mL) containing sodium borohydride (3.97 g, 105 mmol) and BF3-Et2O (22.4 g, 157.5 mmol) at 0 °C. After 5 min the white slurry was carefully poured into sat. NaHCO3. The two phase solution was then extracted with Et2O (2X), dried (MgSO4) and the solvent removed in vacuo. The residual orange oil was purified via column chromatography (hexanes/EtOAc (15:1)) yielding 1.29 g of compound C mixed with what appeared to be des-bromo starting material. The mixture was taken on to the following step.
D. 4-[7-(Dimethylamino)-1-methyl-2,3-dihydro-1 H-indol-5-yl]-4,5,6,7-tetrahydro-1- benzofuran-2-carboxaldehyde.
To a Et2O solution (15 mL) containing compound C (~ 1.3 g, 4.39 mmol) cooled to —40 °C was added 4.65 mL of a 1.7 M pentane solution of t-BuLi (7.91 mmol). The resulting orange solution stirred for 30 min when DMF (578 mg, 7.90 mmol) was added. The reaction was slowly allowed to warm to -20 °C over 30 min and was then quenched with H2O. The solution was poured into additional H2O and the organics extracted with Et2O (2X). After drying over MgSO4 the solvent was removed in vacuo and the residual oil purified via column chromatography (hexanes/EtOAc (4:1)) yielding 620 mg (1.92 mmol) of compound D.
1H NMR (CDCI3) 400 MHz δ 9.43 (s, 1 H), 6.91 (s, 1 H), 6.50 (s, 2H), 3.76 (m, 1 H), 3.32 - 3.24 (m, 2H), 2.91 - 2.84 (m, 5H), 2.76 - 2.66 (m, 2H), 2.61 (s, 6H), 2.11 - 1.98 (m, 2H), 1.82 - 1.66 (m, 2H) ppm. E. Ethyl (2E)-3-{4-[7-(dimethylamino)-1-methyl-2,3-dihydro-1H-indol-5-yl]-4,5,6,7- tetrahydro-1-benzofuran-2-yl}prop-2-enoate.
To a DME solution (5 mL) containing sodium hydride (113 mg, 2.84 mmol, 60% dispersion in mineral oil) was added triethylphosphonoacetate (636 mg, 2.84 mmol) at RT. After 5 min compound D (612 mg, 1.89 mmol) in 6 mL DME was added. The yellow reaction stirred for 30 min at RT and was then quenched with H2O. The solution was poured into additional H2O and the organics extracted with Et2O. After drying over MgSO4the solvent was removed in vacuo and the residual oil purified via column chromatography (hexanes/EtOAc (8:1)) yielding 578 mg (1.47 mmol, 78% yield) of compound E as a yellow solid solid which was immediately taken into the next step.
F. (2E)-3-{4-[7-Dimethylamino)-1 -methyl-2,3-dihydro-1 H-indol-5-yl]-4,5,6,7- tetrahydro-1 -benzofuran-2-yl}prop-2-enoic acid. To a dioxane solution (7 mL) containing compound E (570 mg, 1.45 mmol) and 3 mL H2O was added lithium hydroxide hydrate (608 mg, 14.5 mmol) at RT. The resulting solution stirred for 24 hr and was then quenched with sat. NaHSO4. The organics were extracted with EtOAc and the aqueous layer basified tp pH 7. It was then extracted with EtOAc and the combined organic layers dried (MgSO4). Removal of the solvent in vacuo and purification via column chromatography (CH2CI2/MeOH (15:1)) yieldied 462 mg (1.26 mmol, 87% yield) of compound F, m.p. 105 -108 °C. 1H NMR (CDCI3) 400 MHz δ 7.37 (d, 1 H, J = 15.6 Hz), 6.52 (s, 2H), 6.35 (s, 1 H), 6.18 (d, 1 H, J = 15.5 Hz), 3.72 (m, 1 H), 3.29 - 3.24 (m, 2H), 2.88 - 2.83 (m, 5H), 2.72 - 2.65 (m, 2H), 2.61 (s, 6H), 2.07 - 1.95 (m, 2H), 1.77 - 1.62 (m, 2H) ppm.
Example 22
(2E)-3-[4-butyl-4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-4,5,6,7- tetrahydro-1 -benzofuran-2-yl]prop-2-enoic acid A. A/-methoxy-Λ/-methylpentanamide. To a CH2CI2 solution (200 mL) containing N-methoxy-N-methylamine hydrochloride (8.09 g, 82.9 mmol) and Et3N (12.6 g, 124 mmol) was added valeryl chloride (10 g, 82.9 mmol) dropwise at room temperature. The resulting solution bubbled vigorously and stirred for 2 hours after which time it was carefully quenched with H2O. The organic layer was separated and washed with 2.0 N NaOH. The organics were extracted with CH2CI2, dried (MgSO4) and the solvent removed in vacuo. The resulting colorless oil was taken on without further purification. 1H NMR (CDCI3) 400 MHz δ 3.62 (s, 3H), 3.12 (s, 3H), 2.38-2.34 (m, 2H), 1.60- 1.52 (m, 2H), 1.36-1.26 (m, 2H), 0.90 (t, 3H, J = 7.8 Hz) ppm.
B. 1 -(5,5,8, 8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)pentan-1 -one. To a THF solution (30 mL) containing 5,6,7, 8-tetrahydro-5,5,8,8-tetramethyl-2- bromonaphthalene (8.87 g, 33.2 mmol) cooled to -78 °C was added n-BuLi (14.7 mL, 39.8 mmol) dropwise. After stirring for 30 min at -78 °C a solution of A (3.7 g, 25.5 mmol) in THF (5 mL) was added dropwise. The reaction ran overnight and was quenched with the dropwise addition of H2O. The organics were extracted with Et2O, dried over MgSO4 and the solvent reduced in vacuo. The residual brown oil was then purified via column chromatography (4% EtOAc/hexanes) yielding 1.12 g (4.30 mmol, 17% yield) of compound B as a colorless oil.
1H NMR (CDCI3) 400 MHz δ 7.91 s, 1 H), 7.68 (d, 1 H, J = 6.4 Hz), 7.36 (d, 1 H, J = 8.3 Hz), 2.92 (t, 2H, J = 7.4 Hz), 1.72-1.64 (m, 6H), 1.41-1.36 (m, 2H), 1.29-1.22 (m, 12H), .95 (t, 3H, J = 7.4 Hz) ppm.
C. 1-(2-Furyl)-4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)octan-4-ol. To a dry round bottom flask was added anhydrous THF (50 mL), magnesium turnings (1.0 g, 0.0417 moles) and 2-(3-bromopropyl)furan (2.8 g, 0.0148 moles; prepared as described in: J. Org. Chem. 1994, 59, 23, incorporated herein by reference as related to such preparation). This solution was cooled to 0-5 °C using an ice bath and the reaction mixture was mixed with NaH (1.8 g, 0.074 moles). The magnesium turnings were agitated until the Grignard salt began to form. The formation was allowed to proceed for a period of 1.0 hour. At this time the reaction mixture was mixed with a THF solution (25 mL) of compound B (3.5 g, 0.0129 moles). The reaction was allowed to warm to RT over a period of 1.0 hour and was then cooled to 0-5 °C. The reaction was slowly quenched with water. The aqueous mixture was neutralized (pH 7.0) with dilute HCI and extracted with ether. The organics were dried over MgSO and concentrated to afford a crude oil. The oil was purified using silica gel chromatography (90%hexanes/10% EtOAc) to yield a total of 2.6 g of pure oil (53%).
1H NMR (CDCI3) 400 MHz δ 7.27-7.18 (m, 3H), 7.03 (d, 1 H, J = 8.0 Hz), 6.22 (d, 1 H, J = 1.7 Hz), 5.87 (d, 1H, J = 1.7 Hz), 2.59-2.48 (m, 2H), 1.86-1.38 (m, 12H), 1.31-0.99 (m, 14H), 0.85 (t, 3H, J = 7.8 Hz) ppm. D. 4-Butyl-4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-4,5,6,7- tetrahydro-1 -benzofuran.
To a round bottom flask was added anhydrous CH2CI2 (50 mL) and compound C (2.6 g, 0.0068 moles). This solution was cooled to 0-5 °C using an ice bath and the reaction mixture was mixed dropwise with TFA (852 μL, 0.074 moles). The reaction was allowed to stir at 0-5 °C for 30 minutes followed by quenching with saturated NaHCO3. The reaction was washed with NaHCO3 and the organics were dried over MgSO4. The organics were concentrated to dryness to afford a crude oil. The oil was purified using silica gel chromatography (90%hexanes/10% EtOAc) to yield a total of 2.6 g of pure oil (56%).
1H NMR (CDCI3) 400 MHz δ 7.30 (s, 1 H), 7.12 (d, 1 H, J = 8.4 Hz), 7.04 (s, 1 H, J = 1.7 Hz), 6.91 (dd, 1 H, J = 8.4 Hz), 6.23 (d, 1 H, J = 1 .8 Hz), 2.48-2.60 (m, 2H), 1 .94- 1.71 (m, 6H), 1.68-1.51 (m, 6H), 1.36-1.03 (m, 14H), 0.82 (t, 3H, J = 7.4 Hz) ppm.
E. 4-Butyl-4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-4,5,6,7- tetrahydro-1 -benzofuran-2-carbaldehyde.
A solution containing anhydrous ether (50 mL) and compound D (2.6 g, 0.0071 moles) was cooled to -70 °C while stirring under nitrogen. To this mixture was added 2.7 M t-B U (7.1 mL, 0.0178 moles). The reaction mixture was allowed to stir at -70 to —4-0 °C for 30 minutes at which time it was mixed with DMF (1.2 g, 0.0162 moles). The reaction was stirred at -20 °C to 0 °C over a period of 1.0 hour and the reaction was quenched using 1.0 N HCI. The reaction was extracted with ether followed by drying with MgSO4. The organics were concentrated in vacuo to afford a crude oil. The oil was chromatographed on silica gel (90%hexanes/10%EtOAc) to yield 2.9 g of oil. The reaction product had inseparable impurities by TLC and the product was used without purification.
F. (2E)-3-[4-Butyl-4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthaleή-2-yl)-4,5,6,7- tetrahydro-1-benzofuran-2-yl]prop-2-enoic acid. , To a THF solution (20 mL) containing sodium hydride (239 mg, 0.0095 moles,
95%) was added triethylphosphonoacetate (424 mg, 0.00189 moles) at 0-5 °C. To this reaction mixture was added compound E (500 mg, 0.00126 moles) and the mixture was allowed to warm to RT. The reaction mixture was stirred at RT for 1.0 hour at which time it was quenched via the addition of water (30 mL). The reaction was mixed with NaOH (25 mL) and stirred at RT for 16 hours. The resulting mixture was made acidic using 3.0 N HCI. The reaction mixture was then extracted into ether and dried over MgSO4. The mixture was concentrated to dryness and chromatographed on silica gel (80% hexanes/ 20% EtOAc) yielding 51 mg of pure acid. Η NMR (CDCI3) 400 MHz δ 7.46 (d, 1 H, J = 15.4 Hz), 7.13 (d, 1H, J = 8.4 Hz),
7.04 (s, 1 H), 6.86 (dd, 1 H, J = 8.4 Hz), 6.54 (s, 1 H), 6.23 (d, 1 H, J = 15.4 Hz), 2.64- 2.58 (m, 2H), 1.96-1.77 (m, 5H), 1.63-1.51 (m, 5H), 1.33-1.03 (m, 14H), 0.82 (t, 3H, J = 7.4 Hz) ppm.
Experimentals
The above-referenced examples were subjected to the following assay to identify inhibition and selectivity of the compounds of the present invention, with the results as detailed below:
Binding Assay The compounds were tested for their ability to bind to hRXRα using a
Scintillation Proximity Assay (SPA) as is known in the art. The RXRα ligand binding domain (LBD) was expressed in E. coli as an amino-terminal polyhistidine tagged fusion protein. The LBD was then labeled with biotin and immobilized on streptavidin-modified scintillation proximity beads. 9-cis[3H]-Retinoic acid (9-cis) was the radioligand used for the assay. To each well to be assayed was added the desired concentration of the previously prepared solution of 9-cis previously incubated with receptor-coated SPA bead slurry.
The plates were incubated for at least 1 hour at room temperature and bound radioactivity for each well was determined in a Wallac 1450 Microbeta counter.
In this specification, pKi = -log of the concentration of the test compound required to achieve an apparent Ki value according to the equation Ki = ICso/1 + [L]/Kd, where IC50 = the concentration of test compound required to inhibit 50% of the specific binding of the radioligand, [L] is the concentration of the radioligand used, and Kd is the dissociation constant for the radioligand at the receptor.
Apparent pKi values were > 6.0 for all examples with the exception of Examples 13, 18, and 19, which each had a pKi < 6.0. Transient Transfection Assay
Transcriptional activity of the compounds was measured in a monkey kidney cell line (CV-1 ). These cells were transfected with full length human RXRα and the natural response element, cellular retinol binding protein type II in a reporter gene construct, (CRBP ll-tk-SPAP), consisting of HSV tk promoter, and the secreted placental alkaline phosphatase reporter gene. CV-1 cells were plated at a density of 24,000 cells per well in high glucose DMEM supplemented with 10%> charcoal/ d extra n-treated FBS. Transfection mixes contained 4 ng of receptor expression vector, 8 ng of reporter plasmid, 25 ng of β-galactosidase expression vector (used as an internal control), and 43 ng of carrier plasmid. Transfections were performed with Lipofectamine according to the manufacturer's instructions. Drug dilutions were prepared in phenol red-free DMEM/F-12 with 15 mM HEPES supplemented with 10% charcoal-stripped, delipidated calf serum. Cells were incubated for 24 h in the presence of drugs, after which the medium was sampled and assayed for SPAP activity.
B-galactosidase, which measures transfection efficiency activity, was determined by using 3.6 mM o-nitrophenyl-D-galactopyranoside in 0.1 M sodium phosphate pH 7.2 buffer containing 0.13% Triton X-100 as substrate. These plates were read on a Molecular Devices Vmax spectrophotometer, at a 405nm endpoint reading. Data were reduced using RoboFit.
The results were expressed as percent of maximum or fold activation calculated by the following formulas: fold activation = (((SPAP-SPAPsubstrate blank avg.)/(β-gal-β-gal substrate blank avg.))-DMSO vehicle avg.)/DMSO vehicle avg, and % max. = (fold activation of unknown / positive control fold activation avg.)x100. Curves were fit from these data using RoboFit to determine EC5o's using the following equation: Y = ((Vmax*x)/(K+x))+Y2.
pEC50 values were > 6.0 for all examples with the exception of Examples 13, 18, and 19, which each had pEC50 < 6.0.
Although specific embodiments of the present invention have been illustrated and described in detail, it is to be expressly understood that the invention is not limited thereto. The above detailed description of the preferred embodiment is provided for example only and should not be construed as constituting any limitation of the invention. Modifications will be obvious to those skilled in the art, and all modifications that do not depart from the spirit of the invention are intended to be included within the scope of the appended claims.

Claims

What is claimed is:
1. A compound of Formula I:
Figure imgf000072_0001
including salts, solvates, and physiologically functional derivatives thereof, wherein the broken lines represent optional double bonds; X is CR1 or N, where R1 is halogen, H, or CH3; Z is O, S, or NH; M is N, C, or CR2, when M is N, the A ring is non-aromatic; when M is C, the A ring is aromatic; when M is CR2, then R2 is H or -Y(CH2)nR6, and the A ring is non- aromatic; Y is O or CH2; when n is 0 to 6, R6 is H, alkyl, or CF3; when n is 2 to 5, R6 is H, alkyl, CF3, SO2NHR23, NHSO2R23, or NR23R24, where R23 is alkyl, aryl optionally substituted, heteroaryl optionally substituted or combined with R24 to form a ring of 3 -7 atoms; and R24 is H, alkyl, cycloalkyl or combined with R23 to form a ring of 3 to 7 atoms; G is CO2R7, SO3R7, PO3R7, CONHOH, or
Figure imgf000072_0002
where the broken line represents an optional double bond; J is CHO, CO2R7, SO3R7, PO3R7, CONHOH, or J forms a thiazolidinedione ring with R8;
R7 is H or alkyl;
R8 and R9 are independently H, halogen, alkyl, or CF3; y and z are each 0, 1 , or 2; Q is CR4, CR4R5, O, NR10, or S, where R4 and R5 are independently H or alkyl, provided that when Q is CR4, the A ring is aromatic;
R10 is alkyl, COR11, CONHR11, CO2R11, CONR 1R12, SO2R11, aryl, or cycloalkyl;
R11 and R12 are independently alkyl or cycloalkyl;
R3 is
Figure imgf000073_0001
wherein
D is CR13R14, O, S, NR15, CHOH, CO, SO, SO2, where R13 and R14 are independently H, alkyl, or cycloalkyl; and where R 5 is H, alkyl, or cycloalkyl;
R16 and R17 independently are H, C1-4 alkyl, cycloalkyl, or together form a carbocyclic ring having from 3 to 7 atoms;
R18 is H, OR6, halogen, CF3, alkenyl, SR16, C1-4 alkyl, CO2R16, COR11, or NR16R17, where R 6 and R17 are as above defined; m is 0 or 1 ;
R25 is H or alkyl; or R3 is
Figure imgf000073_0002
where R18 is as defined above; or R3 is
(
Figure imgf000073_0003
where
M2 is C or N, provided however that the optional double bond represented by the broken line is optionally present only when M2 is C; each R19 is, independently, H or alkyl; y and z are as defined above; or R3 is
Figure imgf000074_0001
where each R18 is, independently, as defined above; and
M3 is C-(R16)3 or N-(R16)2, when M3 is N-(R16)2, an R16 may combine with an R18 to form a 5- or 6-membered ring.
2. The compound of claim 1 wherein when either R4 or R5or both are alkyl, said alkyl is C1-5 alkyl; when R6 is alkyl, said alkyl is C1-6 alkyl; when R7 is alkyl, said alkyl is C -5 alkyl; when either R8 or R9or both are alkyl, said alkyl is C1-3 alkyl; when R10 is alkyl, said alkyl is C1-6 alkyl; when either R11 or R12or both are alkyl, said alkyl is C1-5 alkyl; when either R13 or R14or both are alkyl, said alkyl is C1-3 alkyl; when R15 is alkyl, said alkyl is C1-4 alkyl; when either R16 or R17or both are alkyl, said alkyl is C1- alkyl; when R18 is alkenyl, said alkenyl is C-M alkenyl; when R18 is alkyl, said alkyl is C1-4 alkyl; when R19 is alkyl, said alkyl is C1-4 alkyl; when R23 is alkyl, said alkyl is C1-6 alkyl; and when R24 is alkyl, said alkyl is C1-7 alkyl.
3. The compound of claim 1 wherein X is C.
4. The compound of claim 1 wherein Z is O.
5. The compound of claim 1 wherein Q is C.
6. The compound of claim 1 wherein M is C.
7. The compound of claim 1 wherein R1, R2, R4 and R5 is H.
8. The compound of claim 1 wherein
Figure imgf000075_0001
J is CO2H; y and z are each 1 ; R8 and R9 are H; and the olefin geometry is trans.
9. The compound of claim 1 wherein
Figure imgf000075_0002
D is CR13R14;
R13, R14, R16, R17 are each methyl; and
R18 is H.
10. The compound of claim 1 selected from the group consisting of:
(2E)-3[4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)tetrahydro-1- benzofuran-2-yl]-2-propenoic acid;
(2E)-3-[4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7- tetrahydro-1-benzofuran-2-yl]-2-propenoic acid;
(2E)-3-[4-(3-methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7- tetrahydro-1 -benzofuran-2-yl]-2-propenoic acid;
(2E)-3-[4-(5,5,8,8-tetramethyl-3-propoxy-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7- tetrahydro-1-benzofuran-2-yl]-2-propenoic acid; (2E)-3-[6-methyl-4-(5,5,8,8,-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7- tetrahydro[2,3-c]pyridin-2-yl]-2-propenoic acid;
(2E)-3-[4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-1-benzofuran-2-yl]-
2-propenoic acid; (2E)-3-[4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-
1 -benzothien-2-yl]-2-propenoic acid;
(2E)-3-[4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-
1 ,3-benzoxazol-2-yl]-2-propenoic acid; (2E)-3-(4-{[(2,6,6-trimethylcyclohexen-1-yl)methyl]amino}benzofuran-2-yl)-2- propenoic acid;
(2E)-3[4-(4-lsopropoxy-1-naphthalenyl)tetrahydro-1-benzofuran-2-yl]-2-propenoic acid;
(2E)-3-{4-[4-Dimethylamino)-3-ethylphenyl]-4,5,6,7-tetrahydro-1-benzofuran-2-yl}-2- propenoic acid;
(2E)-3-{4-[(E)-2-(2,6,6-Trimethyl-1 -cyclohexen-1 -yl)ethenyl]-1 -benzofuran-2-yl}-2- propenoic acid;
4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1- benzofuran-2-carboxylic acid; [4-(5,5,8,8,-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1- benzofuran]-2-(2,4-thiazolidinedione);
[4-(5,5,8,8,-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1- benzothiaphene]-2-propionic acid;
4-(5,5,8,8,-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4,5,6,7-tetrahydro-1- benzofuran]-2-(2,3(cis)propenoic acid;
(2E)-3-{4-[7-Dimethylamino)-1 -methyl-2,3-dihydro-1 H-indol-5-yl]-4,5,6,7-tetrahydro-1 - benzofuran-2-yl}prop-2-enoic acid;
(2E)-3-[4-butyl-4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-4,5,6,7- tetrahydro-1-benzofuran-2-yl]prop-2-enoic acid; and salts, solvates, or pharmaceutically functional derivatives thereof.
11. A compound of formula II:
Formula II
Figure imgf000076_0001
including salts, solvates, and pharmaceutically functional derivatives thereof, wherein
X is CR1 or N, where R1 is halogen, H, or CH3; Z is O, S, or NH; G is CO2R7, SO3R7, PO3R7, CONHOH, or
Figure imgf000077_0001
where the broken line represents an optional double bond; J is CHO, CO2R7, SO3R7, PO3R7, CONHOH, or J forms a thiazolidinedione ring with R8;
R7 is H or C1-5alkyl;
R8 and R9 are independently H, halogen, C1-3 alkyl, or CF3; y and z are each 0, 1 , or 2;
R3 is
Figure imgf000077_0002
wherein
D is CR13R14, O, S, NR15, CHOH, CO, SO, SO2, where R13 and R14 are independently H, C1-3 alkyl, or cycloalkyl; and where R15 is H, C1- alkyl, or cycloalkyl;
R16 and R17 independently are H, C1- alkyl, cycloalkyl, or together form a carbocyclic ring having from 3 to 7 atoms;
R18 is H, OR6, halogen, CF3r alkenyl, SR16, C1-4 alkyl, CO2R16, COR11, or NR16R17, where R16 and R17 are as above defined; m is 0 or 1 ;
R11 is C-1.5 alkyl, or cycloalkyl; or R3 is
Figure imgf000077_0003
where R18 is as defined above; or R3 is
Figure imgf000078_0001
where
M2 is C or N, provided however that the optional double bond represented by the broken line is optionally present only when M2 is C; R19 is H or CM alkyl; or R3 is
Figure imgf000078_0002
where R18 is as defined above; and
M3 is C-(R16)3 or N-(R16)2, when M3 is N-(R16)2, an R16 may combine with an R 8 to form a 5- or 6-membered ring;
R20 is H or CM alkyl;
R21 is H, OR6, where R6 is as defined for Formula I, or may combine with R22 to form a carbonyl; and
R22 is H, or may combine with R21 to form a carbonyl.
12 The compound of claim 11 wherein X is C.
13 The compound of claim 11 wherein R1 is H.
14 The compound of claim 11 wherein Z is O.
15 The compound of claim 11 wherein R20 is -CH3.
16 The compound of claim 11 wherein R21 and R22 are each H.
17 The compound of claim 11 wherein
Figure imgf000079_0001
J is CO2H; R8 and R9 are H; y and z are each 1 ; and the olefin geometry is trans.
18. The compound of claim 11 wherein 7
Figure imgf000079_0002
D is -CR13R14;
R13, R14, R16 and R17 are each methyl; and R18 is H.
19. The compound of claim 11 selected from the group consisting of: (2E)-3-{4-[(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-2-furyl}-2- propenoic acid; (2E)-3-{4-[(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-2-thienyl}-
2-propenoic acid;
(2E)-3-{4-[(3-Methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-
2-furyl}-2-propenoic acid;
(2E)-3-{5-Methyl-4-[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-2- furyl}-2-propenoic acid; and salts, solvates, or pharmaceutically functional derivatives thereof.
20. A pharmaceutical composition comprising: a compound as claimed in claims 1 to 19; and one or more of a pharmaceutically acceptable carrier.
21. A method for treating a disorder in a mammal, wherein the disorder is characterized by the need for retinoid therapy, comprising: administering to the mammal an effective amount of a compound as claimed in claims 1 to 19.
22. The method of claim 21 wherein the disorder characterized by the need for retinoid therapy is selected from the group consisting of metabolic conditions and disorders, dermatological conditions, cancerous and pre-cancerous conditions, hyperthyroidism, dyslipidemia, and hypertension.
23. The method of claim 22 wherein the disorder is diabetes.
24. The method of claim 22 wherein the disorder is obesity.
25. A compound as claimed in claims 1 to 19 for use as an active therapeutic substance.
26. A compound as claimed in claims 1 to 19 for use in retinoid therapy.
27. A compound as claimed in claims 1 to 19 for use in the treatment or prophylaxis of diabetes.
28. A compound as claimed in claims 1 to 19 for use in the treatment or prophylaxis of obesity.
29. Use of a compound as claimed in claims 1 to 19 in the manufacture of a medicament for use in retinoid therapy.
30. Use of a compound as claimed in claims 1 to 19 in the manufacture of a medicament for use in the treatment or prophylaxis of diabetes.
31. Use of a compound as claimed in claims 1 to 19 in the manufacture of a medicament for use in the treatment of prophylaxis of obesity.
32. A compound as claimed in claim 1 or 19 substantially as hereinbefore described with reference to any of the Examples.
33. A method for manufacturing a retinoid comprising: a) reacting a compound of Formula III, Formula IV, a combination of Formulas and IV, or Formula XVII, with one of a compound of Formulas V, VI, or VII:
Figure imgf000081_0001
Formula Formula IV
20
R ) Formula XVII
Figure imgf000081_0002
Formula V Formula VI Formula VII
wherein,
X is CR1 or N, where R1 is halogen, H, or CH3; Z is O, S, or NH;
Q is CR4, CR4R5, O, NR10, or S, where R4 and R5 are independently H or C1-5 alkyl, provided that when Q is CR4, the A ring is aromatic;
R10 is C1-6 alkyl, COR11, CONHR11, CO2R11, CONR11R12, SO2R11, aryl, or cycloalkyl; R11 and R12 are independently C1-5 alkyl or cycloalkyl;
E is Br or I;
D is CR13R14, O, S, NR15, CHOH, CO, SO, SO2, where R13 and R14 are independently H, C1-3 alkyl, or cycloalkyl; and where R15 is H, CM alkyl, or cycloalkyl; R16 and R17 independently are H, C1-4 alkyl, cycloalkyl, or together form a carbocyclic ring having from 3 to 7 atoms;
R18 is H, OR6, halogen, CF3, alkenyl, SR16, CM alkyl, CO2R16, COR11, or NR16R17, where R16 and R17 are as above defined; R19 is H or alkyl; m is 0 or 1 ; and
M3 is C-(R16)3 or N-(R16)2, when M3 is N-(R16) , an R16 may combine with an R18 to form a 5- or 6-membered ring; b) generating an organometallic species from the product of step (a) via Grignard or metal halogen exchange reaction; c) condensing the organometallic species produced in step (b); d) reducing or oxidizing the condensed product produced in step (c); e) deprotonating the product of step (d) via organolithiums; f) formylating the deprotonated product produced in step (e); g) treating the formylated product with a stabilized Wittig reagent and subsequent aqueous basic hydrolysis, to form a compound having activity for a retinoid receptor.
PCT/US2002/029298 2001-09-25 2002-09-16 Bicyclic heterocycles as rxr ligands WO2003027090A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2002333655A AU2002333655A1 (en) 2001-09-25 2002-09-16 Bicyclic heterocycles as rxr ligands
US10/490,805 US7173134B2 (en) 2001-09-25 2002-09-16 Selective RXR ligands
JP2003530678A JP2005511516A (en) 2001-09-25 2002-09-16 Selective RXR ligand
EP02799584A EP1430042A2 (en) 2001-09-25 2002-09-16 Bicyclic heterocycles as rxr ligands
US11/614,091 US20070099991A1 (en) 2001-09-25 2006-12-21 Selective rxr ligands

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32509201P 2001-09-25 2001-09-25
US60/325,092 2001-09-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/614,091 Division US20070099991A1 (en) 2001-09-25 2006-12-21 Selective rxr ligands

Publications (2)

Publication Number Publication Date
WO2003027090A2 true WO2003027090A2 (en) 2003-04-03
WO2003027090A3 WO2003027090A3 (en) 2003-12-11

Family

ID=23266396

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/029298 WO2003027090A2 (en) 2001-09-25 2002-09-16 Bicyclic heterocycles as rxr ligands

Country Status (5)

Country Link
US (2) US7173134B2 (en)
EP (1) EP1430042A2 (en)
JP (1) JP2005511516A (en)
AU (1) AU2002333655A1 (en)
WO (1) WO2003027090A2 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008022221A1 (en) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitors of human aldosterone synthase CYP11B2
EP2269620A1 (en) 2003-09-24 2011-01-05 Nikken Sohonsha Corporation Therapeutic uses of dunaliella powder
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
CN105884823A (en) * 2016-05-31 2016-08-24 肇庆巨元生化有限公司 Method for preparing 2,6,6-trimethyl-1-cyclohexenyl methylphosphonate
US10588881B2 (en) 2015-10-31 2020-03-17 Io Therapeutics, Inc. Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
US10596133B2 (en) 2005-09-30 2020-03-24 Io Therapeutics, Inc. Treatment of cancer with specific RXR agonists
US10835507B2 (en) 2016-03-10 2020-11-17 Io Therapeutics, Inc. Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones
US10945976B2 (en) 2011-12-13 2021-03-16 Io Therapeutics, Inc. Autoimmune disorder treatment using RXR agonists
US10946001B2 (en) 2016-03-10 2021-03-16 Io Therapeutics, Inc. Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
US11517549B2 (en) 2017-09-20 2022-12-06 Io Therapeutics, Inc. Treatment of disease with esters of selective RXR agonists
US11896558B2 (en) 2021-12-07 2024-02-13 Io Therapeutics, Inc. Use of an RXR agonist and taxanes in treating Her2+ cancers

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007076260A2 (en) * 2005-12-19 2007-07-05 Smithkline Beecham Corporation Farnesoid x receptor agonists
JP5211322B2 (en) * 2008-03-07 2013-06-12 国立医薬品食品衛生研究所長 Novel use of pyrimidine-5-carboxylic acid derivatives as anti-obesity agents
WO2010041449A1 (en) * 2008-10-09 2010-04-15 国立大学法人 岡山大学 Anti-allergic agent comprising rxr agonist as active ingredient
IN2012DN00352A (en) * 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
AU2012346537A1 (en) * 2011-12-01 2014-07-17 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
CA3092682A1 (en) * 2018-03-01 2019-09-06 DJ Therapeutics LLC Bexarotene derivatives and their use in treating cancer

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0123998A2 (en) * 1983-04-27 1984-11-07 Boehringer Ingelheim Kg 4-Phenyl-tetrahydro-furano-pyridines, process for their preparation and pharmaceutical compositions
WO1994015902A1 (en) * 1993-01-11 1994-07-21 Ligand Pharmaceuticals Inc. Compounds having selectivity for retinoid x receptors
US5399586A (en) * 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
WO1997024116A2 (en) * 1995-12-29 1997-07-10 Vision Pharmaceuticals L.P. METHODS OF TREATMENT WITH COMPOUNDS HAVING RARα RECEPTOR SPECIFIC OR SELECTIVE ACTIVITY
WO1999029674A1 (en) * 1997-12-11 1999-06-17 Janssen Pharmaceutica N.V. Retinoic acid mimetic anilides
US5962508A (en) * 1996-09-09 1999-10-05 Societe L'oreal S.A. Retinoid receptor agonists for promoting hair growth and/or retarding hair loss
US6005007A (en) * 1997-07-18 1999-12-21 Farmer; Luc J. Retinoids, methods for their production and use
US6030952A (en) * 1996-12-04 2000-02-29 Centre International De Recherches Dermatologioues Galderma Benzofuran-acrylic acid derivatives and their use as modulators of RXRs or RARs receptors
US6162815A (en) * 1994-04-26 2000-12-19 Centre International De Recherches Dermatologiques Galderma RXR-agonist polycyclic aromatic compounds, pharmaceutical/cosmetic compositions comprising said compound and uses thereof
WO2002071827A2 (en) * 2001-03-14 2002-09-19 Eli Lilly And Company Retinoid x receptor modulators

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0123998A2 (en) * 1983-04-27 1984-11-07 Boehringer Ingelheim Kg 4-Phenyl-tetrahydro-furano-pyridines, process for their preparation and pharmaceutical compositions
WO1994015902A1 (en) * 1993-01-11 1994-07-21 Ligand Pharmaceuticals Inc. Compounds having selectivity for retinoid x receptors
US5399586A (en) * 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
EP0909560A2 (en) * 1993-03-11 1999-04-21 Allergan, Inc. Treatment o tumors with compounds having RXR retinoid receptor agoinst activity
US6162815A (en) * 1994-04-26 2000-12-19 Centre International De Recherches Dermatologiques Galderma RXR-agonist polycyclic aromatic compounds, pharmaceutical/cosmetic compositions comprising said compound and uses thereof
WO1997024116A2 (en) * 1995-12-29 1997-07-10 Vision Pharmaceuticals L.P. METHODS OF TREATMENT WITH COMPOUNDS HAVING RARα RECEPTOR SPECIFIC OR SELECTIVE ACTIVITY
US5962508A (en) * 1996-09-09 1999-10-05 Societe L'oreal S.A. Retinoid receptor agonists for promoting hair growth and/or retarding hair loss
US6030952A (en) * 1996-12-04 2000-02-29 Centre International De Recherches Dermatologioues Galderma Benzofuran-acrylic acid derivatives and their use as modulators of RXRs or RARs receptors
US6005007A (en) * 1997-07-18 1999-12-21 Farmer; Luc J. Retinoids, methods for their production and use
WO1999029674A1 (en) * 1997-12-11 1999-06-17 Janssen Pharmaceutica N.V. Retinoic acid mimetic anilides
WO2002071827A2 (en) * 2001-03-14 2002-09-19 Eli Lilly And Company Retinoid x receptor modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE CROSSFIRE BEILSTEIN [Online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; I. ELGHAMRY: Database accession no. 9073747 XP002235173 & SYNTH. COMMUN., vol. 32, no. 6, 2002, pages 897-902, *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2269620A1 (en) 2003-09-24 2011-01-05 Nikken Sohonsha Corporation Therapeutic uses of dunaliella powder
US10973788B2 (en) 2005-09-30 2021-04-13 Io Therapeutics, Inc. Treatment of cancer with specific RXR agonists
US10596133B2 (en) 2005-09-30 2020-03-24 Io Therapeutics, Inc. Treatment of cancer with specific RXR agonists
DE102008022221A1 (en) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitors of human aldosterone synthase CYP11B2
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
US11246845B2 (en) 2011-12-13 2022-02-15 Io Therapeutics, Inc. Autoimmune disorder treatment using RXR agonists
US11793781B2 (en) 2011-12-13 2023-10-24 Io Therapeutics, Inc. Autoimmune disorder treatment using RXR agonists
US10945976B2 (en) 2011-12-13 2021-03-16 Io Therapeutics, Inc. Autoimmune disorder treatment using RXR agonists
US11166927B2 (en) 2011-12-13 2021-11-09 Io Therapeutics, Inc. Autoimmune disorder treatment using RXR agonists
US11576881B2 (en) 2011-12-13 2023-02-14 Io Therapeutics, Inc. Autoimmune disorder treatment using RXR agonists
US11547684B2 (en) 2011-12-13 2023-01-10 Io Therapeutics, Inc. Autoimmune disorder treatment using RXR agonists
US10588881B2 (en) 2015-10-31 2020-03-17 Io Therapeutics, Inc. Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
US11690831B2 (en) 2016-03-10 2023-07-04 Io Therapeutics, Inc. Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
US10946001B2 (en) 2016-03-10 2021-03-16 Io Therapeutics, Inc. Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
US11690832B2 (en) 2016-03-10 2023-07-04 Io Therapeutics Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
US10835507B2 (en) 2016-03-10 2020-11-17 Io Therapeutics, Inc. Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones
CN105884823A (en) * 2016-05-31 2016-08-24 肇庆巨元生化有限公司 Method for preparing 2,6,6-trimethyl-1-cyclohexenyl methylphosphonate
US11517549B2 (en) 2017-09-20 2022-12-06 Io Therapeutics, Inc. Treatment of disease with esters of selective RXR agonists
US11224583B2 (en) 2019-06-11 2022-01-18 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
US11896558B2 (en) 2021-12-07 2024-02-13 Io Therapeutics, Inc. Use of an RXR agonist and taxanes in treating Her2+ cancers

Also Published As

Publication number Publication date
AU2002333655A1 (en) 2003-04-07
US20040198980A1 (en) 2004-10-07
WO2003027090A3 (en) 2003-12-11
US7173134B2 (en) 2007-02-06
JP2005511516A (en) 2005-04-28
US20070099991A1 (en) 2007-05-03
EP1430042A2 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
US20070099991A1 (en) Selective rxr ligands
DE3834204C2 (en)
AU2001282009B2 (en) Non-steroidal inflammation inhibitors
EP1519915B1 (en) Tricyclic steroid hormone nuclear receptor modulators
KR101852215B1 (en) Heterocyclic compound and use thereof
US6593493B1 (en) RXR modulators with improved pharmacologic profile
EP1373240B1 (en) Retinoid x receptor modulators
NL1031385C2 (en) Substituted sulfonylaminoarylmethylcyclopropanecarbonamide compounds.
JP2655692B2 (en) Sulfonamidothienylcarboxylic acid compound
CA2832202A1 (en) Inhibitors of viral replication, their process of preparation and their therapeutical uses
JPH11500146A (en) (Methylsulfonyl) phenyl-2- (5H) -furanones as COX-2 inhibitors
JP4118675B2 (en) A new retinoid for the treatment of emphysema
JP2002526534A (en) Tetrahydroquinoline derivative having selective activity on retinoid X receptor
DK162524B (en) ANALOGY PROCEDURE FOR THE PREPARATION OF 5-ALKYLTHIO-TETRAZOLD DERIVATIVES
FR2698873A1 (en) Potassium channel activating benzocycloheptenes, benzoxepines and benzothiepins, process for their preparation, pharmaceutical composition containing them
US4897397A (en) Aryl-alkynoic, alkenoic or alkanoic compounds and compositions useful as antiallergy and anti-inflammatory agents
JPH035455A (en) Substituted pyrrole compound and use thereof in medicinal therapy
US6388105B1 (en) Benzofuran, indole or benzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
WO2004069781A2 (en) 7-(3,5-diisopropylphenyl) heptatrienoic acid derivatives having serum glucose reducing activity
IE42116B1 (en) 6-substituted chromones and chromanones
JP2003525227A (en) 4-pyridyl- and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy
JPH03223277A (en) Benzothiophene derivative
HU211554A9 (en) Circulation-active dibenzo/1,5/dioxocin-5-ones
AU2006261048A1 (en) Non-steroidal progesterone receptor modulators
GB2264115A (en) 1h-2-methylimidazo(4,5-c)pyridinyl derivatives as paf antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002799584

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003530678

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 10490805

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002799584

Country of ref document: EP